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Abstract 
 
The N-7 methylguanosine cap structure is conserved from yeast to man. It is 
essential for cell proliferation as it influences several steps in eukaryotic gene 
expression including transcription, pre-mRNA processing, RNA export and translation. 
The N-7 methylguanosine cap is added co-transcriptionally to RNA pol II transcripts. In 
mammals, two enzymes catalyse the synthesis of the N7-methylguanosince cap. 
RNGTT adds an inverted guanosine group to the first transcribed nucleotide and RNMT 
methylates the guanosine cap at the N7-position. 
RNMT consists of a catalytic domain and an N-terminal domain that is absent in 
lower eukaryotes. Experiments presented in this thesis revealed that the N-terminus 
mediates RNMT recruitment to transcription start sites. Furthermore, it was found that 
the RNMT N-terminal domain is phosphorylated at Threonine-77 (T77) by CDK1/Cyclin 
B in a cell cycle-dependent manner during G2/M-phase. 
RNMT T77 phosphorylation activates cap methyltransferase activity in vitro. 
Furthermore, it negatively regulates the interaction of RNMT with KPNA2 (Importin-α), 
which was found to inhibit RNMT activity in vitro.  RNMT T77 phosphorylation is 
required for normal cell proliferation suggesting an important biological function. Initial 
experiments indicated that RNMT T77 phosphorylation functions to regulate gene 
expression in a gene-specific manner. Future work is focused on establishing an 
experimental system to perform a genome-wide study in order to elucidate which 
transcripts are affected by RNMT T77 phosphorylation. 
To summarise, this study for the first time revealed that the RNA cap 
methyltransferase activity is regulated in a cell-cycle dependent manner.  
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Chapter 1:                                                
Introduction 
 
 
1.1 Introduction to eukaryotic gene expression 
 
The principles of gene expression are conserved from bacteria to humans and 
have been described as the central dogma of molecular biology by Francis Crick 
(Crick, 1970, 1958). This includes the general transfer of genetic information from DNA 
to RNA to protein. Despite the general conservation of the mechanics of gene 
expression, its regulation is very diverse between species and the pattern of gene 
expression varies even between different cell types of the same organism. In 
metazoans, hundreds of different cell types contain the same genetic information, but 
still exhibit different functions and respond to physiological and environmental signals 
in different ways. Thus, the tight and differential control of gene regulation is required 
for overall functioning of an organism (Orphanides, 2002). 
In eukaryotic cells, RNA processing is an important step in the expression of genes 
that can affect the fate of an RNA molecule or even alter the coding capacity of a 
particular gene. The addition of a N7-methylguanosine cap to RNA polymerase II 
transcripts is the first of several RNA processing steps and this thesis aims to 
investigate the regulation of N7-methylguanosine cap formation in human cells. Before 
presenting the literature describing the formation and function of the N7-
methylguanosine cap, the basic processes of eukaryotic gene expression are going to 
be illustrated in the next subchapter.  
	   	  2 
1.1.1 RNA Pol II transcription and CTD phosphorylation 
Gene expression starts with the transcription of genetic information from a DNA 
segment into RNA. Protein-coding messenger (m)RNA and some non-coding RNAs 
such as micro (mi)RNA and small nuclear (sn)RNA are transcribed by the multisubunit 
enzyme RNA polymerase II (RNA pol II). Initiation of RNA pol II transcription involves a 
range of different general transcription factors. TFIID recognises the TATA-box in the 
core promoter and TFIIB binds to the TFIID-promoter complex, thus allowing the 
recruitment of the TFIIF/RNA pol II complex. The pre-initiation complex is completed by 
binding of TFIIE and TFIIH and it is stabilised by TFIIA (Orphanides et al., 1996). In 
addition to these basal transcription factors, the transcription initiation complex may 
also include further regulators such as the mediator complex and/or gene-specific 
transcription factors which activate or repress transcription in response to metabolic or 
environmental signals (Sikorski and Buratowski, 2009).  
RNA pol II is recruited to promoters in an unphosphorylated state (Lu et al., 1991). 
However, after the formation of the pre-initiation complex the amino acids of the 
carboxyl-terminal domain (CTD) of the largest subunit of RNA pol II become 
sequentially phosphorylated. The CTD is unique to RNA pol II and it consists of tandem 
heptad repeats with a consensus sequence of Tyrosine1-Serine2-Proline3-Threonine4-
Serine5-Proline6-Serine7. The length of the heptad repeats depends on the complexity 
of the organisms with yeast possessing 26 and vertebrates possessing 52 repeats 
(Chapman et al., 2008; Liu et al., 2010). The CTD serves as a scaffold or landing 
platform for several proteins involved in transcription, messenger (m)RNA maturation 
and chromatin modification (Hsin and Manley, 2012). Binding of these proteins to the 
CTD is dynamically regulated by the phosphorylation of Serine-5 and Serine-2 but also 
Serine-7, Threonine-4 and Tyrosine-1 (Heidemann et al., 2013). The TFIIH subunit 
CDK7/Cyclin H/MAT1 phosphorylates the CTD at Serine-5 during transcription initiation 
(Feaver et al., 1991; Lu et al., 1992; Trigon et al., 1998), which has been shown to 
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correlate with increased promoter clearance and dissociation of the mediator complex 
from RNA pol II (Max et al., 2007). Furthermore, Serine-5 phosphorylation serves to 
recruit the RNA capping machinery as described in detail below. 
Chromatin immunoprecipitation (ChIP) followed by sequencing demonstrated that 
shortly after transcription initiation RNA pol II globally pauses at promoter proximal 
sites in metazoan cells (Guenther et al., 2007; Kim et al., 2005; Rahl et al., 2010). This 
pausing is observed at most protein-encoding genes including those that are thought to 
be transcriptionally inactive, which suggests that transcription is regulated at the 
elongation step rather than at initiation. Promoter-proximal pausing, which occurs 20 - 
60 base pairs (bp) after the transcription start site (TSS), is caused by two factors: 5,6-
dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) sensitive induced elongation factor 
(DSIF) and negative elongation factor (NELF). DSIF consists of the two subunits Spt4 
and Spt5 whereas NELF is composed of five polypeptides named NELF A-E. DRB 
treatment was previously shown to inhibit transcription elongation (Chodosh et al., 
1989) and DSIF and NELF were found to mediate sensitivity to DRB-mediated 
transcription inhibition (Wada et al., 1998; Yamaguchi et al., 1999). Binding of DSIF 
and NELF to RNA pol II was demonstrated to cooperatively cause pausing of RNA pol 
II and accumulation of short 20 - 50 bp transcripts (Wada et al., 1998; Yamaguchi et 
al., 1999). This repression of transcription elongation is reversed by pTEFb-mediated 
phosphorylation of RNA pol II (Yamaguchi et al., 1999). The pTEFb complex contains 
the kinase CDK9/Cyclin T, which phosphorylates the RNA pol II CTD at Serine-2 and 
also phosphorylates Spt5 (Marshall et al., 1996; Yamada et al., 2006). This causes the 
dissociation of NELF from RNA pol II and allows productive transcription elongation. 
In addition to TFIIH and pTEFb, other kinases also phosphorylate the RNA pol II 
CTD during the transcription cycle. These include the mediator subunit CDK8/Cyclin C, 
which phosphorylates Serine-5 during transcription initiation (Galbraith et al., 2010), or 
CDK12, which is responsible for Serine-2 phosphorylation on elongating RNA pol II 
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(Bartkowiak et al., 2010; Blazek et al., 2011). Furthermore, CDK13 was also found to 
phosphorylate RNA pol II CTD Serine-2 in vitro (Bartkowiak et al., 2010). Together 
these kinases create a general CTD phosphorylation pattern with high Serine-5 and 
Serine-7 phosphorylation during transcription initiation and Serine-2, Threonine-4 and 
Tyrosine-1 phosphorylation during transcription elongation (Heidemann et al., 2013). 
Furthermore, recent studies have indicated that the CTD is also modified by other post-
translational modifications including methylation and glycosylation (Heidemann et al., 
2013). Overall, these modifications generate a complex and dynamic CTD code that 
regulates transcription and other nuclear processes as described further below. 
 
1.1.2 mRNA processing and export 
Eukaryotic pre-mRNA must be extensively processed before being exported to the 
cytoplasm where translation occurs. The CTD of RNA pol II serves to recruit several 
processing factors in a timely manner, thus coordinating the processing events. mRNA 
processing includes capping, splicing and polyadenylation, and these processing steps 
are crucial for gene expression since they determine the fate of the transcripts (Hocine 
et al., 2010).  
The first processing event that occurs is the addition of an N7-methylguanosine cap 
to the 5ʼ end of nascent RNA pol II transcripts. The mechanics and function of N7-
methylguanosine cap formation are described in separate subchapters (subchapters 
1.2 and 1.5). 
The removal of non-coding intronic sequences from pre-mRNA and subsequent 
rejoining of exons is called splicing. Splicing is catalysed by the spliceosome, a large 
complex consisting of the small nuclear RNAs snRNA U1, U2, U4, U5 and U6 as well 
as a large number of proteins (Hoskins and Moore, 2012). The selection of splicing 
sites is a highly complex process which not only depends on cis-elements in the RNA, 
but also on trans-acting regulatory factors that enhance or repress recruitment of the 
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splicing machinery to splice sites. Splicing predominantly occurs co-transcriptionally 
and several splicing factors interact with the phosphorylated CTD of RNA pol II 
(Braunschweig et al., 2013). In metazoans, splicing is often differentially regulated 
during development and in various tissues leading to alternative inclusion of exons, a 
process called alternative splicing (Braunschweig et al., 2013). Alternative splicing 
allows production of different protein isoforms from a single gene and with 95 % of 
human multi-exon genes being alternatively spliced, this highly abundant process 
creates an enormous diversity in gene expression (Pan et al., 2008; Wang et al., 2008). 
The final mRNA processing event is the formation of a polyadenylate (poly(A)) tail at 
the 3ʼ end. This process is a two-step reaction that involves the endonucleolytic 
cleavage of the pre-mRNA followed by the synthesis of a poly(A) tail onto the 3ʼ end of 
the upstream cleavage product (Hocine et al., 2010). Several polyadenylation factors 
interact with the Serine-2 phosphorylated CTD of RNA pol II and bind to the conserved 
poly(A) signal on the RNA (Hsin and Manley, 2012). After cleavage of the RNA 10 - 35 
nucleotides downstream of the poly(A) signal the poly(A) polymerase (PAP) adds an 
adenosine tail of 200 - 250 residues. The poly(A) tail influences many aspects of 
mRNA metabolism such as transcription termination, mRNA stability, mRNA export and 
translation (Weill et al., 2012). As with splicing, transcripts can be alternatively 
polyadenylated and this contributes to gene expression by producing alternative protein 
isoforms or by altering stability or localisation of the mRNA (Di Giammartino et al., 
2011). 
After the pre-mRNA is processed into mature mRNA, it is exported via the nuclear 
pore complex into the cytoplasm. While many shorter RNAs such as micro (mi)RNAs 
and transfer (t)RNAs directly associate with export receptors, large RNAs such as 
mRNAs or ribosomal (r)RNAs assemble with RNA binding proteins into complexes that 
are then recognised by the RNA export machinery (Köhler and Hurt, 2007). Several 
proteins deposited during mRNA processing mediate the contact with the heterodimeric 
	   	  6 
mRNA export receptor TAP/p15. Among these proteins are the members of the exon-
junction complex, the TREX complex and also the cap-binding complex, the latter of 
which will be further discussed below (Hocine et al., 2010; Köhler and Hurt, 2007). 
 
1.1.3 Translation initiation 
Efficient translation of most mRNAs is dependent on the N7-methylguanosine cap, 
which is recognised by the eIF4F complex consisting of eIF4E, eIF4G and eIF4A. 
eIF4E binds the N7-methylguanosine cap and interacts with the scaffolding protein 
eIF4G, which has binding sites for the RNA helicase eIF4A and eIF3. eIF3 recruits the 
43S pre-initiation complex consisting of the 40S ribosomal subunit, the initiator 
methionyl tRNA (Met-tRNAiMet) and several translation initiation factors. After 
recruitment to the mRNA this translation pre-initiation complex scans for the AUG start 
codon that would base pair with Met-tRNAiMet. After removal of certain translation 
factors, the 60S ribosomal subunit joins to form the 80S initiation complex, which 
subsequently starts with the synthesis of the polypeptide (Jackson et al., 2010; 
Sonenberg and Hinnebusch, 2009). 
Although most mRNAs use the scanning mechanism described above, a subset of 
mRNAs can initiate translation in a cap-independent manner via secondary structures 
within their 5ʼ untranslated region (UTR) called internal ribosomal entry sites (IRES). It 
is thought that low levels of IRES-mediated translation may occur for mRNAs with 
highly structured 5ʼ UTRs under normal growth conditions, however efficient IRES-
mediated translation is supported when cap-dependent translational initiation is 
compromised during mitosis or following various stress conditions such as viral 
infections, apoptosis, heatshock or hypoxia (Komar and Hatzoglou, 2011; Spriggs et 
al., 2010). IRES-mediated translation initiation is cap-independent since the 43S 
initiation complex is directly recruited to structured RNA elements in proximity of the 
start codon. IRESs have been discovered and extensively studied in viruses, in which 
	   	  7 
certain IRESs can directly recruit the 43S initiation complex whereas others depend on 
translation initiation factors such as eIF4G, eIF4A and eIF3 (Balvay et al., 2009). 
Cellular IRESs generally require IRES-trans-acting-factors (ITAFs) to attain a structure 
that is competent to recruit the ribosomal subunits. However, little is currently known 
about the mechanics underlying cellular IRES function and it can be assumed that 
several different mechanisms exist since the structures of cellular IRES are very 
diverse (Komar and Hatzoglou, 2011). 
 
1.1.4 Protein post-translational modifications 
Once synthesised, the function of many polypeptides is regulated by post-
translational modifications (PTMs). PTMs are highly diverse with well over 200 different 
PTMs identified by mass spectrometry. Some PTMs are chemical modifications 
including protein phosphorylation, acetylation, methylation and glycosylation. However, 
proteins are not only modified by the addition of small chemical moieties but can also 
be targeted for the attachment of small modifier proteins such as ubiquitin, small-
ubiquitin-like modifier (SUMO) or other ubiquitin-like proteins. PTMs can alter protein 
functions in a dynamic manner by changing catalytic activity, subcellular localisation, 
stability or the interactions with other proteins. Some PTMs, such as glycosylation, are 
stable modifications required for protein maturation and folding. Others are reversible, 
dynamic modifications that can be added in response to intracellular or extracellular 
stimuli via the action of signalling pathways (Deribe et al., 2010). 
Protein phosphorylation is a ubiquitous PTM used in many signal transduction 
pathways (Cohen, 2002; Deribe et al., 2010). Signalling pathways can be activated by 
nutrients, growth factors, hormones, cell cycle progression, stress and other signals, 
and serve to transduce or amplify intracellular or extracellular stimuli in order to control 
a cellular response. The addition of phosphate groups to protein substrates is 
catalysed by protein kinases of which there are more than 518 in the human genome 
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(Manning et al., 2002; Martin et al., 2009). Most eukaryotic protein kinases are 
structurally similar and possess a conserved catalytic domain that contains an 
adenosyl triphosphate (ATP) binding pocket. Kinases phosphorylate proteins by 
binding to ATP and the protein substrate and catalysing the transfer of the ATP γ-
phosphate to the hydroxyl group of Serine, Threonine or Tyrosine residues in the 
protein substrate (Endicott et al., 2012; Ubersax and Ferrell, 2007). Although kinases 
share a common catalytic fold, they differ in charge and hydrophobicity of the surface 
residues. Therefore, kinases bind to specific protein substrates and for specific kinases 
consensus sequences can be determined around the phosphorylation site (Endicott et 
al., 2012; Ubersax and Ferrell, 2007). The action of kinases can be opposed by protein 
phosphatases that remove phosphate groups from protein substrates. 
 
1.1.5 Nuclear protein import 
Following synthesis in the cytoplasm, many polypeptides require translocation into 
the nucleus in order to reach their sites of function. Proteins greater than 40 kDa 
depend on active transport across the nuclear envelope through the nuclear pore 
complex. Karyopherins such as importins and exportins mediate nuclear trafficking of 
proteins by directly recognising specific nuclear localisation signals (NLSs) or nuclear 
export signals. Classical NLSs consist of one or two clusters of basic amino acids, 
which are recognised by Importin-α (Dingwall et al., 1982; Kalderon et al., 1984). 
Importin-α itself consists of three structural units: a central NLS-binding domain, an N-
terminal Importin-β binding (IBB) domain and a C-terminal domain of unknown function. 
The central NLS-binding domain consists of a tandem series of 10 Armadillo repeats 
that generate a bent molecule which binds to classical NLSs (Conti and Kuriyan, 2000; 
Conti et al., 1998; Fontes et al., 2000). The IBB domain mediates the interaction with 
Importin-β but, via a cluster of positively charged amino acids resembling a NLS, also 
competes with cargos for binding to the NLS-binding site of Importin-α when 
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dissociated from Importin-β (Kobe, 1999). Importin-β consists of 19 - 20 helical HEAT 
repeats that are arranged into a ring-like structure which binds the Importin-α IBB 
domain (Cingolani et al., 1999). 
Once Importin-α is bound to the NLS-containing cargo and to Importin-β, the 
complex is transported to the nucleus through interactions between Importin-β and the 
nuclear pore complex. Binding of Importin-β by nuclear Ran-GTP induces a 
conformational change that results in dissociation of Importin-α from Importin-β 
(Goldfarb et al., 2004; Stewart, 2007). Once free from Importin-β, the IBB domain of 
Importin-α competes for binding to the NLS binding site and together with interactions 
of nucleoporins with Importin-α causes the release of the cargo from of Importin-α 
(Gilchrist et al., 2002; Matsuura and Stewart, 2005; Matsuura et al., 2003). Finally, 
Importin-β bound to Ran-GTP and Importin-α bound to the nuclear export factor CAS 
and Ran-GTP are transported back to the cytoplasm. There, RanGAP stimulates GTP 
hydrolysis that releases Ran from Importin-β and CAS and thus freeing the Importins 
(Stewart, 2007). 
In addition to the Importin-α/β system recognising classical NLSs there are several 
other nuclear transport pathways recognising non-classical NLSs. Non-classical NLS, 
such as the PY-NLS, have diverse amino acid sequences that are directly recognised 
by different Importin-β family members (Xu et al., 2010). Since Importin-β directly binds 
non-classical NLSs there is no requirement for Importin-α adaptors in these nuclear 
import pathways. 
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1.2 Formation of the N7-methylguanosine cap 
 
1.2.1 The N7-methylguanosine cap structure 
The N7-methylguanosine cap was first identified in viral RNA (Furuichi and Miura, 
1975; Furuichi et al., 1975a) and subsequently also described in HeLa mRNA (Furuichi 
et al., 1975b). It consists of an inverted guanosine group that is linked via a 5ʼ to 5ʼ 
triphosphate bridge to the first transcribed nucleotide and is methylated at the N7 
position (Figure 1.1a). The N7-methylguanosine cap is found on all eukaryotic RNA pol 
II transcripts and on eukaryotic viral RNA but it is absent in bacteria and archea 
(Shuman, 2001).  
The N7-methylguanosine cap structure described above is called Cap0. In addition, 
further methylated cap structures have been identified in HeLa cells with methylation at 
the 2ʼ-O ribose position of the first and second transcribed nucleotides termed Cap1 
and Cap2 respectively (Figure 1.1b) (Furuichi et al., 1975b). Cap1 and Cap2 structures 
are only found in higher eukaryotes, including insects and vertebrates, and are absent 
in yeast (Furuichi and Shatkin, 2000). The enzymes catalysing 2ʼ-O ribose methylation, 
hMTr1 and hMTr2, have been only recently identified and the exact functions of the 
Cap1 and Cap2 structures are still to be determined (Bélanger et al., 2010; Werner et 
al., 2011). 
An alternate methyl cap structure has been described for small nuclear RNAs 
(snRNAs) that carry methylations on the positions 2,2,7 of the terminal guanosine 
resulting in a trimethylguanosine cap (Reddy et al., 1992). snRNAs are transcribed by 
RNA pol II and thus are initially capped with a N7-methylguanosine. However, following 
their assembly into small ribonucleoproteins (snRNPs) in the cytoplasm the cap 
becomes further methylated leading to a trimethyl guanosine cap, which is required for 
the nuclear import of snRNPs (Shaw et al., 2008). 
Figure 1.1 The structure of the N7-methylguoanosine cap (Cap0), Cap1 and 
Cap2. !
a) The N7-methylguaonsine cap (Cap0) consists of a inverted guanosine group 
that is linked via a triphosphate bridge to the first transcribed nucleotide and is 
methylated at the N7-position. The Cap0 structure is conserved from yeast to man.!
b) In higher eukaryotes, Cap1 or Cap2 structures have been identified. In addition 
to the methylation at the N7 guanosine position, the Cap1 structure is methylated 
at the 2ʼ-O ribose of the first transcribed nucleotide and the Cap2 structure is 
further methylated at the 2ʼ-O ribose of the second transcribed nucleotide.!
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The work presented in this thesis focuses on the N7-methylguanosine cap (Cap0) 
and thus the rest of the introduction describes the function of the N7-methylguaosine 
cap structure. 
 
1.2.2 Enzymology of N7-methylguaonosine cap synthesis 
The synthesis of the N7-methylguanosine cap requires a series of three enzymatic 
activities. First, an RNA triphosphatase removes the γ-phosphate from the triphosphate 
end of RNA pol II transcripts, yielding in a diphosphorylated 5ʼ end (pppN  ppN). 
Following this, a guanylyltransferase catalyses the addition of a guanosine 
monophosphate (GMP) to the diphosphate end of the RNA producing the guanosine 
cap (ppN  GpppN). Finally, the guanosine cap is methylated at the N7-position by an 
RNA guanine-7 methyltransferase completing the formation of the N7-methylguanosine 
cap (GpppN  m7GpppN) (Figure 1.2) (Furuichi and Shatkin, 2000). The cap 
methyltransferase does not methylate free GTP but is only active towards guanosine 
triphosphate linked to an RNA molecule (Cowling lab, unpublished observations). While 
the guanylylation reaction is reversible, the triphosphatase and methyltransferase 
reactions are not (Shatkin, 1976). 
N7-methylguaonosine cap formation occurs in all eukaryotes, including eukaryotic 
viruses. Initial insights into cap synthesis were obtained from studying viral systems. 
However, for the purpose of this thesis this introduction focuses and eukaryotic cell 
systems. 
In the budding yeast Saccharomyces cervisiae, the three enzymatic activities 
required for N7-methylguaonosine cap synthesis reside within three separate 
polypeptides (Mao et al., 1995; Shibagaki et al., 1992; Tsukamoto et al., 1997) and the 
same is true for the fission yeast Schizosaccharomyces pombe (Pei et al., 2001; Saha 
et al., 1999; Shuman et al., 1994). The triphosphatases Cet1p and Pct1, the   
Figure 1.2 Reactions that are required for N7-methylguanosine cap synthesis.!
The synthesis of the N7-methylguanosine cap is described in the main text. This 
figure lists the enzymatic reactions on the left and graphically illustrates the 
reaction products on the right. The activities responsible for the reaction catalysis 
are indicated next to the arrows. The name of the actual mammalian enzyme is 
indicated in brackets.!
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guanylyltransferases Ceg1p and Pce1p and the RNA guanine-7 methyltransferases 
Abd1p and Pcm1p in S. cervisae and S. pombe respectively, are all essential for cell 
viability in yeast. 
In contrast to yeast, metazoans possess a two-component system in which the 
triphosphatase and guanylyltransferase activities are combined into a single protein, 
whereas the RNA guanine-7 methyltransferase exists as a separate polypeptide. In 
mammals the bifunctional capping enzyme is called RNA guanylyltransferase and 
triphosphatase (RNGTT) (Pillutla et al., 1998a; Yamada-Okabe et al., 1998; Yue et al., 
1997) and the methyltransferase is termed RNA guanine-7 methyltransferase (RNMT) 
(Pillutla et al., 1998a, 1998b; Saha et al., 1999; Tsukamoto et al., 1998). The capping 
machinery is functionally conserved from single-cell to multicellular organisms. Yeast 
deletion mutants can be rescued by their mammalian orthologues and the yeast 
capping system can be completely replaced by the mammalian enzymes (Saha et al., 
1999; Yamada-Okabe et al., 1998; Yue et al., 1997). As in yeast, the human capping 
enzymes are essential for cell viability (Chu and Shatkin, 2008; Shafer et al., 2005) 
demonstrating the importance of the N7-methylguanosine cap and indicating that no 
other triphosphate, guanylyltransferase or methyltransferase can compensate for the 
loss of RNGTT and RNMT in cells. 
In mammalian cells RNMT was demonstrated to exist in a complex with a 14 kDa 
protein termed RNMT activating miniprotein (RAM) (Gonatopoulos-Pournatzis et al., 
2011). RAM was described as an obligate component of the mammalian cap 
methyltransferase complex and is required for normal cap methylation and gene 
expression. The RAM N-terminus interacts with the catalytic domain of RNMT and 
increases cap methyltransferase activity up to five-fold. In addition to the RNMT-
interaction domain, RAM contains an RNA-binding domain and enhances RNA 
recruitment to RNMT. However, the RNA-binding domain is not required for RNMT 
activation suggesting that binding of RAM to RNMT induces a conformational change 
	   	  15 
that leads to increased cap methyltransferase activity (Gonatopoulos-Pournatzis et al., 
2011). 
 
1.2.3 The mechanics of N7-methylguanosine cap formation 
Structural data on the yeast and mammalian capping machinery has revealed the 
mechanics of capping in further detail. In metazoans, the bifunctional capping enzyme 
RNGTT consist of a N-terminal triphosphatase domain (1-210) and a C-terminal 
guanylyltransferase domain (211-597) (Ho et al., 1998; Yamada-Okabe et al., 1998; 
Yue et al., 1997). The first step of N7-methylguanosine cap formation is the removal of 
the terminal phosphate group of the pre-mRNA by an RNA triphosphatase. Sequence 
and crystal structure analysis demonstrated that the RNA triphosphatase is not 
conserved amongst eukaryotes (Changela et al., 2001; Lima et al., 1999). The crystal 
structure of the mouse RNA triphosphatase domain revealed that it functions in a 
metal-independent way, whereby a cysteine phosphatase motif HCxxxxxR(S/T) (x is 
any amino acid) forms a phospho-enzyme intermediate during ATP hydrolysis 
(Changela et al., 2001). The active site pocket of the RNA triphosphatase domain can 
accommodate a triphosphate group but is too deep to allow diphosphate or 
monophosphate groups to assess the active site, thus providing substrate specificity 
towards the triphosphate 5ʼ ends of pre-mRNA. 
The second step in the capping process is the addition of an inverted guanosine 
group to the 5ʼ end of the diphosphate RNA. The crystal structures of the 
guanylyltransferase from several organisms, including the human RNGTT 229-567 
domain, revealed that the active sites are structurally related in eukaryotes (Chu et al., 
2011; Fabrega et al., 2003; Gu et al., 2010; Hâkansson and Wigley, 1998; Håkansson 
et al., 1997). Insights into the mechanism of the guanylylation reaction were obtained 
from crystal structures of viral and fungal enzymes. The addition the guanosine cap 
occurs in two steps. Firstly, the GTP covalently binds to a Lysine within the 
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guanylyltransferase active site forming an enzyme-GMP intermediate. GTP-binding 
causes a conformational change, which after release of the pyrophosphate exposes 
the RNA binding site and subsequently allows GMP transfer onto the diphosphate RNA 
(Fabrega et al., 2003; Hâkansson and Wigley, 1998; Håkansson et al., 1997). 
The final step in N7-methylguaonsine cap synthesis is the methylation of the 
guanosine cap by the RNA guanine-7 methyltransferase. The crystal structure of the 
cap methyltransferase Ecm1 of the microsporidian parasite Encephalitozoon cuniculi 
has been solved alone and in complex with the methyl donor S-adenosyl-methionine 
(SAM), the methylation biproduct S-adenosyl-homocysteine (SAH) or with a cap 
analogue (m7GpppG) (Fabrega et al., 2004). Furthermore, the crystal structure of the 
catalytic domain of the human RNMT (165-476) in complex with SAH or with the 
methyltransferase inhibitor sinefungin has been deposited online by The Structural 
Gene Consortium (Wu et al., 2007; Zeng et al., 2008). These crystal structures 
demonstrate that the active site is conserved amongst eukaryotes and contains two 
separate ligand-binding pockets for the SAM methyl donor and the guanosine cap 
methyl acceptor. Moreover, the crystal structure of Ecm1 revealed that the cap 
methyltransferase does not directly bind the methyl donor or acceptor suggesting that 
the enzyme optimally orients the substrates to facilitate methyl transfer (Fabrega et al., 
2004). 
 
1.2.4 N7-methylguanosine cap formation occurs 
predominantly co-transcriptionally 
The formation of the N7-methylguanosine cap is the first pre-mRNA processing step 
and several studies demonstrated that this is a co-transcriptional event. In vivo labelling 
experiments with [3H] methyl-L-methionine and [32P] PO4 in Chinese hamster ovary 
cells demonstrated that transcripts shorter than 750 nucleotides (nt) carry a methylated 
cap structure (Salditt-Georgieff et al., 1980). Nuclear run-on reactions performed on 
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purified engaged polymerases at heat shock induced genes from Drosophila 
melanogaster nuclear extracts demonstrated that RNA as short as 20 - 30 nt was 
guanosine capped (Rasmussen and Lis, 1993).  
In vitro transcription experiments with HeLa nuclear extracts demonstrated that 
transcripts as short as 17 nt are not capped but those of 79 nt in length do carry a cap 
structure (Coppola et al., 1983). Another study found 15 nt long transcripts to be 
uncapped but 25 nt or longer transcripts were found to be capped (Moteki and Price, 
2002). Furthermore, pulse chase experiments revealed that capping occurs on 
transcripts of 25 - 35 nt in length and methylation of the cap follows when the 
transcripts reach a size of 35 nt (Moteki and Price, 2002). Two other independent 
studies found that in vitro transcribed RNA associated with the transcription complex as 
short as 22 - 24 nt in length can be efficiently capped in vitro (Chiu et al., 2002; Mandal 
et al., 2004).  
The suggestion that N7-methylguanosine cap formation is coupled to transcription 
came from two studies showing that both in vitro capping and methylation reactions of 
free RNA are much slower than that of RNA associated in transcription complexes 
(Jove and Manley, 1984; Moteki and Price, 2002). It was also observed that the 
inhibitory by-product of the methylation reaction, S-adenosylmethionine (SAH), inhibits 
in vitro transcription. 
All the above studies collectively demonstrate that N7-methylguanosine cap 
formation occurs very early during transcription, probably as soon as the transcript is 
long enough to reach the end of the exit channel of RNA pol II. The model of co-
transcriptional N7-methylguanosine cap formation is supported by reports studying the 
association of the capping machinery with chromatin and RNA pol II. Chromatin 
immunoprecipitation (ChIP) experiments in both yeast and human cells demonstrated 
that the capping enzymes accumulate at TSS (Glover-Cutter et al., 2008; Guiguen et 
al., 2007; Komarnitsky et al., 2000; Schroeder et al., 2000). However in contrast to 
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yeast, in human cells both RNGTT and RNMT were also crosslinked throughout the 
gene body and downstream of the poly(A) sites of the genes studied (Glover-Cutter et 
al., 2008). Furthermore, the capping machinery was found to be associated with the 
TSS at inactive gene promoters that are occupied by paused RNA pol II.  
ChIP experiments in yeast revealed that the recruitment of all three capping 
enzymes is dependent on the Serine-5 phosphorylated CTD of RNA pol II (Komarnitsky 
et al., 2000; Schroeder et al., 2000). Moreover, direct interactions of RNA pol II with 
capping enzymes have also been reported. Yeast guanylyltransferase and cap 
methyltransferase were shown to bind the phosphorylated CTD of RNA pol II, whereby 
the triphosphatase is recruited via binding to the guanylyltransferase (Cho et al., 1997, 
1998; McCracken et al., 1997). Furthermore, it was demonstrated that the CTD is 
required for efficient capping of RNA pol II transcripts (McCracken et al., 1997). A direct 
interaction of the mammalian RNGTT with phosphorylated CTD was also reported by 
several studies (Ho and Shuman, 1999; Ho et al., 1998; Yue et al., 1997) and the 
crystal structure of mouse RNGTT in complex with Serine-5 phosphorylated CTD of 
RNA pol II has been solved (Ghosh et al., 2011). Moreover, the Serine-5 
phosphorylated CTD of RNA pol II is not only required for the recruitment of RNGTT to 
TSS but also stimulates guanylyltransferase activity of RNGTT (Ho and Shuman, 
1999). Unlike in yeast, a direct interaction of the mammalian cap methyltransferase 
RNMT has not been reported despite exploiting yeast-two hybrid screens, 
immunoprecipitation studies, affinity purification experiments and SILAC analysis 
(Shatkin and Manley, 2000) (Cowling lab, unpublished data). However, a direct 
interaction of RNMT with RNGTT was observed with recombinant protein and a trimeric 
complex was detected when recombinant RNMT, RNGTT and cellular RNA pol II were 
incubated together in vitro (Pillutla et al., 1998b). Nonetheless, the exact mechanism of 
how mammalian RNMT is recruited to TSS in vivo remains to be determined. 
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The eukaryotic capping machinery mainly functions in the nucleus and 
immunofluorescence analysis of RNGTT and RNMT confirmed predominant nuclear 
localisation for both enzymes (Gonatopoulos-Pournatzis et al., 2011; Otsuka et al., 
2009; Wen and Shatkin, 2000). However, besides co-transcriptional addition of the N7-
methylguanosine cap, a subset of transcripts has been identified as a target for 
cytoplasmic capping. The initial indication for cytoplasmic capping originates from a 
study that observed the accumulation of truncated β-Globin mRNA harbouring 
premature termination stop codons (Lim and Maquat, 1992). The truncated mRNAs 
lacked parts of their 5ʼ ends but were found to have a N7-methylguanosine cap-like 
structure. A cytoplasmic cap methyltransferase activity was also detected in Xenopus 
laevis oocytes (Gillian-Daniel et al., 1998). Furthermore, an enzyme identical to RNGTT 
in complex with an unidentified kinase was identified at low levels in the cytoplasmic 
fraction of human cell lines (Otsuka et al., 2009). Although a cap methyltransferase 
was not detected in the complex, low levels of RNMT were observed in cytoplasmic cell 
extracts by western blot. This cytoplasmic capping complex was demonstrated to be 
able to phosphorylate the 5ʼ end of monophosphorylated RNAs and catalyse the 
addition of a GMP to the RNA 5ʼ terminus. Furthermore, cytoplasmic capping was 
found to enhance the survival of cells following stress. More recently, a report 
described a subset of mRNAs that depend on cytoplasmic capping for maintenance of 
their transcript levels and translational activity (Mukherjee et al., 2012). These 
cytoplasmic capping targets are enriched for transcripts coding for proteins associated 
with nucleotide binding, protein and RNA localisation, and the mitotic cell cycle. 
Furthermore, enrichment for micro RNA sites and AU-rich elements was detected in 
the 3ʼ UTR of these transcripts. However, the exact mechanism of how transcripts are 
recognised for cytoplasmic capping and its biological relevance remain unclear.  
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1.3 Regulation of N7-methylguoanosine cap 
formation in mammalian cells 
 
1.3.1 Co-transcriptional activation of the capping enzyme  
The guanylylation reaction catalysed by RNGTT occurs via an enzyme-GMP 
intermediate. Binding of the Serine-5 phosphorylated CTD of RNA pol II to the 
guanylyltransferase domain of RNGTT stimulates the formation of the enzyme-GMP 
intermediate and subsequently capping of RNA (Ho and Shuman, 1999; Wen and 
Shatkin, 1999). The extent of this activation was found to be directly proportional to the 
length of the CTD polypeptide ranging between 1.5 – 5.4-fold stimulation for 4 - 42 CTD 
heptad repeats. Experiments with differentially phosphorylated peptides demonstrated 
that this stimulatory effect only occurs with Serine-5 phosphorylated CTD but not 
Serine-2 phosphorylated CTD, despite the latterʼs ability to bind RNGTT (Ho and 
Shuman, 1999). Furthermore, RNGTT is activated by the interaction with the DSIF 
subunit Spt5, which was observed to stimulate enzyme-GMP complex formation by 
two-fold (Wen and Shatkin, 1999). Although Spt5 binds to both the triphosphatase and 
the guanylytransferase domain, only the latter is regulated by this interaction. The 
stimulatory effects of the Serine-5 phosphorylated CTD and Spt5 on RNGTT catalytic 
activity are not cumulative, and thus it is unclear whether RNGTT can bind to both 
proteins simultaneously. However, the requirement of RNA pol II and Spt5 for maximal 
RNGTT activity further supports the model of co-transcriptional capping. 
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1.3.2 Stimulation of the cap methyltransferase activity by 
the interaction with Importin-α  
A direct interaction of RNMT with components of the transcription apparatus has not 
been reported but the Importin-α family member KPNA2 was identified as an RNMT 
binding protein in a yeast-two-hybrid screen (Wen and Shatkin, 2000). Importin-α 
functions in nuclear protein import by binding the NLS of a polypeptide and interacting 
with Importin-β, which mediates the translocation across the nuclear envelope. The 
interaction of RNMT with KPNA2 was confirmed by co-immunoprecipitations in HeLa 
cells, along with pull-down experiments with recombinant RNMT and in vitro translated 
35S-labelled KPNA2. Truncation mutants were used to map the binding domains, which 
revealed that RNMT 96-144 and KPNA2 455-496 are essential for the interaction 
between the two proteins. RNA band shift assays demonstrated that RNMT specifically 
binds to RNA containing a 5ʼ GpppG but not to m7GpppG, whereby KPNA2 increases 
RNA recruitment to RNMT. Furthermore, full length KPNA2 was found to stimulate 
RNMT catalytic activity by up to 10-fold, whereas KPNA2 1-455, which did not bind to 
RNMT, did not alter RNMT activity. Incubation with Importin-β did not abolish the 
interaction between KPNA2 and RNMT, but it did inhibit the stimulatory effect of 
KPNA2 on RNA recruitment and RNMT activity. This was further supported by the 
observation that Ran-GTP, but not Ran-GDP, could reverse this inhibitory effect of 
Importin-β. The biological significance of a regulation of RNMT catalytic activity by 
KPNA2 remains unclear and it is unknown whether it occurs in vivo. 
 
1.3.3 Accumulation of incompletely capped mRNAs under 
stress and normal growth conditions 
The N7-methylguanosine cap is added by the sequential activities of a 
triphosphatase, a guanylyltransferase and a methyltransferase. It has long been 
thought that a complete N7-methylguanosine cap is constitutively added to the 5ʼ 
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termini of all freshly synthesised RNA pol II transcribed RNA. However, recent 
evidence suggests that this may not be the case. The Myc transcription factor was 
found to upregulate cap methylation of specific mRNAs in a transcription-independent 
manner in mammalian cells (Cole and Cowling, 2009; Cowling and Cole, 2007a). 
Moreover, amino acid or glucose starvation of yeast cells leads to accumulation of 
mRNAs lacking the methylated cap structure, which were found not to bind to an anti-
trimethylguanosine antibody column (Jiao et al., 2010). Furthermore, incompletely 
capped mRNAs were also detected under normal growth conditions both in yeast and 
mammalian cells. Unlike the canonical yeast decapping enzyme Dcp2 that targets 
methylated m7GpppN-capped RNA, the yeast decapping enzymes Rai1p and Dxo1p 
preferentially target unmethylated GpppN-capped RNA and thus form a quality control 
mechanism for mRNA 5ʼ ends (Chang et al., 2012; Jiao et al., 2010). In yeast Rai1p 
Dxo1p deletion strains total mRNA levels were found to be increased due to an 
accumulation of incompletely capped mRNAs (Chang et al., 2012). These incompletely 
capped RNA species failed to bind to an anti-trimethylguanosine antibody column but 
were resistant to exoribonucleolytic degradation by Xrn1, which targets 
monophosphorylated RNA, indicating that they either carry an unmethylated cap 
structure or a triphosphate group at their 5ʼ termini.  
When the mammalian homolog of the yeast decapping enzymes Rai1 and Dxo1, 
termed DXO, was depleted with siRNAs from HEK-293 cells, the levels of mature, 
spliced mRNA only increased modestly (Jiao et al., 2013). A more dramatic increase 
was observed in the levels of intron-containing pre-mRNA. Further analysis using an 
anti-trimethylguanosine antibody column demonstrated an increase of RNA lacking a 
methylated cap structure relative to total pre-mRNA in DXO-depleted cells. These 
results suggest that incompletely capped pre-mRNA is produced in human cells, 
however these RNA species are not efficiently processed into mature mRNA but 
instead are degraded by DXO.  
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1.3.4 Stimulation of N7-methylguanosine cap formation by 
regulators of cell proliferation 
There is an accumulation of evidence suggesting that the addition of the N7-
methylguanosine cap is not a constitutive but a regulated process. The detection of 
incompletely capped transcripts demonstrates that N7-methylguanosine cap formation 
does not always occur to completion. Moreover, the observation that RNAs lacking the 
methylated guanosine cap accumulate under nutritional stress suggests that growth 
factors can regulate N7-methylguanosine cap formation. Indeed, the transcription 
factors Myc and E2F1 were found to upregulate N7-methylguanosine cap formation of 
specific transcripts (Cole and Cowling, 2009; Cowling and Cole, 2007a). 
The proto-oncogenes Myc and E2F1 are upregulated in response to growth factors 
and are essential for cell proliferation and cell growth (Iaquinta and Lees, 2007; Meyer 
and Penn, 2008). The Myc family of transcription factors, consisting of N-Myc, c-Myc 
and L-Myc, are weak transcription factors which typically upregulate transcript levels by 
two-fold. A recent study suggested that rather than being an on/off specifier of 
transcription, c-Myc acts as a universal amplifier of expressed genes (Nie et al., 2012). 
Initially, it was reported that N-Myc increases translation of its target genes in a post-
transcriptional manner without elevating their mRNA levels (Cowling and Cole, 2007a). 
Further experiments revealed that this is achieved by increased expression of the 
kinases CDK7 and CDK9. ChIP experiments demonstrated that N-Myc also increases 
recruitment of TFIIH to transcription initiation sites, thus leading to increased 
phosphorylation of the CTD of RNA pol II. This is thought to be required for the 
recruitment of the capping machinery and immunoprecipitation experiments with an 
anti-trimethylguanosine antibody indeed showed elevated N7-methylguanosine cap 
levels upon N-Myc-expression. c-Myc and E2F1 were also found to increase cap 
methylation of their target genes and for most genes investigated this increase was 
more than the increase in total mRNA level (Cole and Cowling, 2009). Moreover, 
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elevated RNA pol II CTD phosphorylation was shown to be required for E2F1-
dependent upregulation of N7-methylguanosine cap levels, as treatment with the 
kinase inhibitor DRB was found to abolish this stimulation effect (Figure 1.3) (Aregger 
and Cowling, 2012). 
In addition to increasing Serine-5 phosphorylation of the RNA pol II CTD and 
presumably promoting recruitment of the capping machinery to transcription initiation 
sites, c-Myc also increases the expression of S-adenosyl homocysteine hydrolase 
(SAHH), which removes the inhibitory bi-product of the methylation reaction 
(Fernandez-Sanchez et al., 2009). Experiments with cells depleted of SAHH 
demonstrated that the upregulation of SAHH is required for c-Myc-induced mRNA cap 
methylation, protein synthesis, cell proliferation and cell transformation. Furthermore, 
treatment with tubercidin at a concentration that inhibits cap methylation but not 
transcription confirmed that increased cap methylation is required for Myc-induced cell 
proliferation and protein synthesis (Figure 1.3). 
 
1.3.5 RNMT overexpression promotes cap methylation of 
specific transcripts 
Exogenous Myc expression does not result in increased RNMT protein levels or 
RNMT catalytic activity (Cowling, 2010). However, overexpression of RNMT leads to 
increased cell transformation allowing human mammary epithelial cells to grow in an 
anchorage-independent manner. Moreover, RNMT overexpression was found to 
increase Cyclin D1 protein expression by specifically elevating N7-methyguanosine cap 
levels on Cyclin D1 mRNA, while total Cyclin D1 mRNA levels did not change.  
  
Figure 1.3 Upregulation of N7-methylguanosine cap synthesis by Myc and 
E2F1. !
Formation of the N7-methylguanosine (m7G) cap occurs predominantly co-
transcriptionally and the recruitment of the the capping machinery is dependent on 
Serine-5 phosphorylated (P) RNA pol II CTD. Myc and E2F1 upregulate the m7G 
cap levels of specific target transcripts by increasing recruitment of TFIIH, which is 
responsible for Serine-5 phosphorylation of the CTD. Furthermore, Myc increases 
the expression of SAHH, an enzyme that removes the inhibitory byproduct of the 
methylation reaction, SAH, and thus Myc can promote the formation of m7G in a 
second manner.!
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The discovery of incompletely capped mRNAs, together with the observation that 
N7-methylguanosine cap levels of specific mRNAs are upregulated in response to 
RNMT, Myc or E2F1 overexpression, suggests that there is a distinct cellular pool of 
mRNA lacking a methylated cap structure. It therefore is possible that induction of N7-
methylguanosine cap formation is used to rapidly and specifically activate the 
expression of certain genes. 
 
 
1.4 Cap-binding proteins 
 
The N7-methylguanosine (m7G) cap functions in several aspects of gene 
expression including transcription, pre-mRNA processing, RNA export and translation. 
Cap-binding proteins that specifically recognise the methylated cap structure mediate 
many of these functions. The Cap-binding complex (CBC), eukaryotic initiation factor 
4E (eIF4E) and the poly(A) deadenylase (PARN) have been demonstrated to interact 
with the m7G cap. These cap-binding proteins will be briefly described below and their 
cap-mediated function will be explained in the subchapter 1.5. In addition to the above 
mentioned cap-binding proteins, other polypeptides have also been reported to bind 
the m7G cap, including the poly(A) binding protein C (PABPC), the RNA-binding 
protein Pumillo2 (Pum2) and the exon junction complex component Y14, but the 
binding specificity for the methylated cap structure or the biological function for these 
interactions in vivo remain unclear (Cao et al., 2010; Chuang et al., 2013; Khanna and 
Kiledjian, 2004). 
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1.4.1 The cap-binding complex (CBC) 
The cap-binding complex (CBC) consists of Cbp20 and Cbp80, 20 and 80 kDa in 
size respectively, and was first purified from HeLa cells using m7Gppp-sepharose 
(Izaurralde et al., 1994, 1995a). Crosslinking of RNA to the CBC in the presence of cap 
analogues demonstrated that CBC specifically binds to m7Gppp-RNA and not to other 
methylated cap structures (Izaurralde et al., 1994). The two components of the 
complex bind to RNA synergistically since neither of the subunits alone binds RNA 
efficiently (Izaurralde et al., 1994, 1995a; Kataoka et al., 1995). The crystal structure 
and mutational analysis of CBC revealed that the N7-methylguanosine-binding pocket 
resides solely in Cbp20, whereas Cbp80 stabilises structural changes required for 
binding to the methylated cap (Calero et al., 2002; Mazza et al., 2001, 2002).  
CBC is predominantly nuclear, however it is also thought to function in the 
cytoplasm (Izaurralde et al., 1995b). In yeast, CBC is not essential for cell viability but 
is required for cell growth (Abovich et al., 1994; Das et al., 2000; Fortes et al., 1999; 
Uemura and Jigami, 1992) and in mammalian cells depletion of CBC by siRNAs also 
results in reduced cell proliferation (Narita et al., 2007; Pabis et al., 2013). The 
essential role of CBC in gene expression will later be described in detail (subchapter 
1.5). 
mTOR is a kinase that acts in the PI3K signal transduction pathway and integrates 
nutrient, growth factor, energy and stress signals to regulate cell growth and 
proliferation (Zoncu et al., 2011). CBC can be regulated by the mTOR pathway: 
orthophosphate labelling experiments demonstrated that Cbp80 is phosphorylated 
upon stimulation by growth factors and this phosphorylation is blocked by Rapamycin, 
an inhibitor of mTOR complex 1 (mTORC1) (Wilson et al., 2000). Cpb80 was found to 
be phosphorylated in vitro by S6 kinase, an mTORC1 target, which was found to 
elevate the cap-binding affinity of CBC (Wilson et al., 2000). 
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1.4.2 The eukaryotic initiation factor 4E (eIF4E) 
Soon after its identification, the m7G cap was revealed to be essential for translation 
and thus it was tested whether translation initiation factors bind to it. A 24 kDa protein, 
that was later named eIF4E, was identified to specifically bind to the methylated cap 
structure and was purified from both human and yeast cells (Altmann et al., 1985, 
1987; Sonenberg et al., 1978, 1979). eIF4E has been co-crystallised with a cap 
analogue and biophysical studies confirmed a specific association with the methylated 
cap structure (Marcotrigiano et al., 1997; Niedzwiecka et al., 2002). eIF4G, a scaffold 
polypeptide, interacts with eIF4E and stimulates its cap binding affinity by an allosteric 
activation mechanism (Gross et al., 2003; Haghighat and Sonenberg, 1997). 
The translation initiation complex, termed eIF4F, consists of eIF4E, eIF4G and the 
RNA helicase eIF4A. The eIF4F complex recruits the 43S initiation complex containing 
the small ribosomal subunit to the mRNA (Sonenberg and Hinnebusch, 2009). Thus the 
binding of the eIF4F complex is essential for initiation of translation of most mRNAs. 
Overexpression of eIF4E causes tumorigenic transformation of fibroblasts and 
promotes tumour formation in mice (Lazaris-Karatzas et al., 1990; Ruggero et al., 
2004). In mammalian cells eIF4E is phosphorylated at Serine-209 by the mitogen-
activated protein kinases Mnk1 and Mnk2 (Waskiewicz et al., 1997). Mnk1 has been 
shown to be recruited via its interaction with eIF4G (Pyronnet et al., 2001). 
Phosphorylation of eIF4E increases its affinity for the cap (Minich et al., 1994). 
Furthermore, eIF4E-promoted tumour formation in mice was found to be dependent on 
Serine-209 phosphorylation (Wendel et al., 2007). 
eIF4E function is negatively regulated via eIF4E-binding proteins (4E-BPs). 4E-BP1, 
2 and 3 comprise a family of low molecular weight proteins that bind to eIF4E and 
inhibit translation (Pause et al., 1994; Poulin et al., 1998). 4E-BPs compete with eIF4G 
for binding to eIF4E and thus inhibit cap-dependent translation by blocking eIF4F 
complex assembly (Haghighat et al., 1995; Mader et al., 1995; Marcotrigiano et al., 
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1999). 4E-BPs are hyperphosphorylated by mTORC1, which abolishes their interaction 
with eIF4E and increases cap-dependent translation (Beretta et al., 1996; Brunn et al., 
1997). In cells eIF4E and 4E-BPs are under homeostatic control, whereby 
overexpression of eIF4E induces dephosphorylation of 4E-BPs which in turn inhibits 
eIF4E activity (Khaleghpour et al., 1999). Furthermore, knockdown of eIF4E results in 
degradation of hyperphosphorylated 4E-BPs leading to only a minor decrease in 
translation (Yanagiya et al., 2012). Nevertheless, aberrant mTOR signalling can still 
lead to tumour formation via increasing eIF4E-mediated cap-dependent translation 
(Zoncu et al., 2011). 
 
1.4.3 PARN 
Deadenylation is the first step in mRNA decay and is catalysed by the poly(A)-
specific ribonuclease (PARN) (Garneau et al., 2007). PARN was found to interact with 
m7G capped RNA and this interaction could be abolished by the cap analogue 
m7GpppG, but not GpppG, suggesting that the interaction is specific (Dehlin et al., 
2000; Gao et al., 2000). Furthermore, experiments performed with HeLa cell extracts 
and Xenopous laevis oocytes demonstrated that capped RNA is deadenylated more 
efficiently than uncapped RNA and the m7GpppG analogue abolishes this 
deadenylation in vitro (Dehlin et al., 2000; Gao et al., 2000; Martinez et al., 2000). 
Recently, the crystal structure of PARN in complex with m7GpppG was solved and 
mutational analysis demonstrated that the residues involved in cap binding are 
essential for cap-stimulated deadenylation activity (Wu et al., 2009). 
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1.5 Functions of the N7-methylguanosine cap in gene 
expression 
 
The m7G cap is conserved in eukaryotes and is essential for cell viability from yeast 
to man. Functions of the m7G cap in eukaryotic gene expression are diverse and some 
of them are species-specific. The m7G cap is involved in RNA stability, transcription, 
splicing, 3ʼ end processing, RNA export, translation and miRNA biogenesis, where 
most of its functions are mediated via the cap-binding proteins described above. This 
subchapter aims to give an overview about the effects of the 5ʼ cap on gene 
expression. 
 
1.5.1 The N7-methylguanosine cap stabilises RNA 
One of the first observed functions of the m7G cap is its ability to increase RNA 
stability. Injection of capped or uncapped RNA into X. laevis oocytes demonstrated that 
RNA with a m7GpppG or GpppG structure at its 5ʼ end is more stable than uncapped 
RNA (Furuichi et al., 1977; Green et al., 1983). Furthermore, the same result was 
obtained when capped RNA or RNA treated with tobacco acid phosphatase (TAP), 
which removes the cap structure by hydrolysing the pyrophosphate bond, was 
incubated in wheat germ extracts (Furuichi et al., 1977; Shimotohno et al., 1977). 
ApppG capped RNA is as stable as m7GpppG capped RNA indicating that the cap 
could act as blocking structure preventing exoribonucleolytic degradation (Inoue et al., 
1989). This was confirmed by a study where capped but not uncapped RNA was 
protected from an exoribonuclease purified from HeLa nuclear extracts (Murthy et al., 
1991). Furthermore, incubation with m7GpppG cap analogues, which compete for 
binding to cap-binding proteins, did not destabilise the capped transcripts. This 
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suggests that the cap structure on its own is sufficient to protect capped RNA from 
exoribonucleolytic attack and cap-binding proteins are not required for this effect.  
Another report found that m7GpppG capped transcripts are more stable than 
GpppG capped transcripts when electroporated into mouse cells, suggesting that the 
addition of the methyl group to the cap further prevents degradation (Grudzien et al., 
2006). Cap-binding proteins such as CBC and eIF4E specifically bind to the m7G cap 
and thus can increase RNA stability by competing with decapping enzymes (Jiao et al., 
2013; Schwartz and Parker, 2000). Furthermore, eIF4E and CBC can also protect the 
m7GpppG-RNA from deadenylation. PARN was found to bind and deadenylate m7G 
capped RNA more efficiently than uncapped RNA (Dehlin et al., 2000; Gao et al., 2000; 
Martinez et al., 2000). The addition of eIF4E to this reaction inhibited deadenylation 
suggesting that eIF4E competes with PARN for binding to the m7G cap. Furthermore, 
CBC directly interacts with PARN and this interaction was found to inhibit PARN 
deadenylation activity (Balatsos et al., 2006). The guanylyltransferase activity of the 
capping enzyme is reversible whereas cap methylation is not (Shatkin, 1976). 
Therefore, another explanation for increased stability of m7GpppG capped RNA is that 
methylation prevents the reversibility of the capping reaction and thus stops formation 
of uncapped RNA, which can be rapidly degraded. 
The influence of the m7G cap on endogenous transcripts was studied in the yeast S. 
cerevisiae using temperature-sensitive mutants of the guanylyltransferase Ceg1p. 
Mutation of Ceg1p reduced total transcript levels of various genes as detected by 
northern blotting (Fresco and Buratowski, 1996; Schwer and Shuman, 1996; Schwer et 
al., 1998). This phenotype was rescued in a Ceg1p Xrn1p double mutant lacking both 
the guanylyltransferase and the 5ʼ to 3ʼ exoribonuclease XRN1 indicating that 
uncapped transcripts are normally degraded by XRN1 (Schwer et al., 1998). 
Mutation of the S. cerevisiae cap methyltransferase Abd1p also reduced transcript 
levels but the reduction was gene-specific and not as strong as in the Ceg1p mutant 
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(Schwer et al., 2000). Interestingly, the loss of mRNA levels in Abd1p mutated cells 
was partially rescued in mutants lacking the decapping enzyme Rai1p, which 
preferentially targets unmethylated GpppG-RNA for degradation (Jiao et al., 2010). 
This further confirms that the observed increase in stability of m7G capped RNA 
compared to unmethlyated guanosine capped RNA is due to its resistance to the 
decapping reaction. 
 
1.5.2 The role of the N7-methylguanosine cap in 
transcription 
ChIP experiments in yeast and mammalian cells demonstrated that CBC is localised 
at the 5ʼ ends of genes and within gene bodies (Glover-Cutter et al., 2008; Lahudkar et 
al., 2011; Listerman et al., 2006; Narita et al., 2007; Zenklusen et al., 2002). The CBC 
subunits Cbp20 and Cbp80 alone do not localise to chromatin but are recruited as a 
complex only (Lahudkar et al., 2011; Wong et al., 2007). Moreover, inhibition of cap 
methylation by deletion of the yeast cap methyltransferase Abd1p results in a reduced 
ChIP signal for CBC (Wong et al., 2007). These experiments suggest that CBC 
recruitment to chromatin is dependent on the m7G cap and that CBC binds to RNA co-
transcriptionally.  
In addition to this, there is also evidence that once recruited, CBC can also regulate 
transcription. In S. cervisiae, CBC interacts with the transcription factor Mot1p, which in 
a gene-specific way activates or represses formation of the transcription pre-initation 
complex (Lahudkar et al., 2011). Furthermore, CBC was reported to bind to the yeast 
homologues of the mammalian pTEFb kinase CDK9 and to CDK12, which are 
responsible for RNA pol II CTD Serine-2 phosphorylation (Hossain et al., 2013). 
Consistent with this, depletion of CBC decreased recruitment of these CDK complexes 
to expressed genes, which in turn lead to reduced transcription due to a reduction in 
Serine-2 phosphorylation levels (Hossain et al., 2013; Lidschreiber et al., 2013).  
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It is not clear whether CBC interacts with the mammalian homologue of Mot1p but 
studies in human cells showed that CBC also binds to pTEFb (Lenasi et al., 2011). 
pTEFb phosphorylates the RNA pol II CTD at Serine-2 and the Spt5 subunit of DSIF, 
which abolishes NELF/DSIF-mediated promoter proximal pausing of RNA pol II and 
thus promotes transcription elongation. Depletion of CBC resulted in reduced pTEFb 
recruitment to promoters, a reduction in Serine-2 phosphorylation and accumulation of 
RNA pol II within gene bodies. Thus CBC can promote transcription elongation in both 
yeast and mammalian cells. 
In addition to CBC-mediated effects, the mammalian capping enzyme, RNGTT, was 
found to promote transcription elongation in vitro (Mandal et al., 2004). The addition of 
RNGTT to paused transcription complexes was found to overcome NELF-mediated 
repression of transcription. This effect is independent of RNGTT catalytic activity and 
may be mediated by the interaction of RNGTT with Spt5 (Wen and Shatkin, 1999).  
An interaction of Spt5 with the capping enzymes was also detected in yeast and was 
found to be essential for the recruitment of the capping machinery to chromatin 
(Lidschreiber et al., 2013; Lindstrom et al., 2003; Pei and Shuman, 2002). Furthermore, 
in S. pombe the RNA triphosphatase and cap methyltransferase were found to bind to 
CDK9 and deletion of the cap methyltransferase resulted in decreased Serine-2 
phosphorylation and promoter-proximal stalling of RNA pol II (Guiguen et al., 2007; Pei 
et al., 2003; St Amour et al., 2012). In addition, the S. cerevisiae cap methyltransferase 
was found to act independently of its catalytic activity as a gene-specific transcription 
factor required for RNA pol II recruitment and promoter clearance (Schroeder et al., 
2004).  
All the above demonstrates, that the capping machinery as well as the m7G cap via 
CBC promote transcription elongation and therefore the capping process may act as a 
quality checkpoint avoiding transcription elongation of uncapped RNA. 
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1.5.3 CBC is required for efficient pre-mRNA splicing 
Pre-mRNA often contains non-coding intronic sequences that are removed co-
transcriptionally by splicing. The effect of the m7G cap on pre-mRNA splicing has been 
extensively studied. In initial experiments, splicing was assessed by incubating in vitro 
transcribed capped and uncapped RNA with HeLa nuclear extracts (Edery and 
Sonenberg, 1985; Izaurralde et al., 1994; Konarska et al., 1984; Ohno et al., 1987; 
Patzelt et al., 1987). These experiments revealed that the m7G cap is required for 
splicing. Interestingly, for RNA containing two introns, only the splicing of the 5ʼ 
proximal intron was found to be dependent on the cap structure (Ohno et al., 1987).  
RNA carrying a methylguanosine (m7GpppG) and guanosine (GpppG) cap were 
both efficiently spliced when incubated with HeLa cell extracts (Edery and Sonenberg, 
1985; Ohno et al., 1987). However, when S-adenosyl homocysteine (SAH) was added 
to inhibit the methylation of GpppG-RNA, splicing of the guanosine capped RNA was 
inhibited suggesting that a methylated cap structure is required for splicing (Ohno et al., 
1987). Furthermore, the cap analogues m7Gppp and m7GpppG inhibit splicing more 
strongly than the GpppG analogue suggesting that the effect of the cap on splicing is 
dependent on a methylguanosine cap binding protein (Edery and Sonenberg, 1985; 
Izaurralde et al., 1994; Konarska et al., 1984; Ohno et al., 1987; Patzelt et al., 1987). 
Indeed, depletion of CBC from nuclear cell extracts strongly inhibited splicing 
(Izaurralde et al., 1994; Lewis et al., 1996). 
Microinjection of RNA into Xenopus laevis oocytes confirmed that splicing of the 5ʼ 
proximal intron is dependent on the cap structure (Inoue et al., 1989). Furthermore, co-
injection of antibodies against Cbp80 into X. laeavis oocytes reduced splicing 
demonstrating the requirement of CBC for splicing in vivo (Izaurralde et al., 1995a). 
The m7G cap and CBC were also found to enhance splicing in S. cerevisiae (Colot et 
al., 1996; Fresco and Buratowski, 1996; Lewis et al., 1996; Schwer and Shuman, 1996; 
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Schwer et al., 2000). Furthermore, splicing in Arabidopsis thaliana was also observed 
to be dependent on CBC (Laubinger et al., 2008). 
A recent study investigated the role of CBC in splicing in mammalian cells and 
identified a direct interaction of CBC with the spliceosomal small nuclear 
ribonucleoprotein particles U4/U6•U5 tri-snRNP (Pabis et al., 2013). This interaction 
was shown to be required for recruitment and assembly of the spliceosome. 
Furthermore, studies investigating the splicing of endogenous transcripts revealed that 
the m7G cap and CBC not only enhance splicing of the 5ʼ proximal intron, but also 
promote removal of downstream introns (Jiao et al., 2013; Pabis et al., 2013). 
However, only selected transcripts were investigated in this study and further 
experiments are required to determine whether this is a gene-specific or a global effect.  
Finally, along with constitutive splicing, CBC has also been reported to influence 
alternative splicing in both humans and plants (Lenasi et al., 2011; Raczynska et al., 
2010). It was demonstrated that CBC is required for the recruitment of the alternative 
splicing factor SRSF1 (Lenasi et al., 2011). 
 
1.5.4 CBC and pre-mRNA 3ʼ end processing 
Following transcription termination the 3ʼ end of the newly synthesised pre-mRNA is 
cleaved and a poly(A) tail is attached. The m7G cap has been reported to influence this 
3ʼ end processing event. Incubation of in vitro transcribed RNA with HeLa nuclear 
extracts or injection of RNA into X. laevis oocytes demonstrated that the m7G cap 
promotes RNA cleavage at the poly(A) site (Cooke and Alwine, 1996; Georgiev et al., 
1984; Gilmartin et al., 1988). A requirement for the m7G cap for 3ʼ end cleavage was 
also observed in HeLa cells where m7G-capped transcripts were found to be more 
efficiently cleaved at the poly(A) site than uncapped transcripts (McCracken et al., 
1997). The addition of the cap analogue m7GpppG inhibits 3ʼ end cleavage suggesting 
an involvement of a m7G cap-binding protein in this process (Cooke and Alwine, 1996). 
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Depletion of CBC from HeLa nuclear extracts was found to reduce mRNA 3ʼ end 
cleavage, which could be rescued by the addition of recombinant CBC, confirming that 
CBC is required for proper mRNA 3ʼ end processing in mammalian cells (Flaherty et 
al., 1997). 
Contrary to this, in yeast the m7G cap does not seem to be required for pre-mRNA 
3ʼ end cleavage since temperature-sensitive Ceg1p capping enzyme mutants showed 
no effect on polyadenylation (Fresco and Buratowski, 1996). Moreover, CBC was found 
to interact with Npl3p, which suppresses recruitment of 3ʼ end cleavage factors, and 
thus reduce termination of transcription at weak terminators (Wong et al., 2007). This 
suggests that the function of the CBC in processing the 3ʼ ends of pre-mRNA is not 
conserved in eukaryotes. 
Unlike other mRNAs, histone mRNAs are not polyadenylated but instead carry a 
conserved stem loop structure at their 3ʼ termini (Marzluff et al., 2008). CBC interacts 
with NELF-E and Ars2 that mediate recruitment of processing factors required for this 
stem loop formation (Gruber et al., 2012; Narita et al., 2007). siRNA-mediated depletion 
of CBC leads to aberrant polyadenylation of the histone mRNA, suggesting its direct 
involvement in the proper formation of histone mRNA 3ʼ ends (Narita et al., 2007). 
 
1.5.5 Involvement of CBC and eIF4E in snRNA and mRNA 
export 
After transcription by RNA pol II, mRNA and snRNA are exported to the cytoplasm 
where mRNA is translated, whereas snRNA is modified and assembled into snRNP 
complexes before translocating back into the nucleus. mRNA and snRNA are exported 
via two different pathways, both of which involve CBC. 
Injection of snRNA into X. laevis oocytes demonstrated that snRNA export requires 
the m7G cap and is mediated by CBC (Hamm and Mattaj, 1990; Izaurralde et al., 1992, 
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1995a). snRNA bound by CBC was reported to be exported in a complex with the 
adaptor protein PHAX (Ohno et al., 2000). In the nucleus, PHAX is phosphorylated and 
forms an export complex with the export receptor CRM1 (Exportin-1), Ran-GTP and 
snRNA-bound CBC (Kitao et al., 2008; Ohno et al., 2000). The complex is exported in 
a Ran-GTP-dependent manner to the cytoplasm where PHAX is dephosphorylated, 
which causes disassembly of the complex and release of the snRNA into the 
cytoplasm. CBC was also found to interact with Importin-α and in vitro studies revealed 
that CBC, capped-RNA and Importin-α form a complex which is disrupted upon binding 
by Importin-β (Dias et al., 2009; Görlich et al., 1996). Inhibition of the interaction 
between Importin-α and Importin-β resulted in the accumulation of microinjected 
snRNA in the nucleus of X. laevis oocytes (Görlich et al., 1996). However, it is unclear 
whether the interaction of CBC with Importin-α and Importin-β is essential for the export 
of snRNA in vivo. 
Similar to snRNA, the export of microinjected mRNA in X. laevis oocytes is 
dependent on the m7G cap and is inhibited by cap analogues (Cheng et al., 2006; 
Dargemont and Kühn, 1992; Jarmolowski et al., 1994). Experiments in mammalian 
cells demonstrated that CBC interacts with Aly/REF, which is a component of the TREX 
complex (Cheng et al., 2006). The TREX complex interacts with the heterodimeric 
export receptor of mRNA transport, TAP/p15 (Köhler and Hurt, 2007). TREX was found 
to be most efficiently recruited to spliced mRNA, which is therefore exported more 
efficiently than unspliced RNA (Cheng et al., 2006). Moreover, RNA lacking introns is 
also exported in a cap-dependent manner and this was also found to depend on the 
interaction of CBC with Aly/REF (Nojima et al., 2007). Although the bulk of mRNA is 
exported in a CBC-dependent manner via the TREX/TAP pathway other TAP-mediated 
mRNA export pathways do exist. Furthermore, a subset of mRNAs containing AU-rich 
elements in their 3ʼ UTRs is exported via a CRM1-dependent pathway (Culjkovic-
Kraljacic and Borden, 2013). 
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snRNA and mRNA both carry the m7G cap that is bound by CBC but are exported 
via two different pathways. A recent study revealed that the RNA length is responsible 
for determining the export pathway (McCloskey et al., 2012). RNAs smaller than 200 - 
300 nt are bound by the nuclear RNA binding protein hnRNP C, which abolishes the 
interaction of PHAX with CBC and selects the TREX/TAP pathway. 
In addition to CBC, eIF4E was also demonstrated to promote mRNA export. It was 
observed that eIF4E enhances gene-specific nuclear export of mRNAs harbouring a 
conserved structural motif in their 3ʼ UTR, such as Cyclin D1 mRNA (Culjkovic et al., 
2006; Rousseau et al., 1996). eIF4E-mediated export of mRNAs occurs in a cap-
dependent manner as a mutant unable to bind to the m7G cap could not promote 
mRNA export (Culjkovic et al., 2006). Furthermore, addition of promyelocytic leukemia 
protein (PML), which reduces eIF4E affinity for the cap, also inhibited eIF4E-mediated 
mRNA export (Cohen et al., 2001; Culjkovic et al., 2006). An eIF4E mutant unable to 
function in translation initiation could still promote mRNA export suggesting that the 
function of eIF4E in mRNA export is independent of its function in translation (Culjkovic 
et al., 2006). In contrast to the bulk of mRNA export, eIF4E-mediated mRNA export is 
CRM1-dependent but the exact mechanism is unclear.  
In yeast, the bulk of mRNA export does not depend on the m7G cap since Ceg1p 
mutants did not display altered RNA distribution between the nucleus and the 
cytoplasm (Fresco and Buratowski, 1996). This indicates that the mechanics of RNA 
export are not conserved in all eukaryotes. However, it should be noted that these 
results were obtained by fluorescence microscopy analysis at rather low resolution. 
 
1.5.6 The N7-methylguanosine cap is required for eIF4E-
mediated translation initiation 
From yeast to man, the m7G cap is essential for translation of most mRNAs. 
Removal of the cap structure from in vitro transcribed RNA abolishes translation in 
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wheat germ cell-free systems (Muthukrishnan et al., 1975; Shimotohno et al., 1977; 
Zan-Kowalczewska et al., 1977). Unmethylated capped RNA added to wheat germ 
extracts was only translated upon the addition of the methyl donor S-adenosyl 
methionine (SAM), whereas translation of methylated RNA did not depend on SAM 
(Both et al., 1975). Furthermore, incubation with the methylation inhibitor S-adenosyl 
homocysteine (SAH) inhibited protein synthesis from unmethylated capped RNA but 
not of methyl-capped RNA, indicating that the methylation of the cap is essential for 
protein synthesis. Finally, the addition of a cap analogue to wheat germ or HeLa cell 
extracts inhibited translation and association of ribosomal proteins with the mRNA 
(Hickey et al., 1976; Weber et al., 1976). 
The m7G cap was also found to be required for translation in vivo. Temperature-
sensitive mutants of the S. cervisiae capping enzyme Ceg1p exhibit near loss of 
translation at the restrictive temperature (Schwer et al., 1998). However, this was 
accompanied with a strong reduction in transcript levels due to instability of the 
uncapped mRNA. Contrary to this, the reduction in transcript levels was less prominent 
in temperature-sensitive mutants of the cap methyltransferase Abd1p. However, 
protein synthesis was nearly abolished in both mutants, thus confirming the function of 
the methylated cap in translation. 
Furthermore, microinjection of in vitro transcribed RNA into X. laevis oocytes 
demonstrated that m7GpppG capped RNA is translated more efficiently than GpppG 
capped or uncapped RNA (Drummond et al., 1985; Gillian-Daniel et al., 1998). 
Furthermore, the cap analogue m7GpppG but not ApppG inhibited protein synthesis 
suggesting an involvement of a methyl cap-binding protein in the process (Gillian-
Daniel et al., 1998).  
The cap-binding protein eIF4E was found to stimulate the translation of m7GpppG 
capped but not uncapped RNA in cell-free systems suggesting that eIF4E mediates the 
role of the m7G cap in translation (Sonenberg et al., 1979, 1980). eIF4E is responsible 
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for the recruitment of eIF4G and eIF4A to the 5ʼ end of mRNA, thus forming the eIF4F 
complex (Lamphear et al., 1995; Mader et al., 1995). eIF4A is an ATP-dependent RNA 
helicase that unwinds secondary structures in the RNA and this activity is required for 
efficient translation (Edery et al., 1984; Koromilas et al., 1992). The scaffolding protein 
eIF4G interacts with eIF4E, eIF4A, eIF3 and the poly(A)-binding protein (PABP) 
(Gingras et al., 1999; Hentze, 1997).  
The eIF4F complex is required for the recruitment of the translation initiation 
complex containing the 40S ribosomal subunit and several translation factors. This is 
mediated by interaction of eIF4G with eIF3, which is part of the 43S initiation complex 
(Sonenberg and Hinnebusch, 2009; Topisirovic et al., 2011). Furthermore, the eIF4F 
complex also promotes translation via its interaction with PABP. PABP interacts with 
the poly(A) tail and eIF4G, which in turn stabilises the association of eIF4E with the cap 
(Kahvejian et al., 2005) and circularises the mRNA (Wells et al., 1998). The formation 
of a closed loop, by linking the cap with the poly(A) tail, is believed to increase 
translation by enhancing recycling of ribosomes on the mRNA and thus facilitating 
translation re-initiation (Sonenberg and Hinnebusch, 2009; Topisirovic et al., 2011). 
However, not all mRNAs are equally dependent on eIF4E-mediated translation 
initiation (Hsieh et al., 2012; Thoreen et al., 2012). eIF4E function can be inhibited by 
eIF4-BPs, which in an unphosphorylated state bind to eIF4E and inhibit its ability to 
interact with eIF4G (Sonenberg and Hinnebusch, 2009; Topisirovic et al., 2011). ATP 
site-specific inhibition of the kinase mTOR, which is responsible for phosphorylation of 
eIF4-BPs, was found to reduce global protein synthesis. However, ribosome profiling 
demonstrated that the translation of a subset of mRNAs was much more impaired than 
that of others (Hsieh et al., 2012; Thoreen et al., 2012). These mRNAs were shown to 
harbour a 5ʼ terminal oligopyrimidine tract (TOP) and further experiments found the 
translation of these 5ʼ TOP mRNAs to be particularly dependent on the interaction of 
eIF4G with eIF4E. 
	   	  41 
 
1.5.7 CBC-mediated pioneer round of translation 
The majority of translation is dependent on eIF4E but the translation of m7G capped 
mRNA can also be mediated by CBC, which is referred to as the pioneer round of 
translation. As opposed to eIF4E-mediated steady-state translation, which functions to 
generate large amount of protein, the CBC-mediated pioneer round of translation is 
thought to serve as a quality control mechanism coordinating nonsense-mediated 
mRNA decay (NMD) (Maquat et al., 2010; Topisirovic et al., 2011). NMD is a 
translation-dependent surveillance pathway that recognises and degrades aberrant 
mRNAs harbouring a premature termination stop codon (Schweingruber et al., 2013). 
The mechanism of CBC-mediated translation initiation is not completely clear and is 
disputed in the field. CBC, similarly to eIF4E, was found to interact with eIF4G in yeast 
and mammalian cells (Chiu et al., 2004; Fortes et al., 2000; Lejeune et al., 2004; 
McKendrick et al., 2001). However, this interaction could not be confirmed by other 
studies and instead it was reported that CBC binds to CTIF, which contains a domain 
also found in eIF4G (Choe et al., 2012; Kim et al., 2009). CTIF was found to interact 
directly with eIF3g, which is part of the eIF3 complex responsible for the recruitment of 
the small ribosomal subunit (Choe et al., 2012). The depletion of CTIF from cell 
extracts selectively inhibited the translation of CBC-bound mRNA while the addition of 
recombinant CTIF restored CBC-mediated translation in vitro (Kim et al., 2009). 
Furthermore, CTIF knockdown caused a redistribution of CBC from polysomal to 
subpolysomal fractions in human cells (Choe et al., 2012; Kim et al., 2009).  This 
suggests that CBC may mediate translation initiation by interacting with CTIF that 
recruits the eIF3 complex containing the 40S ribosomal subunit. 
After mRNA export into the cytoplasm, translation promotes the removal of several 
nuclear mRNPs, such as the exon-junction complex or PABPN1. However, the 
exchange of CBC by eIF4E is independent of translation and seems to depend on the 
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interaction of CBC with the nuclear protein import machinery (Sato and Maquat, 2009). 
Inhibition of the binding of Importin-β to Importin-α resulted in the accumulation of 
CBC-bound mRNA and reduced binding of mRNA to eIF4E. 
The detailed mechanism and the portion of mRNA that undergoes a pioneer round 
of translation remain unclear. Furthermore, the exclusive role of the pioneer round of 
translation in quality control has been questioned since it was revealed that nonsense-
mediated mRNA decay (NMD) not only occurs in connection with CBC-mediated 
translation (Ishigaki et al., 2001; Lejeune et al., 2002) but also during any round of 
translation including eIF4E or IRES-mediated translation (Durand and Lykke-Andersen, 
2013; Maderazo et al., 2003; Rufener and Mühlemann, 2013). 
 
1.5.8 CBC is required for miRNA biogenesis 
miRNAs are 21 – 23 nt short RNAs that function to silence expression of specific 
genes in animals and plants. miRNA genes are transcribed by RNA pol II as primary 
miRNA (pri-miRNA), which carry a m7G cap and a poly(A) tail. pri-miRNA folds back 
into stem loop structures, which are cleaved by Drosha in the nucleus producing pre-
miRNA and are then processed into short miRNAs by Dicer in the cytoplasm. miRNAs 
bind to Ago and are incorporated into the RNA-induced silencing complex (RISC), 
which by pairing with complementary mRNA sequences induces translational 
repression or degradation of the bound mRNA (Bartel, 2009). 
CBC was found to interact with Ars2, which is required for miRNA biogenesis 
(Gruber et al., 2009; Sabin et al., 2009). Gel shift assays performed with HeLa nuclear 
extracts demonstrated that Ars2 exists in a complex with CBC and m7G capped RNA 
in vivo (Gruber et al., 2009). siRNA-mediated depletion of CBC in mammalian and fly 
cells resulted in a reduction of miRNA-mediated silencing (Gruber et al., 2009, 2012; 
Sabin et al., 2009). Northern-blot analysis revealed a reduction of pri-miRNA levels, 
suggesting that CBC might stabilise the miRNA precursors. In plants, miRNA 
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biogenesis was impaired upon deletion of the CBC, however pri-miRNA levels 
accumulated which suggests a defect in miRNA processing (Laubinger et al., 2008). In 
agreement with this observation, Ars2 was found to interact with Drosha, and this may 
explain how CBC promotes processing of miRNAs (Gruber et al., 2009; Sabin et al., 
2009). However, the exact details of how CBC regulates miRNA biogenesis remain 
unclear. 
miRNAs act by repressing translation and inducing subsequent mRNA degradation. 
miRNA-mediated repression of translation occurs during the translation initiation step 
by interfering with the function of the eIF4F initiation complex (Meijer et al., 2013). Not 
surprisingly, miRNA silencing of several reporter constructs and in vitro transcribed 
RNA was found to be dependent on the m7G cap whereas IRES-mediated translation 
was resistant to miRNA-mediated translation inhibition (Iwasaki and Tomari, 2009; 
Iwasaki et al., 2009; Pillai et al., 2005; Thermann and Hentze, 2007) 
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1.6 Decapping and RNA degradation 
The regulation of mRNA stability is an essential step in gene expression since the 
steady state level of mRNA is determined not only by transcription but also by mRNA 
degradation. The removal of the cap structure by decapping enzymes plays a critical 
role in mRNA decay. The bulk of mRNA decay initiates with the shortening of the 
poly(A) tail followed by exoribonucleolytic degradation of the mRNA either in 3ʼ to 5ʼ or 
5ʼ to 3ʼ direction (Garneau et al., 2007). In the 3ʼ to 5ʼ directed mRNA decay, the mRNA 
is degraded by the exoribonuclease complex, called the exosome, which functions both 
in the cytoplasm and the nucleus (Chlebowski et al., 2013). The exosome degrades 
most of the mRNA leaving a short, capped oligonucleotide behind, which after 
decapping can be degraded completely. In contrast, the 5ʼ to 3ʼ mRNA decay initiates 
with the decapping step, which is then followed by mRNA degradation by 
exoribonucleases such as the cytoplasmic XRN1 and the nuclear XRN2 (Nagarajan et 
al., 2013). 
Five different decapping enzymes have been identified in yeast. The decapping 
scavenger enzyme, DcpS, was found to be associated with the exosome and is 
involved in the 3ʼ to 5ʼ mRNA decay pathway (Wang and Kiledjian, 2001). DcpS has 
decapping activity against capped RNA shorter than 10 nt and it hydrolyses the 
methylated cap structure releasing m7Gp (Liu et al., 2002). 
In contrast to the 3ʼ to 5ʼ pathway, decapping enzymes involved in the 5ʼ to 3ʼ 
pathway target longer RNA oligonucleotides. The Dcp2p/Dcp1p complex hydrolyses 
the cap of m7GpppG-RNA longer than 25-29 nt in length into m7Gpp (Dunckley and 
Parker, 1999; LaGrandeur and Parker, 1998; Steiger et al., 2003). Dcp2p alone 
possesses decapping activity, but this is strongly stimulated by the interaction with the 
cofactor Dcp1p. The Dcp2p/Dcp1p complex localise to P-bodies, which are discrete 
foci in the cytoplasm where mRNA decay occurs (Sheth and Parker, 2003). 
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Furthermore, Ddp1p, the yeast homologue of mammalian Nudt3, was recently found to 
be able to decap m7G capped RNA in vitro producing m7Gp and m7Gpp, however this 
activity was not investigated in vivo (Song et al., 2013). 
Two yeast decapping enzymes were found to exhibit stronger decapping activity 
towards unmethylated compared to methylated caps. Rai1p functions in the nucleus 
together with the exoribonuclease Rat1p, a homologue of mammalian XRN2 (Xiang et 
al., 2009; Xue et al., 2000). It has both decapping and pyrophosphatase activities, but it 
preferentially targets unmethylated capped RNA and cleaves off the entire cap 
structure, (m7)GpppG (Jiao et al., 2010; Xiang et al., 2009). The second enzyme, 
Dxo1, is active in the cytoplasm and possesses both decapping and exoribonuclease 
activity (Chang et al., 2012). Similar to Rai1p, Dxo1p exhibits stronger decapping 
activity against unmethylated capped RNA and also removes the entire cap structure. 
Both Rai1p and Dxo1p are thought to function in a quality control mechanism targeting 
mRNAs carrying an aberrant cap structure (Chang et al., 2012; Jiao et al., 2010). 
Most of the yeast decapping activities are conserved in mammalian cells. As in 
yeast, DcpS hydrolises the m7G cap structure from short oligonucleotides following 3ʼ 
to 5ʼ degradation by the exosome (Liu et al., 2002; Wang and Kiledjian, 2001). 
Dcp2, the human homologue of the yeast Dcp2p, interacts with Dcp1 and 
preferentially targets methylated capped RNA and catalyses the release of (m7)Gpp 
and monophosphorylated RNA (van Dijk et al., 2002; Lykke-Andersen, 2002; Wang et 
al., 2002). It is mainly cytoplasmic and accumulates in foci, presumably P-bodies 
(Lykke-Andersen, 2002; Wang et al., 2002). However, recently the Dcp2/Dcp1 complex 
was also found to associate with the exoribonuclease XRN2 in the nucleus, where it 
functions to release mRNA from prematurely terminated transcription complexes and 
possibly limit bidirectional transcription (Brannan et al., 2012).  
Dcp2 expression seems to be tissue-specific but another decapping enzyme, 
Nudt16, was found to be expressed in all tissues (Song et al., 2010). Nudt16 is a 
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cytoplasmic enzyme that targets both methylated and unmethylated capped RNA 
catalysing the release of (m7)Gp and m7Gpp (Song et al., 2010, 2013). Nudt16 is a 
member of the Nudix hydrolase family, which consists of several other proteins 
demonstrating in vitro decapping activity (Song et al., 2013). These include Nudt2, 
Nudt3, Nudt12, Nudt15, Nudt17 and Nudt19. 
DXO, the mammalian homologue of the yeast Rai1p and Dxo1p, has decapping, 
pyrophosphatase and exoribonucleotase activities (Jiao et al., 2013). DXO exhibits 
stronger decapping activity towards unmethylated compared to methylated capped 
RNA and it hydrolyses the entire cap structure releasing (m7)GpppG. Similar to yeast 
Rai1p and Dxo1p, DXO is involved in a 5ʼ quality control pathway targeting aberrantly 
capped RNA lacking a functional m7G cap.  
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1.7 Summary and aims of this thesis 
 
The N7-methylguanosine (m7G) cap structure added to the 5ʼ end of RNAs 
transcribed by RNA pol II is conserved from yeast to man. The m7G cap is essential for 
cell viability as it is involved in several steps of eukaryotic gene expression. Most of the 
effects are mediated via CBC and eIF4E that bind to the m7G cap (Figure 1.4). 
The m7G cap is added to the 5ʼ ends of RNA Pol II transcripts co-transcriptionally 
and in mammalian cells the two enzymes RNGTT and RNMT are required for its 
synthesis. RNGTT catalyses the addition of an inverted guanosine group to the first 
transcribed nucleotide, whereas RNMT methylates the cap at the N7 position. Although 
the capping enzymes were discovered in the 1990s in yeast and subsequently 
identified in mammalian cells, the mechanistic details and the regulation of m7G cap 
formation remain elusive. RNMT consists of a catalytic domain and an N-terminal 
domain that is yet to be characterised. This thesis aims to investigate whether the 
RNMT N-terminal domain has a biological function in human cells in order to gain 
better understanding of the mechanics of cap methylation. 
In contrast to previous theories, newly synthesised RNA pol II transcripts are not 
constitutively capped but the formation of the m7G cap is a regulated process. Several 
studies reported the finding of incompletely capped transcripts lacking the methyl 
moiety on the cap structure (Chang et al., 2012; Cole and Cowling, 2009; Cowling and 
Cole, 2007b; Fernandez-Sanchez et al., 2009; Jiao et al., 2010, 2013). Furthermore, it 
was shown that growth factors and transcription factors essential for cell growth and 
proliferation can stimulate the synthesis of m7G caps (Aregger and Cowling, 2012; 
Cole and Cowling, 2009; Cowling and Cole, 2007b; Fernandez-Sanchez et al., 2009; 
Jiao et al., 2010). Recent studies suggested that m7G cap formation could potentially 
by targeted for cancer therapeutics: deregulated RNMT expression can induce  
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Figure 1.4 Summary of the functions of the N7-methylguanosine cap.!
This schematic diagram depicts the functions of the N7-methylguasnosine cap in 
eukaryotic gene expression. Most of the listed functions are mediated by the two 
cap-binding proteins, CBC and eIF4E. In the nucleus, CBC promotes transcription, 
pre-mRNA splicing and 3ʼ end processing, miRNA biogenesis as well as snRNA 
and mRNA export. After mRNA export, CBC mediates the pioneer round of 
translation in the cytoplasm. eIF4E promotes the export of specific mRNAs and in 
the cytoplasm is required for cap-dependent steady state mRNA translation. The 
N7-methylguasnosine cap structure itself stabilises RNA which is further promoted 
by the binding of CBC or eIF4E to the cap. Transcription can be promoted by the 
capping enzymes (e.g. RNGTT) independently of their catalytic activity.!
RNGTT! Transcription!
!
48!
	   	  49 
oncogenic cell transformation in cell culture (Cowling, 2010). Moreover, inhibition of cap 
methylation is synthetically lethal with c-Myc overexpression and can abolish c-Myc 
induced cell transformation (Fernandez-Sanchez et al., 2009). Therefore, this thesis 
aims to further elucidate the regulation of m7G formation and in particular aims to 
investigate whether RNMT is regulated by signalling pathways. 
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Chapter 2:                                                       
Material and Methods 
 
 
2.1 Material 
 
2.1.1 Laboratory equipment 
40C Axivert microscope (Zeiss) 
Bioruptor (Diagenode) 
Cell Countess (Invitrogen) 
Centrifuge Avanti J26 (Beckman Coulter) 
Centrifuge 5415R (Eppendorf) 
Centrifuge Allegra X-22R (Beckman Coulter) 
Ettan IPGphor isolectric focusing system (Amersham) 
FACS Calibur (Becton Dickinson) 
iQ5 RTPCR (BioRad) 
Liquid Scintillation Analyser (Perkin Elmer)  
LSM 700 microscope (Zeiss) 
Mini Trans-Blot Cell (Bio-Rad).  
Mini-Protean Tetra Electrophoresis system (BioRad) 
Mini-Sub Cell GT Cell (Bio-Rad) 
phosphor screen (FujiFilm)  
Phosphorimager FLA-5100 (FujiFilm) 
Pipettes (Greiner) 
Plate reader (Versamax) 
Speed-vacum pump (SciQuip) 
Trans-Blot Cell (Bio-Rad) 
UV transilluminator (UVP) 
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2.1.2 Lab consumables 
Cell Lifter (Corning Incorporated) 
Eppendorf Tubes (Star Lab) 
Falcon Tubes (Greiner) 
Filter 45 µm (Sartorius) 
Filter Units (Thermo Scientific) 
Gel Loading Tips (Star Lab) 
Pipette Tips (Star Lab) 
Syringe needles (Terumo) 
 
2.1.3 Chemicals 
2-Mercaptoethanol (Sigma) 
3-(N-morpholino)propanesulfonic acid (MOPS) (VWR International) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) (Sigma) 
Acetic Acid (VWR International) 
Calcium Chloride (VWR International) 
Dithiothreitol (DTT) (Formedium) 
Ethanol (VWR International) 
Ethylene glycol tetraacetic acid (EGTA) (VWR International) 
Ethylenediamine tetraacetic acid (EDTA) (VWR International) 
Formaldehyde (Sigma) 
Glycerol (VWR International) 
Glycine (VWR International) 
Hydrochloric Acid (VWR International) 
Isopropanol (VWR International) 
Magnesium Chloride (VWR International) 
Methanol (VWR International) 
piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) (Sigma) 
Potassium Chloride (VWR International) 
Sodium Chloride (VWR International) 
Sodium Deoxycholate (Sigma) 
Sodium Dodecyl Sulfate (SDS) (Sigma) 
Sodium Fluoride (Sigma) 
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Sodium Hydroxide (VWR International) 
Tris-Base (VWR International) 
TritonX-100 (VWR International) 
Tween 20 (VWR International) 
Urea (Fisher Scientific) 
 
2.1.4 Mammalian cell culture and maintenance 
100 mm Petri Dishes (Helena) 
150 mm Petri Dishes (Helena) 
6-Well Plate (Greiner) 
Cover Glass 13 mm (VWR International) 
Cryovials (Alpha Labs) 
DAPI (Sigma) 
DPBS (Invitrogen) 
Dulbeccoʼs Modified Eagle Medium (DMEM) (Invitrogen) 
Dulbeccoʼs Modified Eagle Medium (DMEM) High glucose, pyruvate (Invitrogen) 
Dulbeccoʼs Modified Eagle Medium (DMEM) Methionine-, cysteine-free (Invitrogen) 
Dulbeccoʼs Modified Eagle Medium (DMEM) Sodium phosphate-free (Invitrogen) 
Dulbeccoʼs Modified Eagle Medium Nutrient Mixture F-12 HAM (Sigma) 
Epidermal Growth Factor (EGF) (Sigma) 
Fetal Bovine Serum (FBS) E.C. Approved (Invitrogen) 
Fetal Bovine Serum (FBS) E.C. Approved Dialysed (Invitrogen) 
G-418 (Geneticin) (ForMedium) 
GeneJuice Transfection Reagent (Novagen) 
Hydrocortisone (Sigma)  
Insulin Solution Human (Sigma) 
Lipofectamine 2000 (Invitrogen) 
Penicillin/Streptomycin (Invitrogen) 
Polybrene (Sigma) 
Puromycin (Sigma) 
Trypan Blue solution (0.4%) (Sigma) 
Trypsin-EDTA solution (Invitrogen) 
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2.1.5 Molecular biology 
[32P]-orthophosphate (Perkin Elmer) 
[γ- 32P]-ATP (Perkin Elmer) 
1 Kb DNA Ladder (Invitrogen) 
5x Green GoTaq reaction buffer (Promega) 
96-well PCR frame Plate (VWR International) 
Agarose (Invitrogen) 
All Restriction Enzymes (NE BioLabs) 
cDNA Synthesis Kit (Quanta Bioscience) 
Chromatin immunoprecipitation (ChIP) kit (Millipore) 
CIP alkaline phosphatase (NE BioLabs) 
DH5α Competent E.Coli Cells (DSTT) 
dNTPs (Promega) 
Ethidium Bromide (Sigma) 
Expand High Fidelity PCR System (Roche) 
GelRed (Biotium) 
Go Taq (Promega) 
PCR tubes (Axygen) 
Plasmid Maxi Kit (Qiagen) 
QIAprep Miniprep Kit (Qiagen) 
QIAquick Gel Extraction Kit (Qiagen) 
QIAquick PCR Purification Kit (Qiagen) 
QuickChange Site-directed Mutagenesis Kit (Stratagene) 
RNase A (Sigma) 
RNeasy Mini Kit (Qiagen) 
SYBR Green Fastmix IQ (Quanta Bioscience) 
T4 DNA Ligase (NE Biolabs) 
T4 Polynucleotide kinase (PNK) (NE BioLabs) 
Transcription Buffer (Promega) 
TRIzol Reagent (Invitrogen) 
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2.1.6 Biochemistry 
[35S] Protein Labelling Mix (Perkin Elmer) 
[α-32P]-GTP (Perkin Elmer) 
Ammonium Acetate (Ambion) 
DEPC-Water (Ambion) 
DMSO (Merck) 
DRB (Sigma)  
Nocodazole (Sigma) 
P1 nuclease (Sigma) 
Phenol/Chloroform Premixed with Isoamyl Alcohol (Ambion) 
Propidium iodide (Sigma) 
RNasin (Promega) 
RO-3306 (Merck) 
Roscovitine (Sigma)  
S-Adenosyl-Methionine (Sigma) 
Saturated Phenol (Ambion) 
Sodium Acetate (Ambion) 
T7 RNA polymerase (Promega) 
Thymidine (Sigma) 
TLC PEI Cellulose F Sheets (Merck Milipore) 
tRNA (Sigma) 
 
2.1.7 Protein analysis 
40% Acrylamide : Bis-acrylamide 29:1 (Flowgen Biosciences) 
Ammonium Persulfate (APS) (Sigma) 
anti-FLAG antibodies conjugated to agarose (Sigma) 
anti-HA antibodies conjugated to agarose (Sigma) 
Aprotinin (Sigma) 
BenchMark Prestained Protein Ladder (Invitrogen) 
Bio-Rad Protein Assay (Bio-Rad) 
Bovine Serum Albumin (BSA) (NE BioLabs) 
Brilliant Blue g – Colloidal Concentrate (Sigma) 
CDK1/Cyclin B1 (NEB) 
DAPI Fluorescent Stain (Invitrogen) 
	   	  55 
Donkey Serum (Sigma) 
Dried Skimmed Milk (Marvel) 
Gradient SDS-PAGE 4-12% (Invitrogen) 
Hydromount (National diagnostics) 
Immobilon Transfer Membrane (Millipore) 
IPG strip with a pH range of pH 3-10 (BioRad) 
Leupeptin Hydrochloride (Sigma) 
NNNʼNʼ-Tetramethyletylenediamine (TEMED) (VWR International) 
NuPAGE 4-12% Bis-Tris Gel (Invitrogen) 
Pepstatin (Sigma) 
Phosphatase Inhibitor Cocktail 2 (Sigma) 
Phosphatase Inhibitor Cocktail 3 (Sigma) 
Protein A/G PLUS-Agarose (Santa Cruz Biotechnology) 
Salmon sperm DNA/Protein A agarose (Upstate) 
West Pico Chemiluminescent Substrate (of HRP) (Thermo Scientific) 
X-RAY FILM (Konica Minolta) 
 
2.1.8 Recombinant protein production 
BL21 CodonPlus (DE3)-RIL Competent E.coli Cells (Roche) 
BL21(DE3) Competent E.coli Cells (DSTT) 
Cuvettes (Sarstedt) 
Glutathione (VWR International) 
Glutathione Sepharose 4B (GE Healthcare) 
IMAC Sepharose High Performance (GE Healthcare) 
Imidazole (Sigma) 
LB medium (in house) 
Nickel Sepharose (GE Healthcare) 
Poly-Prep Chromatography Columns (Bio-Rad) 
PreScission Protease (Produced and provided by Daan Van Aaltenʼs lab) 
Slide-A-Lyzer Dialysis Cassette (Thermo Scientific) 
Snakeskin dialysis tubing 10,000 Mw (Thermo) 
Streptavidin Sepharose High Performance beads (GE Healtcare) 
Terrific broth (in house) 
Vivaspin 20 Concentrator (Sartorius Stedim) 
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2.1.9 Antibodies 
 
Table 2.1 List of primary antibodies employed in this study for western blot and 
immunoprecipitation analysis. The antibody name, the species in which the 
antibody was raised and the supplier are indicated. 
Antibody Species Supplier 
RNMT Sheep, polyclonal in house, DSTT 
RNMT pT77 Sheep, polyclonal in house, DSTT 
HA (H3663) Mouse, monoclonal, IgG1 Sigma 
RAM Sheep, polyclonal in house, DSTT 
RNGTT Sheep, polyclonal in house, DSTT 
β-Tubulin (sc-9104) Rabbit, polyclonal Santa Cruz 
RNA pol II PAN (sc-899) Rabbit, polyclonal Santa Cruz 
RNA pol II 3-3 PAN Mouse, monoclonal, IgG2a Dirk Eick Lab 
RNA pol II 3E10 pS2 Rat monoclonal, IgG1 Dirk Eick Lab 
RNA pol II H14 pS5/pS2 Mouse, monoclonal, IgM Covance 
RNA pol II 3E8 pS5 Rat monoclonal, IgG2a Chromotek 
Cyclin B1 Rabbit, monoclonal, IgG Cell Signalling 
Histone 3 pS10 Rabbit, monoclonal, IgG Abcam 
Cyclin D1 (2922) Rabbit, monoclonal, IgG Cell Signalling 
KPNA2 (PA5-21034) Rabbit, polyclonal Thermo 
9E10 Sheep, polyclonal in house, DSTT 
9E10 Mouse, monoclonal, IgG Santa Cruz 
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Table 2.2 List of HRP-conjugated secondary antibodies employed in this study 
for western blot analysis. The antibody name, the species in which the antibody 
was raised and the supplier are indicated. 
Antibody Supplier 
Rabbit anti-Sheep Thermo 
Goat anti-Mouse Thermo 
Goat anti-Rabbit Thermo 
Mouse anti-Sheep, light chain specific Jackson IR 
 
 
Table 2.3 List of primary antibodies employed in this study for 
immunofluorescence analysis. The antibody name, the species in which the 
antibody was raised and the supplier are indicated. 
Antibody Species Supplier 
HA  Sheep in house, DSTT 
RNMT Sheep in house, DSTT 
Tubulin Rat Abcam 
Lamin B1 Rabbit Abcam 
 
 
Table 2.4 List of fluorescent secondary antibodies employed in this study for 
immunofluorescence analysis. The antibody name, the species in which the 
antibody was raised and the supplier are indicated. 
Antibody Species Supplier 
Alexa 488 anti-Sheep Donkey Invitrogen 
Alexa 594 anti-Sheep Donkey Invitrogen 
Alexa 642 anti-Sheep Donkey Invitrogen 
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2.1.10 Peptides 
 
Table 2.5 Peptide sequences employed for peptide affinity purification. Peptides 
were purchased from GL Biochem. T* is the phosphorylated Threonine. 
Peptide Sequence 
T77 (4817) Biotin-C12-RKRKEFEDDLVKESSSCGKDTPSKKRKLDPEIVPE 
pT77 (4816) Biotin-C12-RKRKEFEDDLVKESSSCGKDT*PSKKRKLDPEIVPE 
 
 
2.1.11 Oligonucleotides 
 
Table 2.6 Oligonucleotide sequence of the siRNA employed in this study. The 
siRNA was purchased from Dharmacon. 
siRNA Sequence 
Human siRNMT GUUCUAAACUUGUCUCUGA 
 
 
Table 2.7 Oligonucleotide sequences employed for transcript analysis by RT-
PCR. The oligonucleotides were purchased from Eurofins MWG. The transcripts 
were amplified using each set of primers. 
Primer Sequence 
CCNE1 forward TGAAGCACTTCAGGGGCGTCG 
CCNE1 reverse TGCTCGGGCTTTGTCCAGCAA 
MCM2 forward ACCCCATAGGAGGGCGCTACG 
MCM2 reverse GGTCCACGGTGTCCCTCACCA 
PCNA forward TGAAGCACCAAACCAGGAGAAAGTT 
PCNA reverse ACGTGCAAATTCACCAGAAGGCA 
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TOP2A forward GATGCAGGGGGCCGAAACTCC 
TOP2A reverse CCCAACCACACCAAGGCCTGAA 
CCNF forward ACAAGACAGCCCCGACCCCC 
CCNF reverse GGCTGTTCTCCCGCTTCCGTT 
KPNA2 forward GAACGCAGTCGCCCTACAGCC 
KPNA2 reverse GGGAGAAAGCTGCGAAGCGGG 
STK15 forward GTCCCCTGTCGGTTCCTCCGT 
STK15 reverse TCGGTCCATGATGCCTCTAGCTGT 
CCNB2 forward GCAGTCCTAACGGCGCCTCG 
CCNB2 reverse ATCACTGGACACCGTCGGGC 
TKK forward CCGGTTCACTTGGGCATTTACAGA 
TKK reverse CTTGTGGTGGCATGTTCTCTCCAT 
PRC1 forward TCGGGGCCGTGTGGAGTAGG 
PRC1 reverse TCCGCCAGCACCTCACTTCT 
TROAP forward AGGGGCCTCGGTAAGCCATCA 
TROAP reverse CAGTGGGGAAAGGCGTGCGT 
CCND1 forward GCTGGAGGTCTGCGAGGAACA 
CCND1 reverse GGCGGCTCTTTTTCACGGGC 
NME1 forward TCATGCAAGCTTCCGAAGATC 
NME1 reverse GCCCTGAGTGCATGTATTTCAC 
RuvBL1 forward CATTGGGCTGCGAATAAAG 
RuvBL1 reverse TCTGTCTCACACGGAGTT 
NPM1 forward GAAGAGGAGGAGGATGTG 
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NPM1 reverse TTCTGTGGAACCTTGCTA 
c-Myc forward TCTGAGGAGGAACAAGAA 
c-Myc reverse GAAGGTGATCCAGACTCT 
RNMT 5ʼUTR forward TGGGTACTGTACAACTTCAAG 
RNMT 5ʼUTR reverse TTCAATGACTTTGTGAAGC 
RNMT forward ATTCACTATCACGACGATT 
RNMT reverse GTACTGATATTGCCGATGT 
 
 
Table 2.8 Oligonucleotide sequences employed for ChIP analysis by RT-PCR. 
The oligonucleotides were purchased from Eurofins MWG. The DNA segments 
were amplified using each set of primers. 
ChIP-Primer Sequence 
RNMT TSS forward TGAGTGTGACGGCTGGAACTC (+27) 
RNMT TSS reverse CACGCGTTGGGTAGTGAAG (+164) 
RuvBL1 TSS forward TGTGGCCAGTGGACC (+247) 
RuvBL1 TSS reverse ACTTCCCTGAGGAAATAATGG (+374) 
CCND1 TSS forward AGCTGCCCAGGAAGAGC (+186) 
CCND1 TSS reverse CCGCCTTCAGCATGG (+312) 
c-Myc TSS forward GCACTGGAACTTACAACACC (+390) 
c-Myc TSS reverse ATCCAGCGTCTAAGCAGC (+531) 
c-Myc -2000 forward AAGACGCTTTGCAGCAAAATC 
c-Myc -2000 reverse AGGCCTTTGCCGCAAAC 
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Table 2.9 Oligonucleotide sequences employed for site-directed mutagenesis. 
The oligonucleotides were purchased from Eurofins MWG. The constructs were 
prepared using each set of primers. 
Mutagenesis-Primer Sequence 
RNMT WBL forward AGCCATATCCTGCAAATGAGTCCAGCAAGTTAGTCAGCGAGAAGGTGGATGACTATGAACATGCAGC 
RNMT WBL reverse ATGTTCATAGTCATCCACCTTCTCGCTGACTAACTTGCTGGACTCATTTGCAGGATATGGCTCCAAG 
 RNMT 5A forward GCAAAAGCGGCAGTGAATGCTGAAGCAGAGGCTGCATTCAATATTAATG 
RNMT 5A reverse GAATGCAGCCTCTGCTTCAGCATTCACTGCCGCTTTTGCCTGTTCAAG 
RNMT 2A forward GGGAAAGACGCTCCAGCCAAGAAGAGAAAACTTGATCCTGAAATTGTCCC 
RNMT 2A reverse CAGGATCAAGTTTTCTCTTCTTGGCTGGAGCGTCTTTCCCACAACTAG 
RNMT T77A forward AGTTCTAGTTGTGGGAAAGACGCTCCATCCAAGAAGAGAAAACTTGATCC 
RNMT T77A reverse TGGGACAATTTCAGGATCAAGTTTTCTCTTCTTGGATGGAGCGTCTTTCC 
RNMT T77D forward AGTTCTAGTTGTGGGAAAGACGATCCATCCAAGAAGAGAAAACTTGATCCA 
RNMT T77D reverse TGGGACAATTTCAGGATCAAGTTTTCTCTTCTTGGATGGATCGTCTTTCC 
RNMT S79A forward AGTTCTAGTTGTGGGAAAGACACTCCAGCCAAGAAGAGAAAACTTGATCC 
RNMT S79A reverse TGGGACAATTTCAGGATCAAGTTTTCTCTTCTTGGCTGGAGTGTCTTTCC 
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Table 2.10 Oligonucleotide sequences employed for cloning. The 
oligonucleotides were purchased from Eurofins MWG. The constructs were 
prepared using each set of primers. 
Cloning primer Sequence 
HA-RNMTcat forward ACAGGATCCATGTACCCATACGATGTTCCAGATTACGCTGATGGCACTCAAAATAAGAGA 
HA-RNMTcat reverse ACACTCGAGTCACTGCTGTTTCTCAAAGG CAAA 
HA-RNMT-N forward ACAGGATCCATGTACCCATACGATGTTCCAGATTACGCTGCAAATTCTGCAAAAGCA 
HA-RNMT-N reverse ACACTCGAGTCATCCAGTAGAAGATTTATCT 
6xHIS-RNMT_KasI forward ACAGGCGCCATGGCAAATTCTGC 
6xHIS-RNMT_BamHI reverse ACAGGATCCCTGCTGTTTCTCAAAGGC 
 
 
2.1.12 Buffers and solutions 
 
F buffer: 
10 mM Tris (pH 7.05), 50 mM NaCl, 30 mM Na pyrophosphate, 50 mM NaF, 10% 
Glycerol, 0.5% Triton X-100 
Buffer A:  
20mM HEPES – KOH (pH 7.5), 1.5 mM MgCl2, 10 mM KCl, 1mM EDTA, 1mM 
EGTA 
RIPA buffer: 
25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% 
SDS 
SDS running buffer: 
25 mM Tris, 250 mM glycine, 0.1% SDS 
Transfer buffer: 
25 mM Tris, 192 mM glycine, 20% methanol 
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TBST: 
25 mM Tris (pH 8.1), 155 mM NaCl, 0.1% tween 20 
4x Laemmli buffer: 
240 mM Tris, 8% SDS, 40% glycerol, bromophenol blue, 100 mM DTT 
RNGTT buffer: 
50 mM Tris (pH 7.5), 5.5 mM DTT, 1.25 mM MgCl2 
MT assay buffer: 
50 mM Tris (pH 8.0), 6 mM KCl, 1.25 mM MgCl2 
2x HEPES-buffered saline (HBS):  
50 mM HEPES (pH 7.05), 1.5 mM Na2HPO4, 275 mM NaCl 
TAE buffer: 
40 mM Tris (pH 8.0), 40 mM acetic acid, 1 mM EDTA 
TBE buffer: 
89 mM Tris (pH 8.0), 89 mM boric acid, 2.5 mM EDTA  
PHEM: 
60 mM PIPES, 27 mM HEPES, 10 mM EGTA, 8.22 mM magnesium sulphate 
Abdil: 
25 mM Tris (pH 8.1), 155 mM NaCl, 0.25 % Tween 20, 0.2% BSA, 0.1 % sodium 
azide  
2D Lysis Buffer: 
8M urea, 4% CHAPS, 40 mM Tris 
2D rehydration solution: 
7M urea, 2M thiourea, 1.2% CHAPS, 0.4% ASB-14, 0.25% ampholytes, 65 mM DTT 
2D SDS equilibration solution 1: 
50 mM Tris (pH 8.8), 6M Urea, 30% glycerol, 2% SDS, bromophenol blue, 
containing DTT 
2D SDS equilibration solution 2: 
50 mM Tris (pH 8.8), 6M Urea, 30% glycerol, 2% SDS, bromophenol blue, 135 mM 
iodoacetamide  
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2.2 Methods 
 
2.2.1 Cell culture and maintenance 
Cells were maintained at 37 °C under humidified atmosphere containing 5% CO2 in 
γ-sterilised tissue culture treated plastic ware. Cells were grown to near confluence in 
10 cm dishes and then sub-cultured by removing the old media, washing with PBS and 
treating with trypsin solution to detach the cells. Cells were diluted in fresh medium and 
seeded at 5 x 105 cells per 10 cm dish. Trypsinised IMEC cells were resuspended in 
DMEM supplemented with 10% FBS and centrifuged for 3 minutes at 1,800 rpm before 
diluting the cells in DMEM F-12 HAM medium. 
 
Table 2.11 Cell lines employed for the purpose of this study. The cell line origin 
and a brief description of their maintenance are indicated. 
Cell line Origin Maintenance 
HEK 293 Human embryonic kidney cells 
Adherent cells maintained in DMEM 
supplemented with 10% FBS, 2 mM L-
glutamine and 1mM Sodium Pyruvate 
HeLa Human cervical epithelial carcinoma 
Adherent cells maintained in DMEM 
supplemented with 10% FBS and 2 mM 
L-glutamine 
IMEC 
Human immortalised 
mammary epithelial 
cells 
Adherent cells maintained in DMEM 
nutrient mixture F-12 HAM 
supplemented with L-glutamine, 5 μg/ml 
insulin, 10 ng/ml EGF and 0.5 μg/ml 
hydrocortisone 
Aʼ Human embryonic kidney cells 
Adherent cells maintained in DMEM 
supplemented with 10% FBS, 2 mM L-
glutamine and 1 mM Sodium Pyruvate 
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2.2.2 Transient plasmid and siRNA transfections 
2.2.2.1 DNA transfection using calcium phosphate method 
Aʼ and HEK 293 cells were transiently transfected with recombinant DNA vector 
using the calcium phosphate method. For transfection of Aʼ and HEK 293 cells 4 and 6 
μg of DNA vector respectively were added to 500 μl of 250 mM CaCl2 and 500 μl of 2 x 
HBS was added dropwise to the mixture with continual mixing and incubated for 20 
minutes to allow the formation of a fine co-precipitate of DNA-Ca3(PO4)2. This mixture 
was added to 500,000 cells seeded into a 10 cm dish. Fresh media was added 4 hours 
post-transfection.  
 
2.2.2.2 DNA transfection using transfection reagents 
HeLa cells were transiently transfected with recombinant DNA vectors using Gene 
Juice and Lipofectamine 2000 according to manufacturerʼs instructions. 1 x 106 HeLa 
cells were seeded in 10 cm dishes and transfected 16 hours later with 4 μg DNA. 
 
2.2.2.3 siRNA transfection 
HeLa and IMEC cells were transfected with siRNAs using Lipofectamine 2000 
according to manufacturerʼs instructions. 125,000 cells were seeded in 6-well plates 
and transfected 16 hours later with 200 pmoles siRNMT (Dharmacon) (Table 2.6). As a 
control, cells were treated with the transfection reagent alone without addition of any 
siRNAs. 
 
2.2.3 Stable transfection procedure 
HEK-293, HeLa and IMEC cells were stably transfected with recombinant DNA 
vectors using retroviral infection method. 500,000 Phoenix Aʼ packaging cells were 
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seeded in a 10 cm plate and transiently transfected 16 hours later using the calcium 
phosphate method. The medium was changed 24 hours later, collected 48 hours post-
transfection, passed through a 45 µm filter and mixed 1:1 with the medium of 500,000 
recipient cells which were plated in 10 cm dishes 16 hours earlier. 5 μg/ml of polybrene 
was added to increase viral infection rates by neutralising the charge repulsion of the 
virions and the recipient cell surface. Pools of stably transfected cells were selected 
using 0.5 mg/ml G418. 
 
2.2.4 Cell counting 
Cells were counted using a Neubauer chamber. Cells were trypsinised, 
resuspended in media and diluted 1:1 with trypan blue. The Neubauer chamber was 
filled with 20 µl of the mixture and cells were counted in four 1x1 mm squares. Average 
numbers were calculated and multiplied with 20,000 to get the actual cell number/ml 
media. 
Alternatively, cells were counted using a Countess cell counter according to 
manufacturerʼs instructions. 
 
2.2.5 Cell synchronisation 
2.2.5.1 Double thymidine block 
HeLa cells were arrested at G1/S-phase using a double Thymidine block. 1 x 106 
cells were seeded in 10 cm plates and 16 hours later 2.5 mM thymidine was added. 
After 16 to 18 hours cells were washed three times with PBS and cells were released 
into normal medium for 8 to 10 hours. Cells were treated with 2.5 mM thymidine for a 
second time for 16 to 18 hours. Finally, cells were either harvested or washed three 
times with PBS and released into normal medium. 
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2.2.5.2 Nocodazole block 
HeLa cells were arrested in M-phase using a double Thymidine block followed by a 
nocodazole block. 2 x 106 cells were seeded in 10 cm plates and 16 hours later 2.5 mM 
thymidine was added. After 24 hours cells were washed three times with PBS and cells 
were released into normal medium for 3 hours. 100 ng/ml nocodazole was added for 
12 to 13 hours. Finally, cells were either harvested or washed three times with PBS 
and released into normal medium. 
 
2.2.6 Mammalian protein extraction and analysis 
2.2.6.1 Total cell extracts 
Culture medium was removed and cells were washed twice with ice-cold PBS. F-
Buffer supplemented with 0.1 TIU (trypsin inhibitor unit) aprotinin, 1 μM pepstatin, 10 
μM leupeptin and 1% phosphatase inhibitor cocktail 2 and 3 (Sigma) each was used for 
cell lysis. Cells were scraped in ice-cold F-Buffer using a cell lifter, incubated for 10 to 
15 minutes on ice and centrifuged for 10 minutes at 16,000 x g to separate the lysate 
from cell debris. The supernatant was collected and protein concentration was 
determined using the Bradford method. 
 
2.2.6.2 Nuclear cell extracts 
Culture medium was removed and cells were washed twice with ice-cold PBS and 
once with ice-cold Buffer A. Cells were scraped in ice-cold Buffer A supplemented with 
0.1 TIU (trypsin inhibitor unit) aprotinin, 1 μM pepstatin, 10 μM leupeptin and 1% 
phosphatase inhibitor cocktail 2 and 3 (Sigma) each using a cell lifter. Cells were left to 
swell for 10 to 15 minutes on ice before passing through a 45 μm syringe needle ten 
times. The nuclei were pelleted by centrifugation for 10 minutes at 3,300 x g to 
separate the cytoplasmic fraction from the nuclei. The supernatant was discarded and 
	   	  68 
the pellet washed once with Buffer A. The nuclei were pelleted and lysed in F-Buffer 
supplemented with 0.1 TIU (trypsin inhibitor unit) aprotinin, 1 μM pepstatin, 10 μM 
leupeptin and 1% phosphatase inhibitor cocktail 2 and 3 (Sigma) for 10 to 15 minutes 
on ice. Nuclear extracts were centrifuged for 10 minutes at 16,000 x g to separate the 
lysate from cell debris. The supernatant was collected and protein concentration was 
determined using the Bradford method. 
 
2.2.6.3 Protein concentration determination 
Protein concentration was determined using Bradford reagent with reference to a 
standard curve obtained with a dilution series of BSA (Bovine Serum Albumin).  
For the standard curve BSA was diluted in distilled water and 4 µl of the dilution 
series was combined with 200 µl of 1x BioRad protein assay reagent in a 96 well plate. 
Absorbance at 595 nm was measured with a plate reader. Blank measurement of a 
sample containing distilled water and BioRad protein assay reagent only was 
subtracted from all other samples. The standard curve was obtained by plotting the 
absorbance at 595 nm against the BSA concentration (mg/ml). 
For estimation of sample protein concentration, cell extracts were diluted in distilled 
water and analysed as above. A blank measurement of a sample containing F-Buffer 
diluted in H2O and BioRad protein assay reagent was subtracted from all other 
samples. The reading was plotted in the standard curve for estimating the protein 
concentration of the sample. 
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Figure 2.1 Standard curve based on BSA dilutions for the estimation of protein 
concentration 
 
2.2.6.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
SDS-PAGE was performed to separate proteins according to their molecular weight 
using a Mini-Protean Tetra Electrophoresis system (BioRad). Polyacrylamide gels were 
prepared in a final volume of 10 ml by combining 4 ml of 1 M Tris pH 8.8 (final 
concentration 400 mM), 100 µl 10 % SDS (final concentration 0.1%), acrylamide : 
bisacrylamide solution and distilled water. The composition of acrylamide : 
bisacrylamide and water is described in Table 2.12. 
 
Table 2.12 Amount of water and 40% Acrylamide : bisacrylamide used for 
preparation of different percentage acrylamide gel. 
Final Acrylamide concentration 5% 8% 10% 12% 14% 
H2O (ml) 4.5 3.8 3.3 2.8 2.3 
40% Acrylamide : bisacrylamide (ml) 1.2 2 2.5 3 3.5 
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The lower gel described above filled ¾ of the gel whereas the rest was filled with a 
stacking gel of lower pH and acrylamide content. Stacking gels of 4% and 5% 
acrylamide were prepared for lower gels containing 5% or more than 5% acrylamide 
respectively. The stacking gel was made by combining 4 ml 1 M Tris base, pH 6.8 (final 
concentration 400 mM), 100 μl 10% SDS (final concentration 0.1%), acrylamide : 
bisacrylamide solution and distilled water. The composition of acrylamide : 
bisacrylamide and water is described in Table 2.13. 
 
Table 2.13 Amount of water and 40% Acrylamide : bisacrylamide used for 
preparation of different percentage stacking acrylamide gel. 
Final Acrylamide concentration 4% 5% 
H2O (ml) 4.8 4.5 
40% Acrylamide : bisacrylamide (ml) 1 1.2 
 
For the polymerization reaction APS and TEMED were added to a final 
concentration of 0.1% (v/v) and 0.01% (v/v) respectively.  
Protein samples were combined with 4x Laemmli buffer complemented with 100 mM 
DTT and F-buffer to prepare a 1 mg/ml protein sample in 1x Laemmli buffer. Samples 
were boiled for 2 min and centrifuged at 16,000 x g for 3 min at room temperature. 
Proteins were resolved alongside molecular weight markers at 180 V. The amount of 
protein resolved and the percentage of acrylamide gel used for the detection of specific 
proteins is demonstrated in Table 2.14. 
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Table 2.14 List of proteins detected by western blot during this study. The 
amount of total protein extracts analysed and the percentage of SDS-PAGE used are 
indicated. 
Western blot against Amount of protein analysed (μg) % Acrylamide gel 
RNMT 
(endogenous + HA-RNMT) 
6 8 
HA-RNMT 12 8 
RAM 18 14 
Fg-RAM 12 14 
RNGTT 10 8 
Tubulin 6.5 8 
RNA Pol II 25 5 
Cyclin B1 3.5 8 
Histone 3 10 14 
Cyclin D1 12 12 
KPNA2 10 8 
9E10-KPNA2 8 8 
 
 
2.2.6.5 Two-dimensional SDS-PAGE (2D SDS-PAGE) 
HA-RNMT was immunoprecipitated overnight from 2 mg HEK-293 cells stably 
expressing HA-RNMT using 5 µg mouse monoclonal anti-HA antibodies. 
Immunoprecipitates were resuspended in 25 µl of 2D lysis buffer and incubated with 
100 µl of 2D rehydration solution for 2 hours at room temperature. The sample was 
added into a strip holder and a 7 cm BioRad IPG strip with a pH range of pH 3-10 was 
	   	  72 
added onto the solution. The IPG strip was overlaid with cover fluid and rehydrated 
overnight for 13 hours. Isoelectric focusing was performed on an Ettan IPGphor 
isolectric focusing system using the following three-step protocol: 250 Vhr (0.5 hours at 
500 V, 500 Vhr (0.5 hours at 1000 V) and 8000 Vhr (1 hour at 800 V). After isoelectric 
focusing strips were equilibrated for 10 minutes in 5 ml of 2D SDS equilibration solution 
1 and 2 containing iodacematide and DTT respectively. The IPG strip was placed on 
top of polyacrylamide gel and protein was resolved by SDS-PAGE. 
 
2.2.6.6 Western blot 
Protein separated by SDS-PAGE were transferred onto polyvenylfluoride (PVDF) 
membranes in transfer buffer by wet blotting at 66 V for 90 min at 4 °C using Mini 
Trans-Blot Cell (Bio-Rad). For RAM western blots, transfer was performed using Trans-
Blot Cell (Bio-Rad) at 60 V for 300 min at room temperature.  
Protein detection was carried out at room temperature. Membranes were blocked for 
45 minutes in TBST containing 5 % milk or 3 % BSA depending on the primary 
antibody (Table 2.15). Primary antibodies were diluted in blocking solution (Table 2.16) 
and incubated with the membrane for 60 minutes. For RAM and RNA polymerase II 
western blots primary antibodies were incubated for 90 and 120 minutes respectively. 
The membranes were washed four times for 5 minutes with TBST containing 5 % milk. 
HRP-conjugated secondary antibodies were diluted 1:2000 in TBST containing 5 % 
milk and incubated with the membrane for 45 minutes. The membranes were washed 
four times for 5 minutes with TBST. Antibody-bound proteins were visualised on X-ray 
film using enhanced chemiluminescence reagent according to manufacturerʼs 
instructions. 
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Table 2.15 Concentrations of primary antibodies employed in this study for 
western blot analysis. The dilution of the antibody and the blocking reagent 
used are indicated 
Antibody Working concentration 
Blocking 
solution 
RNMT 1:1000 Milk 
RNMT pT77 1:1000 BSA 
HA (H3663) 1:250 BSA 
RAM 1:100 Milk 
RNGTT 1:1000 Milk 
Tubulin (sc-9104) 1:1000 Milk 
RNA pol II PAN (sc-899) 1:250 BSA 
RNA pol II 3-3 PAN 1:10 BSA 
RNA pol II pS2 1:10 BSA 
RNA pol II H14 pS5 1:10 BSA 
RNA pol II 3E8 pS5 1:10 BSA 
Cyclin B1 1:1000 Milk 
Histone 3 pS10 1:1000 BSA 
Cyclin D1 (2922) 1:1000 Milk 
KPNA2 (PA5-21034) 1:1000 Milk 
9E10 1:1000 Milk 
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Table 2.16 Concentrations of HRP-conjugated secondary antibodies employed in 
this study for western blot analysis. The dilution of the antibody and the 
blocking reagent used are indicated. 
Antibody Working concentration Blocking solution 
Rabbit anti-Sheep 1:500 Milk 
Goat anti-Mouse 1:500 Milk 
Goat anti-Rabbit 1:500 Milk 
Mouse anti-Sheep, light chain-specific 1:200 Milk 
 
RNMT, RAM, RNGTT and RNMT pT77 antibodies were raised in sheep by the in 
house Division of Signal Transduction (DSTT) against full-length recombinant human 
RNMT, RAM, RNGTT and the phosphorylated RNMT peptide CGKDT*PSKKR 
respectively. Sera were affinity purified on the recombinant protein or phospho-peptide. 
All other antibodies were acquired commercially or as specified in the material section. 
 
2.2.6.7 Coomassie blue staining 
After SDS-PAGE the polyacrylamide gel was washed three times with distilled water 
for five minutes and protein was stained in Simply Blue Safe stain (Invitrogen) solution 
for one hour. The gel was washed with distilled water to remove background staining.  
 
2.2.6.8 Immunoprecipitation 
Immunoprecipitations were performed at 4 °C with the amount of cell extracts and 
antibodies stated in the figure legends. In general, cell extracts were precleared with 
Protein A/G PLUS-Agarose (Santa Cruz) for 45 minutes. Stably expressed exogenous 
HA-RNMT was immunoprecipitated using mouse monoclonal anti-HA antibody-
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conjugated agarose. For endogenous RNMT immunoprecipitation sheep polyclonal 
anti-RNMT or sheep polyclonal anti-HA (control, DSTT) antibody was used and Protein 
A/G PLUS-Agarose was added for 1.5 hours to precipitate the antibodies. 
Immunoprecipitations were performed for 4 hours except for RNMT phosphorylation 
analysis in which RNMT was immunoprecipitated for 2.5 hours only. 
Immunoprecipitates were centrifuged at 800 x g for 1.5 minutes washed 4 times with F-
Buffer, resuspended in 1x Laemmli dye and resolved by SDS-PAGE. 
For exogenous immunoprecipitation 35 and 6.5 % and for endogenous 
immunoprecipitation 70 and 9 % of immunoprecipitates were resolved to detect RNMT 
pT77 and total RNMT levels respectively. 
 
2.2.6.9 Large scale immunoprecipitation coupled with mass 
spectrometry analysis 
For RNMT mass spectrometry analysis 40 mg of HEK-293 cell extract was 
precleared for 5 hours using 50 µl murine IgG-conjugated agarose (Sigma) and 20 µl 
50 % slurry Protein A/G PLUS-Agarose (Santa Cruz). HA-RNMT was 
immunoprecipitated overnight using 20 µg mouse monoclonal anti-HA antibody-
conjugated agarose (Sigma) and 20µl protein A/G PLUS-Agarose. Immunoprecipitates 
were washed and resolved by 4 - 12 % gradient SDS-PAGE. The gel was fixed (40 % 
methanol, 7 % glacial acetic acid) and stained with brilliant blue G-Colloidal (Sigma) for 
2 hours.  
Mass spectrometry analysis was performed by the FingerPrints Proteomics Facility 
located in the College of Life Sciences at the University of Dundee. In brief, Coomassie 
stained gel bands were excised, washed, and incubated overnight with trypsin. 
Peptides were extracted and separated by nanoLC-MS/MS on a 4000 QTRAP mass 
spectrometer for protein identification. Precursor ion scanning was performed before 
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nanoLC-MS/MS on a LTQ Orbitrap Velos Pro mass spectrometer to identify 
phosphorylation sites. Results were searched against the SwissProt or IPI human 
databases using the Mascot Daemon. 
 
2.2.6.10 Peptide affinity purification 
Peptide affinity purification was performed at 4 °C with the amount of cell extracts 
and peptides stated in the figure legends. In general, streptavidine sepharose high 
performance beads were pelleted at 800 x g for 1.5 minutes and washed five times with 
F-Buffer. The cell lysate was precleared with 20 µl 50 % slurry streptavidine sepharose 
five times for 10 minutes. The precleared lysate was incubated with biotinylated 
peptides (Table 2.5) for 10 minutes and 20 µl 50 % slurry streptavidine-sepharose was 
added for an additional 5 minutes. The sepharose was pelleted at 800 x g for 1.5 
minutes and washed three times with F-Buffer and one time with Buffer A. The 
precipitates were resuspended in 1x Laemmli dye and resolved by SDS-PAGE 
 
2.2.6.11 Peptide affinity purification coupled to mass spectrometry 
analysis 
For mass spectrometry analysis of peptide-bound proteins, peptide affinity 
purification was performed as described above. Precipitates were resuspended in 1x 
LDS sample buffer (Invitrogen) containing 10 mM DTT and boiled for 5 minutes at 70 
°C. Iodoactematide was added to 50 mM and the sample was incubated in the dark for 
30 minutes at room temperature. The protein was resolved by 4 - 12 % gradient SDS-
PAGE and stained with Coomassie blue. Protein bands were extracted as described 
below and send for mass spectrometry analysis, which was performed by the mass 
spectrometry facility at the MRC Protein Phosphorylation and Ubiquitylation Unit 
located in the College of Life Sciences at the University of Dundee. In brief, protein was 
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trypsinised and peptides separated on a nanoLC system, which was coupled with an 
LTQ-Orbitrap mass spectrometer (for peptide mass fingerprinting). Results were 
searched against the SwissProt or IPI human databases using the Mascot Daemon. 
The mass spectrometry results were subsequently analysed using OLMAT (Online 
MassSpec data Analysis Tool) available online at www.proteinguru.com.  
 
2.2.6.12 Processing protein bands for mass spectrometry analysis 
To minimise contamination with keratin, samples were handled in a laminar flow 
hood. Indicated gel pieces were cut into small cubes of 1 mm size. The pieces were 
sequentially washed for 10 minutes in 0.5 ml distilled water, 50% acetonitrile, 0.1 M 
NH4HCO3 and 50 % acetonitrile / 50 mM NH4HCO3 on a shaking platform. Gel pieces 
were briefly spun in a microcentrifuge and all liquid was aspirated. The wash in 50 % 
acetonitrile / 50 mM NH4HCO3 was repeated until the gel pieces were colourless. Next, 
gel pieces were shrunk by incubating them with 0.3 ml of acetonitrile for 15 minutes at 
room temperature and subsequently dried with Speed-Vac at 45 °C for 20 to 30 
minutes. The gel pieces were swollen with 80 µl 25 mM Triethylammonium bicarbonate 
buffer containing 5 ug/ml Trypsin and incubated at 30 °C for 16 hours on a shaking 
platform. Next day, 80 µl of acetonitrile was added and the peptides obtained from the 
trypsin digestion were extracted for 15 minutes on a shaking platform. The supernatant 
was frozen on dry ice and dried at 45 °C using Speed-Vac. To further extract the 
peptides, 100 µl of 50 % acetonitrile supplemented with 2.5 % formic acid were added 
to the gel pieces and incubated for 15 minutes at room temperature on a shaking 
platform. The supernatant was combined with the first dried peptide extract, frozen on 
dry ice and dried using Speed-Vac. Dried peptides were stored at -20 °C and submitted 
to the mass spectrometry facility at the MRC Protein Phosphorylation and 
Ubiquitylation Unit located in the College of Life Sciences at the University of Dundee. 
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2.2.6.13 Affinity purification with nuclear extracts 
2 mg of nuclear HeLa cell extracts were incubated for 3 hours at 4 °C with 1.5 µg of 
purified recombinant GST, GST-RNMT or GST-RNGTT respectively. Recombinant 
protein was affinity purified with 25 µl of 50% slurry glutathione sepharose and washed 
five times with F-Buffer. Precipitates were dissolved in 1x Laemmli buffer, separated by 
SDS-PAGE and analysed by western blot. 
 
2.2.6.14 Immunofluorescence 
IMEC cells were seeded on round cover slides and fixed with fresh 4% 
paraformaldehyde in PHEM for 7 minutes at 37 °C. All other steps were performed at 
room temperature. Cells were washed in fresh TBST for 5 minutes and permeabilised 
with 0.02 % Triton X-100 in TBST for 2.5 minutes. After a wash in TBST for 5 minutes 
cells were blocked with 10 % Donkey serum in Abdil (antibody dilution solution) for 30 
minutes. Primary antibodies were incubated in Abdil for 1 hour (Table 2.17) and 
washed three times in TBST for 5 minutes. Secondary antibodies in Abdil (Table 2.18) 
were incubated for 50 minutes in the dark. Cells were washed tree times in TBST and 
stained with 1:50,000 DAPI in Abdil for 20 minutes. Cells were washed in TBST and 
mounted on glass plates. Fluorescence microscopy was performed on a Zeiss LSM 
700. 
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Table 2.17 Concentrations of primary antibody employed in this study for 
immunofluorescence analysis. 
Antibody Working concentration 
HA  1:2000 
RNMT 1:2000 
Tubulin 1:500 
Lamin B1 1:1000 
 
 
Table 2.18 Concentrations of secondary antibodies employed in this study for 
immunofluorescence analysis. 
Antibody Working concentration 
Alexa 488 anti-Sheep 1:500 
Alexa 594 anti-Sheep 1:500 
Alexa 642 anti-Sheep 1:500 
 
 
2.2.6.15 Orthophosphate labelling 
HEK-293 cells were washed twice with PBS and starved in sodium phosphate-free 
DMEM supplemented with 10 % dialysed FBS for 4 hours at 37 °C. 30 µCi/ml [32P]-
orthophosphate (Perkin Elmer) was added and cells were labelled for 2 hours at 37 °C. 
Cells were lysed in F-Buffer as described before and HA-RNMT was 
immunoprecipitated for 4 hours from 2 mg of cell extracts using 10 µg of mouse 
monoclonal anti-HA antibodies. Immunoprecipitates were washed, dissolved in 1x 
Laemmli dye and resolved by SDS-PAGE. The polyacrylamide gel was fixed (50 % 
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methanol, 10 % acetic acid and 7 % methanol, 7 % acetic acid, 10 % glycerol), dried 
and subjected to autoradiography. 
 
2.2.6.16 35S amino acid labelling 
HeLa cells were starved for 15 minutes at 37 °C in methionine- and cysteine-
deficient DMEM supplemented with 10 % dialysed FBS. Subsequently cells were 
labelled for 15 minutes at 37 °C with 33 µCi/ml 35S protein labelling mix (Perkin Elmer) 
containing 35S-methionine and 35S-cysteine. Cells were lysed in F-Buffer and 12 µg of 
extracted protein was resolved by 10 % SDS-PAGE. The polyacrylamide gel was fixed 
(50 % methanol, 10 % acetic acid and 7 % methanol, 7 % acetic acid, 10 % glycerol), 
dried and subjected to autoradiography. 
 
2.2.6.17 Autoradiography 
Radioactive signal was visualised on a phosphor screen using a phosphorimager. 
 
2.2.6.18 Kinase inhibitor treatment 
The following kinase inhibitor stock solutions were prepared: DRB (Sigma) was 
dissolved in EtOH to form a stock solution of 31mM. Roscovitine (Sigma) was 
dissolved in DMSO to form a stock solution of 10 mM. RO-3306 (Merck) was dissolved 
in DMSO to form a stock solution of 9 mM. HeLa cells were incubated with these 
compounds at a concentration and time indicated in the figure legends. 
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2.2.7 RNA extraction and analysis 
2.2.7.1 RNA extraction 
RNA from transiently transfected HeLa cells (Figure 3.8) was extracted using 
QIAGEN RNeasy mini kit according to manufacturerʼs instructions. RNA from stably 
transfected HeLa cells (Figure 6.7) was extracted using the TRIzol reagent (Invitrogen) 
according to manufacturerʼs instructions. 
 
2.2.7.2 RT-PCR 
750 ng of RNA was converted into complementary DNA (cDNA) with random 
hexamer primers using the qScript cDNA Synthesis Kit (Quanta) according to 
manufacturerʼs instructions. 
The cDNA was diluted 30 times in distilled water and 2 µl were subjected to real-
time polymerase chain reaction (RT-PCR) analysis with a BioRad iQ5 RT-PCR 
detection system using Quanta Biosciences SYBR Green FastMix for iQ. RT-PCR 
reactions were performed in a volume of 20 µl using the primers depicted in Table 2.7 
at a concentration of 0.3 µM and the following thermo cycle protocol: Cycle 1 (1x) 30 
seconds, 95 ºC ; Cycle 2 (40x) 1 second, 95 ºC , 25 seconds 57 ºC.  
 
2.2.8 Biochemical assays 
2.2.8.1 In vitro cap methyltransferase activity assay 
To prepare RNA substrate for the methyl reaction 10 µg of pGEM Cem4 plasmid 
was linearised with 40 U EcoRI (Roche) in Buffer 3 (NEB) and a 55 nt long transcript 
driven by a T7 promotor was in vitro transcribed using 2 µl TNT T7 RNA polymerase 
(Promega) in the prescence of 250 µM NTPs, 20 U RNasin (Promega) and 
Transcription Buffer (Promega) for 2 hours at 37 °C. The transcript was purified by 
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phenol:chloroform extraction, precipitated in ethanol and dissolved in 50 µl nuclease-
free water. 200 ng of in vitro transcribed RNA was capped with 10 µCi [α-32P] GTP 
(Perkin Elmer) in the presence of 2 µg recombinant RNGTT, 40 U RNasin and RNGTT 
Buffer for 1 hour at 37 °C. The capped transcript was purified by phenol:chloroform 
extraction, acetate precipitated and dissolved in 50 µl nuclease-free water.  
For cap methylation assays the indicated amount of immunoprecipitated RNMT or 
total cell extract was incubated in a total volume of 10 µl with 2 ng of RNA substrate, 
200 µM S-adenosyl methionine, 20 U RNasin and MT Buffer at 37 °C for the indicated 
time. 
Cap methylation assays with recombinant RNMT were performed at 30 °C with the 
amount and time indicated in the figure legend. 
Following the reaction, RNA was purified by phenol:chloroform extraction, acetate 
precipitated, and resuspended in 4 µl of 50 mM NaAcetate (pH 5.5) and incubated with 
0.75 U P1 nuclease (Sigma) for 60 minutes at 37 °C to release free GpppG and 
m7GpppG. Cap structures were resolved by 0.4 M ammonium sulphate on PEI 
cellulose plates. Labelled GpppG and m7GpppG spots were visualized and quantified 
by autoradiography. 
 
2.2.8.2 Phenol/Chloroform extraction 
RNA was purified by phenol/chloroform extraction to remove any protein 
contamination. An equal amount of phenol/chloroform was added to the nucleic acid 
solution and shaken for 10 seconds to form an emulsion. The aqueous and organic 
fractions were separated by centrifugation at 16,000 x g for 10 minutes. The upper 
aqueous phase was transferred into a new tube and mixed with 1/10 volume of 5 M 
Ammonium acetate and 2 volumes of Ethanol and incubated at -20 °C overnight. For 
RNA purification from capping reaction and methyltransferase activity assay, 1/10 
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volume of 2 mg/ml polyU or 1/50 volume of 1 mg/ml tRNA was added respectively as a 
carrier. The precipitated RNA was pelleted by centrifugation at 16,000 x g for 60 
minutes at 4 °C and washed with 70 % Ethanol. The pellet was dried for 20 minutes 
and dissolved in the solution specified. 
 
2.2.8.3 Chromatin immunoprecipitation (ChIP) 
For chromatin immunoprecipitations presented in chapter 3, 1 x 106 HeLa cells were 
transfected with i)1.5 µg pcDNA4, ii) 0.75 µg pcDNA4 HA-RNMT and 0.75 µg pcDNA4 
FLAG-RAM, iii) 0.53 µg pcDNA4 HA-RNMTcat, 0.75 µg pcDNA4 FLAG-RAM and 
0.22µg pcDNA4, iv) 0.2 µg pcDNA4 HA-RNMT-N, 0.75 µg pcDNA4 FLAG-RAM and 
0.55 µg pcDNA4 using Lipofectamine 2000 (Invitrogen).   
For chromatin immunoprecipitations presented in chapter 6, 1 x 106 HeLa cells were 
transfected with i) 4 µg pcDNA5, ii) 2 µg pcDNA5 HA-RNMT WT and 2 µg pcDNA5 
FLAG-RAM and iii) 1.6 µg pcDNA5 HA-RNMT T77A, 2 µg pcDNA4 FLAG-RAM and 0.4 
µg pcDNA5 using Lipofectamine 2000 (Invitrogen).   
Chromatin immunoprecipitations were performed using the Millipore ChIP kit 
according to manufacturerʼs instructions. In brief, cells were crosslinked with 
formaldehyde for 10 minutes at 37 °C, washed with PBS and lysed in SDS lysis buffer. 
The lysate was sonicated to shear the DNA to lengths between 200 and 500 basepairs 
using a bioruptor (Diagenode) at medium amplitude at cycles of 30 seconds ON/OFF 
for 10 minutes. Lysates were centrifuged at 16,000 x g for 10 minutes and the 
supernatant was diluted in ChIP dilution buffer.  After preclearing with salmon sperm 
DNA/Protein A agarose 1 % of the sample was kept as input sample. The remaining 
solution was incubated overnight at 4 °C with 15 µg anti-HA or anti-FLAG antibodies 
conjugated to agarose (both Sigma) to immunoprecipitate HA-RNMT and FLAG-RAM 
proteins. Immunoprecipitates were subsequently washed with low salt immune 
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complex wash buffer, high salt immune complex wash buffer, LiCl immune complex 
wash buffer and TE buffer. Protein was eluted in 1 % SDS, 0.1 M NaHCO3 at room 
temperature, histone-DNA crosslink was reversed in 200 mM NaCl at 65 °C for 4 hours 
and protein was digested with 0.1 mg/ml proteinase K. The DNA was purified with a 
QIAquick PCR purification kit (Qiagen) and eluted in 50 µl distilled water. 2µl of input 
and immunoprecipitated DNA were subjected to RT-PCR analysis with a BioRad iQ5 
RT-PCR detection system using Quanta Biosciences SYBR Green FastMix for iQ. RT-
PCR reactions were performed in a volume of 20 µl using the primers depicted in Table 
2.8 at a concentration of 0.3 µM and the following thermo cycle protocol: Cycle 1 (1x) 
30 seconds, 95 ºC ; Cycle 2 (40x) 1 second, 95 ºC , 25 seconds 57 ºC. ChIP signal 
was determined relative to input.  
 
2.2.8.4 Flow cytometry analysis 
HeLa cells were trypsinised, resuspended in medium and washed in PBS. Cells 
were resuspended in 430 µl PBS and fixed by dropwise addition of 1 ml cold Ethanol 
whilst vortexing to avoid clumping cells. Cells were washed twice in 3 ml PBS, 1 % 
FBS and stained in 300 to 500 µl PI solution (PBS, 1 % FBS, 50 µg/ml RNase A, 50 
µg/ml propidium iodide) for 30 minutes at room temperature in the dark. DNA content 
was assessed by flow cytometry using a FACS Calibur (Becton Dickinson). 10,000 
events were counted per sample and the fluorescence data (DNA content) was plotted 
on a histogram from channel number 0 to 1023 using the FlowJo software. The G1 
peak was set to 200 to allow good resolution of the G1, S and G2/M phase distribution. 
Cell cycle distribution was estimated with FlowJo using the Watson distribution model. 
 
	   	  85 
2.2.8.5 In vitro phosphorylation 
In vitro phosphorylation was performed with purified recombinant HIS-RNMT WT or 
T77A in complex with GST-RAM 1-90 and activated CDK1/Cyclin B1 (NEB) or 
CDK2/Cyclin A2 (DSTT). 0.33 µM HIS-RNMT/GST-RAM 1-90 was incubated with 0.01 
µM CDK1/Cyclin B1, 100 µM non-radioactive or [γ-32P]-ATP (500 cpm/pmol) (Perkin 
Elmer), 10 mM MgCl2, 2 mM DTT, 50 mM Tris pH 7.5 and 0.1 mM EGTA. Kinase 
assays were performed in total volumes of 20 or 30 µl at 30 °C in a shaking incubator 
at 1200 rpm for the time indicated in the figure legends. Reactions were stopped by 
addition of 4x Laemmli dye. Samples were separated by SDS-PAGE and analysed by 
western blot or stained with Coomassie blue and subjected to autoradiography. To 
estimate the stoichiometry of [32P] incorporation into RNMT, RNMT bands were excised 
and counted for 60 seconds using a scintillation counter. At the same time the specific 
activity of the input [γ-32P]-ATP was measured by scintillation counting. The RNMT 
counts were divided by the specific activity of the [γ-32P]-ATP and by the amount of 
RNMT used for the in vitro phosphorylation reaction. 
 
2.2.8.6 In vitro phosphorylation coupled to methyltransferase 
activity assay 
In vitro phosphorylation was performed as described above in the presence or 
absence of cold ATP or CDK1/Cyclin B1 for 30 minutes. After in vitro phosphorylation 
the reaction mix was diluted in F-Buffer and 900 ng of HIS-RNMT in complex with GST-
RAM 1-90 was subjected to glutathione affinity purification using 20 µl 50 % slurry 
glutathione sepharose for 1.5 hours. Precipitates were washed in F-Buffer and MT-
Buffer and dissolved in 150 µl MT-Buffer supplemented with 0.05 % Triton X-100. 5 µl 
(1/30) was used to perform in vitro cap methyltransferase assays.   
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2.2.8.7 In vitro affinity assay 
1.5 or 2 µg of purified recombinant proteins were mixed in RIPA buffer (Figure 3.6) 
or F-Buffer (Figure 5.6) and incubated with 25 µl 50% slurry glutathione sepharose for 
3 hours at 4 °C. GST tagged protein was affinity purified with glutathione sepharose 
and washed precipitates were resolved in 1x Laemmli buffer, separated by SDS-PAGE 
and stained by Coomassie blue or analysed by western blot. 
 
2.2.9 Recombinant protein production 
2.2.9.1 Preparation of HIS-RNMT 
A pNIFTY-based vector expressing RNMT fused N-terminally to a 6 x HIS tag was 
transduced into BL21 CodonPlus (DE3)-RIL E. coli. A single colony was expanded to a 
1 L culture in terrific broth. At an OD600 of 1.2, expression of recombinant protein was 
induced with 1 M IPTG (isopropyl-β-D-thiogalactopyranoside) for 18 hours at 14 °C.  
Cells were harvested by centrifugation at 4,000 x g, washed in PBS and frozen at -80 
°C. Pellets were resuspended in 25 ml lysis buffer [50 mM Tris/HCl (pH 7.5), 250 mM 
NaCl, 0.5 mM EGTA, 0.5 mM EDTA, 0.5 % Triton X-100, 1 mM DTT, 20 μg/ml 
leupeptin, 1 mM Pefabloc, 0.5 mM TCEP, 20 mM immidazole] and sonicated six times 
on ice for 30 sec. Insoluble material was removed by centrifugation for 25 min at 
60,000 x g. 250 µl Ni2+ resin was incubated with the soluble material for 1.5 hours at 4 
°C and washed in 25 ml wash buffer [50 mM Tris/HCl (pH 7.5), 250 mM NaCl, 0.03% 
Brij-35, 40 mM immidazole]. HIS-RNMT was eluted from the Ni2+ resin in 2 ml elution 
buffer [50 mM HEPES, 150 mM NaCl, 0.03% Brij-35, 400 mM immidazole]. The purified 
protein was dialysed overnight at 4 °C in dialysis buffer (50 mM HEPES, 150 mM NaCl, 
0.03% Brij-35) using 10,000 Mw snakeskin dialysis tubing (Thermo). 
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2.2.9.2 Preparation of GST-RNMT 
A pGEX6P1-based vector expressing RNMT fused N-terminally to a GST tag was 
transduced into BL21 (DE3) E. coli. A single colony was expanded to a 1 L culture in 
LB medium. At an OD600 of 0.6, expression of recombinant protein was induced with 1 
M IPTG (isopropyl-β-D-thiogalactopyranoside) for 18 hours at 16 °C.  Cells were 
harvested by centrifugation at 4,000 x g, washed in PBS and frozen at -80 °C. Pellets 
were resuspended in 12 ml lysis buffer [50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.1 
mM EGTA, 0.1 mM EDTA, 0.1 % Triton X-100, 0.1 % β-mercaptoethanol, 0.2 mM 
PMSF, 1 mM benzamidine, 20 μg/ml leupeptin, 1 mg/ml lysozyme] and sonicated six 
times on ice for 30 sec. Insoluble material was removed by centrifugation for 25 min at 
60,000 x g. 1 ml glutathione sepharose was incubated with the soluble material for 1.5 
hours at 4 °C and washed five times in 25 ml wash buffer [50 mM Tris/HCl (pH 7.5), 
150 mM NaCl, 0.1 mM EGTA, 0.1 mM EDTA]. GST-RNMT was eluted from the 
glutathione sepharose in 5 ml elution buffer [50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 
0.1 mM EGTA, 0.1 mM EDTA, 0.1 % β-mercaptoethanol, 0.2 mM PMSF, 1 mM 
benzamidine, 20 μg/ml leupeptin 50 mM glutathione]. The purified protein was buffer-
exchanged in elution buffer without glutathione and concentrated to 2 ml using a 
diafiltration column.  
The GST tag was removed by incubating GST-RNMT bound to glutathione 
sepharose overnight in wash buffer containing 200 μg of precision protease. 
 
2.2.9.3 Preparation of other recombinant protein  
The following recombinant proteins were purified in house by the Division of Signal 
Transduction Therapy (DSTT): HIS-RNMT/GST-RAM 1-90 (DU42422), HIS-RNMT 
T77A/GST-RAM 1-90 (DU43251), GST, GST-RNGTT, GST-KPNA2 and KPNA2 GST-
OFF (DU42444).  
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2.2.10 Cloning methodology 
All constructs prepared for this study are presented in Table 2.20. 
 
2.2.10.1 Site-directed mutagenesis 
DNA vectors were subjected to site-directed mutagenesis using the QuickChange 
site-directed mutagenesis kit (Stratagene) according to manufacturerʼs instructions. In 
brief, 50 and 5 ng of DNA templates were combined with a 50 μl reaction mixture 
containing 1x site-directed mutagenesis buffer, 200 μM dNTPs, 0.5 μM of each primer 
(Table 2.9) and 5 U of high fidelity DNA polymerase. PCR reactions were performed in 
a DNA Engine Dyad Peltier Thermal Cycler (Bio-Rad). DNA was first denatured at 95 
°C for 30 seconds before entering a cycle of denaturation at 95 °C for 30 seconds, 
primer annealing at 55 °C for 30 seconds and extension at 68 °C for 7 minutes. After a 
total of 18 cycles the original methylated and non-mutated plasmid derived from 
bacterial source was digested by the addition of 2 U DpnI to the PCR products and 
incubation for 1 hour at 37 °C. Products from the two PCR reactions were combined 
and purified with a QIAquick PCR purification kit (Qiagen) and used for E. coli cell 
transformation. 
 
2.2.10.2 PCR 
DNA was amplified using polymerase chain reaction (PCR) from vector templates 
using Expand High Fidelity PCR System (Roche) according to manufacturerʼs 
instruction. In brief, 100 ng vector was combined with a 100 μl reaction mixture 
containing 1x High Fidelity PCR System buffer supplemented with 1.5 mM MgCl2, 200 
μM dNTPs, 0.5 μM of each primer (Table 2.10) and 5 U of high fidelity DNA 
polymerase. PCR reactions were performed in a DNA Engine Dyad Peltier Thermal 
Cycler (Bio-Rad). DNA was first denatured at 95 °C for 2 minutes before entering a 
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cycle of denaturation at 95 °C for 30 seconds, annealing at 55 °C for 30 seconds and 
extension at 72 °C for 30 (RNMT-N), 60 (RNMTcat) or 90 seconds (HIS-RNMT). After a 
total of 28 cycles the reaction entered a final extension phase at 72 °C for 2 minutes. 
The PCR products were purified with a QIAquick PCR purification kit (Qiagen). 
 
2.2.10.3 PCR purification 
PCR products were purified using the QIAquick PCR purification kit (Qiagen) 
according to manufacturerʼs instructions. DNA was eluted in 50 μl distilled water. 
 
2.2.10.4 Restriction enzyme digestion 
Restriction digests of DNA were performed with restriction enzymes using the 
buffers recommended by the manufacturer. Typically, digestions were performed for 4 
hours at 37 °C in a total volume of 50 μl containing two different restriction enzymes 
and 1x NEB buffer compatible for both enzymes. In general 2 μg of backbone vector, 6 
μg of insert-containing vector or 15 μl of insert-containing PCR product was digested 
with 20 U of restriction enzymes.  For the backbone vector digestion, after 3 hours 
digestion, 10 U CIP phosphatase (NE biolabs) was added to the reaction mixture in 
order to dephosphorylate 5ʼ-phosphate ends created by the restriction digestion and 
reduce self-ligation of vector during cloning. Digestion products were analysed by 
agarose gel electrophoresis and purified using QIAquick gel extraction kit (Qiagen).  
 
2.2.10.5 Agarose gel electrophoresis 
Double stranded DNA was purified after restriction digestion by agarose gel 
electrophoresis. Typically, 1% (w/v) Agarose was dissolved in 1x TAE buffer by heating 
up the solution. Gels were cast into a gel tray after addition of 0.1 % gel red (Biotium). 
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DNA samples were combined with 5x Green GoTaq reaction (Promega) buffer as 
loading dye. Electrophoresis was performed in a Mini-Sub Cell GT Cell (Bio-Rad) in 1x 
TAE buffer at 120 V for approximately 40 minutes. DNA was visualised with a UV 
transilluminator, extracted and purified by QIAquick Gel Extraction Kit (Qiagen).  
 
2.2.10.6 Gel extraction 
DNA was purified after agarose gel electrophoresis using QIAquick Gel Extraction 
Kit (Qiagen) according to manufacturerʼs instructions.  DNA was eluted in 50 μl distilled 
water. 
 
2.2.10.7 Ligation 
Digested insert DNA and vector backbones were ligated in a molar ration of 3:1 
using T4 DNA ligase (NE BioLabs) according to manufacturerʼs instruction. In general, 
10 μl ligation reaction containing 1 μl vector, 3 μl insert, 1x T4 ligation buffer and 1 U 
T4 DNA ligase were incubated for 1 hour at room temperature. 5 μl of the reaction were 
used to transform competent DH5α E. coli cells.  
 
2.2.10.8 Transformation of E. coli cells with plasmids 
Competent E. coli cells (Table 2.19) were thawed on ice and mixed with 50 to 200 
ng DNA or 5 μl ligation mix. After 20 minutes on ice cells were heat-shocked for 45 
seconds at 42 °C and incubated on ice for 2 minutes. The bacteria were plated on 
selective LB agar plates containing the appropriate antibiotic (50 μg/ml ampicillin or 50 
μg/ml kanamycin) and incubated overnight at 37 °C. 
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Table 2.19 E. coli strains and their genotype used in this study. 
Bacterial strain Genotype 
DH5α 
Fʼ φ80dlacZΔΜ15 Δ(lacZYA-argF) U169 deoR 
recA1 endA1 hsdR17 phoA supE44 λ- thi-1 
gyrA96 reA1 
BL21 (DE3) B F- ompT hsdS(rB-mB-) dcm+ Tetr gal endA 
BL21 CodonPlus (DE3)-RIL B F
- ompT hsdS(rB-mB-) dcm+ Tetr gal endA Hte 
[argU ileY leuW Camr] 
 
2.2.10.9 Plasmid preparation  
Plasmid DNA was purified from DH5α E. coli cells growing overnight at 37 °C. DNA 
QIAprep Miniprep Kit (Qiagen) was used to purify 5-10 μg DNA eluted in 50 μl distilled 
water according to manufacturerʼs instructions.  
To produce large amount of plasmids DNA Maxi Kit (Qiagen) was used according to 
manufacturerʼs instructions. Typically 500-1000 μg DNA were resuspended in 700 μl 
distilled water. 
 
Table 2.20 Table of all constructs generated 
Construct Backbone Cloning method 
HA-RNMTcat pcDNA4 
HA-RNMT 121-476 was amplified from 
pBMN RNMT-GFP construct by PCR 
using primers described at Table 2.13. 
BamHI and XhoI restriction enzymes in 
NEB 2 buffer were used for double 
digestion of vector and insert. 
HA-RNMT-N pcDNA4 
HA-RNMT was amplified from pBMN 
RNMT-GFP construct by PCR using 
primers described in Table 2.13. BamHI 
and XhoI restriction enzymes in NEB 2 
buffer were used for double digestion of 
vector and insert. 
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HA-RNMT WBL pcDNA5 
HA-RNMT was cut out from INI HA-
RNMT WBL with BamHI and NotI in 
NEB 3 and ligated into pcDNA5 that was 
digested with the same enzymes. 
HA-RNMT T77A WBL pcDNA5 
Site-directed mutagenesis with 
mutagenesis primers (Table 2.12) using 
pcDNA5 HA-RNMT WBL as template. 
HA-RNMT 5A 
pBMN-Z-
IRES-NEO 
(INI) 
Site-directed mutagenesis with 
mutagenesis primers (Table 2.12) using 
INI HA-RNMT as template. 
HA-RNMT 2A 
pBMN-Z-
IRES-NEO 
(INI) 
Site-directed mutagenesis with 
mutagenesis primers (Table 2.12) using 
INI HA-RNMT as template. 
HA-RNMT 7A 
pBMN-Z-
IRES-NEO 
(INI) 
Site-directed mutagenesis with 
mutagenesis primers (Table 2.12)  using 
INI HA-RNMT 5A as template. 
INI HA-RNMT T77A 
WBL 
pBMN-Z-
IRES-NEO 
(INI) 
Site-directed mutagenesis with 
mutagenesis primers (Table 2.12) using 
INI HA-RNMT WBL as template. 
HA-RNMT T77D WBL 
pBMN-Z-
IRES-NEO 
(INI) 
Site-directed mutagenesis with 
mutagenesis primers (Table 2.12) using 
INI HA-RNMT WBL as template. 
HA-RNMT S79A WBL 
pBMN-Z-
IRES-NEO 
(INI) 
Site-directed mutagenesis with 
mutagenesis primers (Table 2.12) using 
INI HA-RNMT WBL as template. 
HIS-RNMT pNIFTY 
RNMT was amplified from pBMN RNMT-
GFP by PCR using primers described in 
Table 2.13. KasI and BamHI restriction 
enzymes in NEB 2 buffer were used for 
double digestion of vector and insert. 
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2.2.10.10 Additional constructs used in this study 
The following constructs used in this study were cloned in the Cowling lab: pcDNA4 
HA-RNMT, pcDNA4 Fg-RAM, pcDNA5 Fg-RAM, INI HA-RNMT WBL, pGEX6P1 GST-
RNMT. 
The following construct used in this study was cloned in the Division of Signal 
Transduction (DSTT): pcDNA5 9E10-KPNA2, pGEX6P1 GST-KPNA2, pGEX6P1 GST-
RNMT T77A, pGEX6P1 GST-RNMT T77D. 
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Chapter 3:                                                       
Human cap methyltransferase (RNMT) N-terminal 
non-catalytic domain mediates recruitment to 
transcription initiation start sites 
 
 
3.1 Introduction 
The N7-methylguanosine cap is a structure found on the 5ʼ end of RNAs transcribed 
by RNA polymerase II. The N7-methylguanosine cap is conserved in eukaryotes and is 
essential for cell viability. It protects transcripts from degradation, and via interactions 
with cap-binding proteins, mediates several RNA processing events and ensures 
efficient translation of mRNAs. In mammals, two enzymes are required for the 
formation of the N7-methylguanosine cap: the capping enzyme, RNA 
guanylyltransferase and 5ʼ triphosphatase (RNGTT), removes the terminal phosphate 
from the 5ʼ end of nascent RNA and catalyses the addition of a reverse guanosine 
group (referred to as cap) and the RNA guanine-7 methyltransferase, RNMT, 
methylates the cap at the N-7 position. Furthermore, RNMT functions in a complex with 
the small RNMT-activating mini protein RAM. 
RNMT contains a catalytic domain, which is conserved to yeast, responsible for the 
transfer of a methyl group from S-adenosyl methionine to the N7 position of the cap. 
Several studies with yeast cap methyltransferases as well as with human RNMT have 
identified essential amino acids that are required for cell viability and in vitro catalytic 
activity (Mao et al., 1996; Saha et al., 1999; Schwer et al., 2000; Wang and Shuman, 
1997). Crystal structure analysis of the cap methyltransferase of Encephalitozoon 
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cuniculi and the catalytic domain of human RNMT localised these essential amino 
acids in the two binding pockets for the methyl donor, S-adenosyl methionine, and for 
the cap structure (Fabrega et al., 2004; Wu et al., 2007; Zeng et al., 2008). 
In addition to the highly conserved catalytic domain, mammalian RNMT contains a 
N-terminal domain of approximately 144 amino acids that is absent or not conserved in 
lower eukaryotes. The N-terminus is not required for catalytic activity since human 
RNMT 120-476 was able to complement cap methyltransferase-deficient yeast and 
both recombinant RNMT 120-476 and 144-476 retained cap methyltransferase activity 
in vitro (Saha et al., 1999; Wen and Shatkin, 2000). Furthermore, the N-terminal 
domain is dispensable for the RNMT-RAM interaction which is essential for cell viability 
in mammalian cells (Gonatopoulos-Pournatzis et al., 2011). However, the RNMT N-
terminus carries three functionally redundant nuclear localisation signals (NLS) that 
ensure nuclear localisation required for RNMT function in vivo and thus for cell viability 
(Shafer et al., 2005). The three NLS 80KKRK, 103KKRKR and 126KRK are all located 
towards the 3ʼ end of the N-terminus and thus the biological role of the upstream amino 
acids remains elusive. Thus, this chapter aims to elucidate whether the RNMT N-
terminus has a molecular function besides mediating nuclear localisation. 
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3.2 Results 
3.2.1 Influence of the RNMT N-terminus on cap 
methyltransferase activity 
Human RNMT consists of a well-characterised catalytic domain and a N-terminal 
domain without a defined function. To elucidate the function of the non-catalytic N-
terminal domain HA-tagged constructs expressing wild type RNMT and a N-terminal 
truncation mutant, RNMTcat, that lacks the first 120 amino acids were made (Figure 
3.1). RNMTcat lacks most of the N-terminus but still contains a functional NLS at amino 
acid 126. In addition, a construct expressing the N-terminus alone, RNMT-N, consisting 
of the first 120 amino acids was created (Figure 3.1). 
RNMT functions in the nucleus and its nuclear localisation is essential for cell 
viability (Shafer et al., 2005). Immunofluorescence analysis of endogenous RNMT 
confirmed nuclear localisation of the cap methyltransferase (Figure 3.2a). The three 
NLS have been shown to be functionally redundant in studies performed with GFP-
tagged constructs (Shafer et al., 2005). To confirm nuclear localisation of full-length 
HA-RNMT and the N-terminal truncation mutant RNMTcat, containing all three or only 
one NLS respectively, immunofluorescence studies were performed with HeLa cells 
transiently transfected with HA-tagged constructs (Figure 3.2b). As expected, HA-
RNMT wild type, HA-RNMTcat and the N-terminus alone (HA-RNMT-N) were observed 
to be nuclear. 
In an attempt to investigate the role of the RNMT N-terminus we compared cap 
methyltransferase activities of cellular wild type RNMT and the N-terminal truncation 
mutant, RNMTcat. The cap methyltransferase activity of RNMT can be assessed in 
vitro in an assay first described by the Shuman laboratory (Mao et al., 1995). Briefly, 
recombinant RNMT, immunoprecipitated cellular RNMT or total cell extracts are 
combined with the methyl donor S-adenosyl methionine (SAM) and an in vitro 
1! 121! 476!
Catalytic domain!N-term!
RNMT!
RNMTcat!
RNMT-N!
Figure 3.1. RNMT consists of a catalytic domain and a N-terminal domain of 
unknown function. Human RNMT consists of a catalytic domain (amino acids 
121-476, represented by a grey box) and a uncharacterised N-terminal domain 
(amino acids 1-120, represented by a white box). This schematic diagram 
represents the constructs used in this chapter; full length RNMT (1-476), RNMTcat 
(121-476) and RNMT-N (1-120). The position of nuclear localisation signals (NLS) 
are indicated with an asterisk.!
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Figure 3.2 RNMT nuclear localisation does not require the N-terminal domain.!
a) Immunofluorescence analysis was performed on HeLa cells transfected with 
siRNAs against RNMT or a control for 48 hours. The subcellular localisation of 
RNMT was detected with an anti-RNMT antibody. DAPI was used to stain DNA to 
detect nuclei and a bright field view to detect the cell membrane.!
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Figure 3.2 RNMT nuclear localisation does not require the N-terminal domain.!
b) Immunofluorescence analysis was performed on HeLa cells transiently 
transfected with pcDNA4 (control) or pcDNA4 HA-RNMT, HA-RNMTcat, HA-RNMT-
N plus pcDNA4 FLAG-RAM. The subcellular localisation of RNMT was detected via 
the HA tag. DAPI stain was used to detect nuclei and a bright field view to detect 
the cell membrane.!
!
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transcribed short piece of RNA containing a radioactively labelled cap. After incubation 
with RNMT the RNA is digested with a nuclease to cleave off the cap and the 
nucleotide mixture is resolved by thin layer chromatography (TLC). The guanosine cap 
and N7-methylguanosine cap are resolved differentially on the TLC plate and thus are 
separated. After exposure to autoradiography, the conversion of radioactively labelled 
guanosine to N7-methylguoanosine cap can be quantified using a phosphorimager 
(Figure 3.3). 
To assess whether the RNMT N-terminus influences cap methyltransferase activity 
of cellular RNMT, HEK-293 cells were transiently transfected with constructs 
expressing full-length RNMT or the catalytic domain only. Western blots were 
performed to detect expression of transiently transfected constructs and the 
transfection protocol was optimised for equal protein levels of the two RNMT variants. 
HA-RNMT and HA-RNMTcat were immunoprecipitated from HEK-293 cells using 
mouse monoclonal anti-HA antibody (Figure 3.4a). In vitro cap methyltransferase 
activity assays were performed with immunoprecipitates over a time course of 15 
minutes (Figure 3.4b) or with a titration of immunoprecipitates obtained from 5 to 40 µg 
of cell extracts (Figure 3.4c). In agreement with data published with recombinant RNMT 
(Saha et al., 1999), RNMTcat retained cap methyltransferase activity. However, 
whereas recombinant RNMTcat showed a 2-fold reduction in activity, RNMTcat 
immunoprecipitated from human cells exhibited a 1.5 to 2-fold increase in cap 
methylation compared to full-length RNMT. 
  
Figure 3.3 In vitro cap methyltransferase activity assay. RNMT activity was 
assessed in a in vitro cap methyltransferase activity assay. This schematic diagram 
represents the major steps of the assay. A typical picture of an autoradiography 
exposure is shown on the right.!
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Figure 3.4 RNMT amino acids 1-120 are not required for catalytic activity. !
a) HEK-293 cells were transiently transfected by the calcium phosphate method 
with 6 μg pcDNA4 HA-RNMT or HA-RNMTcat or vector control. Western blots were 
performed with an anti-HA antibody to detect expression of HA-RNMT and HA-
RNMTcat in 10 μg cell extracts or after immunoprecipitation from 50 μg cell 
extracts using 1.5 μg anti-HA antibody. Tubulin was detected as a loading control.	  
b) HA-RNMT and HA-RNMTcat were immunoprecipitated from 50 μg of cell 
extracts of transiently transfected HEK-293 cells using 1.5 μg anti-HA antibody. 
Following immunoprecipitation cap methyltransferase assays were performed for 
the time points indicated.!
c) As for b) but HA-RNMT and HA-RNMTcat were immunoprecipitated from the 
quantity of cell extracts indicated and cap methyltransferase assays were 
performed for 5 minutes. The charts depict the average and standard deviation of 
three independent experiments (T-test p-values of data series <0.001 for both 
charts).	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3.2.2 Analysis of RNMT recruitment to transcription start 
sites by chromatin immunoprecipitation (ChIP) 
The formation of the N7-methylguanosine cap occurs predominantly at transcription 
start sites (TSS) (Coppola et al., 1983; Rasmussen and Lis, 1993). The capping 
enzyme, RNGTT, has been shown to be recruited to Serine-5 phosphorylated CTD of 
RNA Pol II, an interaction which was shown to activate RNGTT (Ghosh et al., 2011; Ho 
and Shuman, 1999). RNMT is also recruited to TSS and interactions with RNGTT and 
RNA pol II, in combination with RNGTT, have been detected with recombinant proteins 
in vitro (Glover-Cutter et al., 2008; Pillutla et al., 1998b). To test whether the RNMT N-
terminus is required for RNMT recruitment to TSS, chromatin immunoprecipitation 
(ChIP) were performed.  
HeLa cells were transiently transfected with HA-RNMT or HA-RNMTcat together 
with FLAG-RAM. Western blots were performed to optimise equal protein levels of the 
two RNMT variants (Figure 3.5a). ChIP was performed with both anti-HA (Figure 3.5b) 
and anti-FLAG (Figure 3.5c) antibodies to provide independent confirmation of RNMT-
RAM recruitment to chromatin. Recruitment of RNMT and RAM to four c-Myc 
responsive genes, RNMT, CCND1, RuvBL1 and c-Myc, was measured. qPCR was 
performed with primers that bind to the promoter proximal regions of the described 
genes. ChIP with both HA-RNMT and FLAG-RAM showed strongly impaired 
recruitment of RNMTcat to TSS compared to full-length RNMT. The signal of RNMTcat 
was comparable to that of the negative control ChIP whereas full-length RNMT showed 
significant, although low, recruitment to chromatin. As a negative control recruitment of 
RNMT-RAM 2000 bases upstream of the c-Myc transcription initiation site (-2000) was 
measured (Figure 3.5b and c). c-Myc -2000 is a location which had previously been 
demonstrated to have reduced RNMT binding (Glover-Cutter et al., 2008).  
  
Figure 3.5 RNMT N-terminus is required for recruitment to transcription 
initiation sites.!
a) HeLa cells were transiently transfected with pcDNA4 HA-RNMT or HA-RNMTcat 
plus pcDNA4 FLAG-RAM or with pcDNA4 (control). Western blots were performed 
with anti-HA antibody to detect expression of HA-RNMT and HA-RNMTcat. Anti-
RAM antibodies were used to detect FLAG-RAM and Tubulin was detected as a 
loading control.!
b) Chromatin immunoprecipitation was performed using HeLa cells transiently 
transfected with pcDNA4 HA-RNMT or HA-RNMTcat plus pcDNA4 FLAG-RAM or 
with pcDNA4 (control). Anti-HA antibody was used to immunoprecipitate RNMT. 
PCR analysis was performed against promoter proximal regions of the genes 
indicated or 2000 bases upstream of the transcription start site of c-Myc (-2000). 
The charts depict the average mean signal relative to input and normalised to 
control for three independent experiments and the error bars represent the 
standard deviation. T-test p-value <0.05 is indicated with an asterisk.!
c) As in b) but immunoprecipitations were performed with anti-FLAG antibody to 
detect RAM. !
!
Acknowledgement of contribution: Cell transfections and immunoprecipitations 
were performed by Victoria Cowling.!
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Figure 3.5 RNMT N-terminus is required for recruitment to transcription 
initiation sites.!
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No significant ChIP signal was detected at c-Myc -2000 for either RNMT or RNMTcat 
compared to vector control.  
The most likely explanation of the observation that RNMTcat is not efficiently 
recruited to chromatin is that the first 120 amino acids are required for recruitment to 
TSS. To investigate whether the RNMT N-terminus alone is sufficient for chromatin 
recruitment, the experiments were repeated with full length and the N-terminal domain 
of RNMT. HeLa cells were transiently transfected with HA-RNMT or HA-tagged N-
terminal domain, HA-RNMT- N (amino acids 1-120, Figure 3.1) and western blots were 
performed to optimise equal protein levels of the two RNMT variants (Figure 3.6a). 
ChIP was performed with anti-HA antibody to detect chromatin recruitment of RNMT 
(Figure 3.6b). Interestingly, RNMT-N exhibited a strong ChIP signal for all tested 
genes. For three out of the four genes the recruitment was even higher than full-length 
RNMT. These experiments show that the RNMT N-terminus is not only essential but 
sufficient for RNMT recruitment to TSS. 
Cellular RNMT exists as a heterodimer with its activating subunit, RAM, and thus, an 
obvious question is whether RAM is required for RNMT recruitment. Since RAM binds 
to RNMTcat but does not bind to RNMT-N (Gonatopoulos-Pournatzis et al., 2011) it 
should follow that RAM is not required for RNMT recruitment to TSS (Figure 3.5b and 
3.6b). 
 
3.2.3 Investigating the molecular mechanism for RNMT 
chromatin recruitment 
RNMT recruitment to TSS is mediated by its first 120 amino acids. Unlike RNGTT, 
no direct interaction with RNA pol II has been demonstrated for RNMT, however, 
recombinant RNMT was immunoprecipitated with recombinant RNGTT alone or in a 
tertiary complex with RNA pol II (Pillutla et al., 1998b). To test whether the RNMT N- 
terminus mediates an interaction with RNGTT and/or RNA pol II CTD affinity 
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Figure 3.6 RNMT is recruited to chromatin via the N-terminus.!
a) HeLa cells were transiently transfected with pcDNA4 HA-RNMT or HA-RNMT-N 
plus pcDNA4 FLAG-RAM or with pcDNA4 (control) and lysates were subjected to 
SDS-PAGE and western blot were performed. Anti-HA, anti-RAM and anti-Tubulin 
antibodies were used to detect HA-RNMT, RAM and Tubulin from cell extracts.!
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Figure 3.6 RNMT is recruited to chromatin via the N-terminus.!
b) Chromatin immunoprecipitation was performed with lysates of HeLa cells 
transiently transfected as in a). Anti-HA antibody was used to immunoprecipitate 
RNMT. PCR analysis was performed against promoter proximal regions of the 
genes indicated. The charts depict the average mean signal relative to input and 
normalised to control of three independent experiments and the error bars 
represent the standard deviation. T-test p-value <0.05 is indicated with an asterisk.!
!
Acknowledgement of contribution: Cell transfection and immunoprecipitation were 
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purification assays and immunoprecipitations were performed with recombinant HIS-
RNMT and GST-RNGTT. However, despite extensive effort using a range of buffers 
(RIPA buffer, F-Buffer, Dignam C and Dignam C + 0.1 % NP40) no direct and specific 
interaction could be detected (Figure 3.7). Furthermore, previous attempts to detect an 
interaction with cellular RNMT and RNGTT were not successful (data not shown). 
Finally, it was tested whether RNMT interacts directly with RNA pol II. Due to 
previous unsuccessful attempts to co-immunoprecipitate cellular exogenous or 
endogenous RNMT and RNA pol II, affinity purification with recombinant protein was 
attempted. Recombinant GST, GST-RNGTT and GST-RNMT were incubated with 
HeLa nuclear cell extracts and affinity purified using glutathione sepharose. 
Precipitated proteins were analysed by SDS-PAGE and western blotting (Figure 3.8). A 
robust interaction of RNGTT with Serine-5 phosphorylated but not unphosphorylated 
RNA pol II CTD was detected, confirming the results of previous publications (Yue et 
al., 1997). However, no interaction was detected between recombinant GST-RNMT 
and RNA pol II. Furthermore, no interaction was observed between recombinant GST-
RNMT or GST-RNGTT with cellular RNGTT or RNMT respectively (Figure 3.8). These 
data indicate that RNMT may not be recruited to chromatin via a direct interaction with 
either RNGTT or RNA pol II. However, a transient interaction between RNMT and 
RNGTT or RNA pol II, or the requirement of additional proteins for mediating such an 
interaction cannot be excluded. 
 
  
Figure 3.7 An interaction between RNMT and RNGTT is not detectable.!
2 μg of purified recombinant HIS-RNMT was incubated with 1.5 μg of purified 
recombinant GST-RNGTT and affinity purified with nickel agarose or glutathione 
sepharose. Proteins eluted were resolved by SDS-PAGE and stained by 
Coomassie blue (upper panel) or analysed by western blot using anti-RNGTT or 
anti-RNMT antibodies (lower panel).!
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Figure 3.8 A direct interaction between RNMT and phosphorylated RNA 
polymerase II is not detectable.!
1.5 μg of purified recombinant GST, GST-RNMT or GST-RNGTT was incubated 
with 2 mg of HeLa nuclear cell extracts and affinity purified with glutathione 
sepharose. Proteins eluted were resolved by SDS-PAGE and analysed by western 
blotting to detect Serine-5 phosphorylated (pS5) or total (PAN) RNA polymerase II 
CTD, GST, RNGTT or RNMT. Nonspecific bands are indicated with an asterisk.!
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3.3 Discussion 
Human RNMT consists of a well-characterised catalytic domain at the C-terminus 
and an uncharacterised N-terminal domain. While the catalytic domain is conserved to 
yeast the N-terminal domain is only found in mammalian RNMT. The N-terminus is not 
required for complementing cap methyltransferase deficient yeast cells and it is also 
dispensable for recombinant RNMT activity (Saha et al., 1999). Human RNMT carries 
three nuclear localisation signals (NLS) that ensure nuclear localisation and are 
required for cell viability (Shafer et al., 2005). Two of the NLS are located within the first 
120 amino acids whereas the third one is located immediately next to the N-terminus in 
the catalytic domain. Previous work using GFP-tagged constructs has demonstrated 
that the three NLS are functionally redundant (Shafer et al., 2005). Thus not 
surprisingly, our immunofluorescence analysis confirmed nuclear localisation of wild 
type RNMT and also RNMTcat, which only contains the 126 KKKR NLS. 
In order to characterise the function of the human RNMT N-terminus it was 
investigated whether the N-terminal domain regulates cellular cap methyltransferase 
activity. As observed with recombinant protein, RNMT purified from HeLa cells did not 
require the first 120 amino acids for its catalytic activity. However, in contrast to 
previously described measurements made with recombinant RNMTcat, which exhibited 
a 2-fold decrease in cap methyltransferase activity (Saha et al., 1999), cellular 
RNMTcat was 1.5 - 2-fold more active than full-length RNMT. This contrast between 
recombinant and cellular RNMT may be due to differences in protein folding, post-
translational modifications or interactions with other proteins. 
The recruitment of RNMT to TSS is essential since N7-methylguanosine cap 
formation occurs co-transcriptionally (Chiu et al., 2002; Coppola et al., 1983; Moteki 
and Price, 2002; Rasmussen and Lis, 1993). ChIP analysis of both yeast cap 
methyltransferase Abd1p and human RNMT have demonstrated that the cap 
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methyltransferase links to promoters, coding regions or even 3ʼ ends (Glover-Cutter et 
al., 2008; Komarnitsky et al., 2000; Schroeder et al., 2000). To test whether the N-
terminus is required for RNMT recruitment to chromatin ChIP analysis was performed 
using exogenously expressed proteins. RNMT was observed to be recruited to TSS, 
though the ChIP signal was low. Interestingly, RNMTcat was not recruited to chromatin. 
Furthermore, ChIP of RNMT-N demonstrated that the RNMT N-terminus is sufficient to 
mediate the recruitment to TSS.  
The yeast methyltransferase Abd1p recruitment to chromatin was demonstrated to 
be dependent on phosphorylated RNA pol II CTD (Schroeder et al., 2000). However, to 
date no direct interaction has been observed between mammalian RNMT and RNA pol 
II. In contrast, a direct interaction between mammalian RNGTT and phosphorylated 
RNA pol II CTD has been reported and confirmed by several laboratories (Ghosh et al., 
2011; McCracken et al., 1997; Yue et al., 1997). It was found that recombinant RNMT 
can interact with RNGTT in vitro and a trimeric complex was detected when 
recombinant RNMT, RNGTT and cellular RNA pol II were incubated together (Pillutla et 
al., 1998b). However, despite exploiting different experimental approaches a direct 
interaction between RNMT and RNGTT could not be confirmed. Abundant nonspecific 
immunoprecipitation of RNMT was observed in control experiments using antibodies 
alone. Such control experiments were not shown in Pillutla et al., 1998. In the present 
study a robust interaction between RNGTT and phosphorylated RNA pol II was 
observed but no direct interaction was detectable between RNMT and RNA pol II. 
Further work in the Cowling laboratory demonstrated however that recruitment of 
RNMT and RNMT-N is dependent on phosphorylated RNA Pol II CTD (Aregger and 
Cowling, 2013). 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) was 
demonstrated to inhibit the transcription-regulating subset of CDKs including CDK7, 
CDK8 and CDK9 leading to inhibition of RNA pol II CTD phosphorylation (Dubois et al., 
1994; Yankulov et al., 1995). ChIP experiments with DRB-treated cells demonstrated 
	   	  114 
that inhibition of RNA pol II CTD phosphorylation significantly reduces recruitment of 
RNMT to transcription initiation sites (Aregger and Cowling, 2013). However, the 
precise molecular details of how RNMT is recruited to TSS still remain unclear. 
The RNMT N-terminus is not conserved in yeast homologs but yeast Abd1p was 
demonstrated to be recruited to chromatin in an RNA pol II-dependent manner 
(Komarnitsky et al., 2000; Schroeder et al., 2000). Although we could not detect an 
interaction with RNA pol II additional data from our laboratory suggests that chromatin 
recruitment of human RNMT is also dependent on RNA pol II, thus sharing a common 
mechanism with yeast. Whereas in yeast the catalytic domain is sufficient for 
recruitment to TSS the mammalian cap methyltransferase requires the N-terminus for 
efficient recruitment. The transcription machinery is much more complex in vertebrates 
and thus it can be speculated that the RNMT N-terminus may have evolved to maintain 
recruitment of RNMT to TSS when confronted with the mammalian RNA pol II complex. 
It is also possible that the N-terminal domain may have evolved to regulate RNMT 
recruitment to chromatin. 
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Chapter 4:                                                            
RNMT is phosphorylated at Threonine-77 in a cell 
cycle-dependent manner by CDK1/Cyclin B 
 
 
4.1 Introduction 
Until recently, the addition of the N7-methylguanosine cap to the 5ʼ termini of RNA 
pol II transcripts was thought to be a ubiquitous process and the three enzymatic 
reactions required for N7-methylguanosine cap formation (triphosphate, 
guanylyltransferase and methyltransferase) always occur to completion producing a 
functional N7-methylguanosine cap. However, recent evidence suggests that methyl 
cap formation can be regulated. Several studies identified incompletely capped mRNAs 
lacking the methyl moiety on the cap structure and also revealed a special machinery 
targeting these aberrantly capped mRNAs (Chang et al., 2012; Cole and Cowling, 
2009; Cowling and Cole, 2007c; Fernandez-Sanchez et al., 2009; Jiao et al., 2010, 
2013). Furthermore, it was observed that growth factors can stimulate formation of the 
N7-methylguanosine cap. In addition, the Myc and E2F1 transcription factors, which 
are essential for cell growth and proliferation, were found to upregulate N7-
methylguanosine cap formation of specific target genes (Aregger and Cowling, 2012; 
Cole and Cowling, 2009; Cowling and Cole, 2007a; Fernandez-Sanchez et al., 2009).  
All these studies suggest that N7-methylguanosine cap formation can be regulated in 
cells and this chapter aims to investigate whether signalling pathways directly regulate 
the cap methyltransferase RNMT. 
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Enzymatic function can be modulated in response to signalling cascades, which 
results in the addition or removal of chemical moieties to the protein. These post-
translational modifications often alter protein properties and are widely used in 
signalling pathways. One of the most frequently observed and arguably the most 
widespread type of post-translational modification used in signalling pathways is 
protein phosphorylation. Protein phosphorylation was found to regulate most eukaryotic 
cellular processes and it is thought that 30% of all proteins are phosphorylated in 
human cells (Cohen, 2002). Not all phosphorylation events necessarily have a 
biological role, however the addition or removal of phosphate groups can modify the 
function of a protein in several different ways; it can increase or decrease catalytic 
activity, alter protein movement and thus localisation, increase protein stability or mark 
proteins for degradation and inhibit or create protein-protein interactions. 
In chapter 3 the RNMT N-terminus was observed to negatively regulate cellular 
RNMT activity contradicting previous studies with recombinant protein (Saha et al., 
1999). Thus, an intriguing possibility is that cellular signaling pathways use the N-
terminal domain to regulate RNA cap methylation. Several studies exploiting large-
scale phosphoproteomic analysis have identified phosphorylated RNMT peptides in 
mouse and human cells (Hornbeck et al., 2012). However, no site-specific analysis was 
reported to date characterising sites and functions of any RNMT post-translational 
modifications. Therefore, the aim of this chapter is to investigate whether RNMT carries 
post-translational modifications and if so to determine their nature and localisation. 
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4.2 Results 
4.2.1 Biochemical analysis of RNMT to detect post-
translational modifications 
For the identification of post-translational modifications HEK-293 cells stably 
transfected with retroviral constructs expressing HA-RNMT to levels equivalent to 
endogenous RNMT or vector control were used (Figure 4.1a). 
Initially, two-dimensional gel electrophoresis (2D SDS-PAGE) analysis was 
performed to separate RNMT by its molecular weight and its isoelectric point (pI) (the 
pH at which the protein carries no electrical charge). Unmodified HA-RNMT has a 
theoretical pI of 5.94, which can be altered by post-translational modifications; for 
example, one phospho-group would lower the pI of RNMT to 5.81. 
Stably expressed HA-RNMT was immunoprecipitated from HEK-293 cells, subjected 
to 2D SDS-PAGE and analysed by western blot (Figure 4.1a and b). RNMT was found 
to exist with more than one isoelectric point indicating that it is post-translationally 
modified. The fact that several spots are visible suggests that RNMT carries several 
post-translational modifications. 
Preliminary work in the Cowling laboratory using orthophosphate-labelling showed 
that endogenous RNMT is phosphorylated. In order to confirm this work with 
exogenous RNMT, HEK-293 cells stably expressing HA-RNMT were labelled with [32P]-
orthophosphate and HA-RNMT was immunoprecipitated and subjected to 
autoradiography (Figure 4.2). A specific radiolabelled band was visible after 
immunoprecipitation with anti-HA antibody suggesting that HA-RNMT is 
phosphorylated and thus confirming the observation obtained with endogenous RNMT. 
  
Figure 4.1 Analysis by two-dimensional gel electrophoresis demonstrates 
that RNMT is post-translationally modified. !
a) HA-RNMT was immunoprecipitated from extracts of HEK-293 cells stably 
expressing HA-RNMT or vector control using anti-HA antibody. Western blots were 
performed to detect RNMT and Tubulin.!
b) Immunoprecipitated HA-RNMT was analysed by two-dimensional gel 
electrophoresis using a pH range from 3 to 10 and separated protein was 
subsequently detected by western blotting using anti-RNMT antibody.!
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Figure 4.2 Exogenous RNMT is phosphorylated. HEK-293 cells stably 
expressing HA-RNMT or a vector control were incubated with 32P-orthophosphate 
and HA-RNMT was immunoprecipitated with anti-HA antibody, resolved by SDS-
PAGE and subjected to autoradiography.!
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4.2.2 Mass spectrometry analysis of RNMT post-
translational modifications 
Having observed that RNMT is phosphorylated and possibly carries several post-
translational modifications, we wanted to identify the modified sites and the nature of 
the post-translational modifications. To this end, mass spectrometry analysis was 
performed with HA-RNMT immunoprecipitated from HEK-293 cells. 
Immunoprecipitates were resolved by SDS-PAGE and stained with Coomassie blue 
(Figure 4.3a). After trypsin-digestion of the visible protein band mass spectrometry 
analysis was performed in house by the Fingerprints Proteomics Facility. The samples 
were analysed by LC-MS/MS on a 4000 QTrap mass spectrometer for protein 
identification. A protein coverage of 66% of total RNMT amino acids was obtained. 
Having identified RNMT in the immunoprecipitates, precursor ion scanning was 
performed to identify phosphorylated peptides. This technique detects 
phosphopeptides prior to generation of MS/MS data. Precursor ion scanning followed 
by LC-MS/MS was run on a more sensitive LTQ Orbitrap Velos Pro mass 
spectrometer. The MS/MS data was subsequently searched against the SwissProt or 
IPI human databases using the Mascot Daemon to identify the site(s) of 
phosphorylation. Precursor ion scanning identified two phosphopeptides located at the 
RNMT N-terminus carrying one phospho group each (Figure 4.3b and c). The Mascot 
probability based score of the first peptide was statistically significant (p-value < 0.05) 
whereas the score for the second peptide was not significant but still relatively high 
compared to its expected value. The exact phosphorylation sites could not be 
determined by mass spectrometry since both peptides contained multiple candidate 
phosphorylated amino acids with high scores (Figure 4.3b). 
  
HA-RNMT!
a)!
Co
nt
ro
l!
HA
-R
NM
T!
100!
160!
80!
60!
50!
40!
30!
20!
LC!
HC!
kDa!
Figure 4.3 RNMT is phosphorylated at the N-terminus.!
a) HA-RNMT was immunoprecipitated from 40 mg cell extracts of HEK-293 cells 
stably expressing HA-RNMT or an empty vector control using 40 µg of anti-HA 
antibody. Immunoprecipitates were resolved by SDS-PAGE and stained by 
Coomassie blue. The band marked with an asterisk (HA-RNMT) was excised and 
analysed by mass spectrometry. HA-RNMT, antibody heavy chain (HC) and light 
chain (LC) are indicated.!
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Figure 4.3 RNMT is phosphorylated at the N-terminus.!
b) Mass spectrometry analysis using LC-MS/MS precursor ion search identified two 
phosphorylated RNMT peptides. The table depicts the amino acid sequence of the 
two peptides with the candidate phosphorylated amino acid underlined and lists the 
mascot score and expected value for each candidate. Mascot probability based 
scores higher than 38 are considered to be significant (p-value < 0.05).!
c) The diagram depicts the human RNMT amino acid sequence. The two 
phosphorylated peptides identified by mass spectrometry are underlined and 
candidate phosphorylated amino acids are marked with grey shadows.!
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In addition to phosphorylation, mass spectrometry analysis also identified acetylated 
and methylated RNMT peptides. The highest acetylation scores were obtained for K83 
and K348 whereas the highest methylation scores were detected on E25 and D97. 
However, due to time constrains the acetylation and methylation sites were not 
validated or investigated further in order to focus on understanding RNMT 
phosphorylation. 
 
4.2.3 Identification of the major RNMT phosphorylation site 
In order to validate the phosphoproteomic analysis and more specifically determine 
the exact phosphorylation sites, orthophosphate labelling was performed in 
combination with a site-specific mutation approach. Candidate phosphorylated amino 
acids located on the phosphopeptides identified by mass spectrometry were mutated to 
Alanine, which cannot be phosphorylated (Figure 4.4a). Initially, all possible 
phosphorylation sites were mutated and stably expressed in HEK-293 cells. HA-RNMT 
5A contains mutations of the five candidates of the first phosphopeptide, HA-RNMT 2A 
carries two mutations of the second phosphorylated peptide and HA-RNMT 7A has all 
possible candidates mutated to Alanine. The cells were incubated with P32-
orthophosphate and HA-RNMT was immunoprecipitated and subjected to 
autoradiography (Figure 4.4b, left panel). Interestingly, the mutation of the 
phosphorylation candidates of the first phosphopeptides (HA-RNMT 5A) did not abolish 
the radioactive signal whereas mutation of all candidates (7A) or the ones from the 
second phosphorylated peptide (2A) resulted in the loss of the radiolabelled band. This 
suggests that the major phosphorylation site(s) reside on the second identified peptide. 
To investigate the contribution of the candidate amino acid of the second phospho 
peptide to total RNMT phosphorylation, the single Alanine mutants T77A and S79A 
were created and P32-orthophosphate labelling was repeated with these single mutants 
(Figure 4.4b, right panel). Mutation of Threonine-77 reduced the radioactive signal in 
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Figure 4.4 RNMT is predominantly phosphorylated at Threonine-77.!
a) Schematic diagram depicting the two identified phosphorylation sites and RNMT 
candidate phosphorylation mutants. Candidate phosphorylated amino acids were 
mutated to Alanine. RNMT 5A contains the five mutations S21A, S24A, T26A, 
S28A and S29A whereas RNMT 2A contains the two mutations T77A and T79A. 
RNMT 7A has all seven phosphorylation candidates mutated to Alanine while 
RNMT T77A and RNMT S79A contain single amino acid mutations.!
b) HEK-293 cells stably expressing HA-RNMT WT, 5A, 2A, 7A, T77A and S79A or 
an empty vector control (C) were incubated with 32P-orthophosphate. HA-RNMT 
was immunoprecipitated from 2.5 mg of cell extracts using 10 µg of anti-HA 
antibody, resolved by SDS-PAGE and subjected to autoradiography (upper panel). 
HA-RNMT is indicated with an arrow and an asterisk indicates nonspecific bands. 
Immunoprecipitates were analysed by western blotting to detect RNMT (lower 
panel).!
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average by 70 % whereas mutation of Serine-79 only reduced the signal by 52 %. The 
observation that mutation of a single amino acid led to loss of incorporation of [32P]-
orthophosphate suggests that in the cell system studied there is only one major 
phosphorylation site. Although a second phosphorylation event has been observed by 
mass spectrometry this site seems to be phosphorylated less abundantly or its 
phosphorylation may be dependent on Threonine-77. Overall we concluded that 
Threonine-77 (T77) is the major phosphorylation site of RNMT.  
In order to test whether this phosphorylation site has a biological function cell 
proliferation assays were performed by Victoria Cowling. Endogenous RNMT-RAM was 
depleted from HeLa cells using siRNAs and RNMT-RAM was replaced with HA-RNMT 
wild type or T77A in combination with FLAG-RAM (data not shown). Depletion of 
RNMT-RAM results in loss of cell accumulation (Gonatopoulos-Pournatzis et al., 2011). 
While wild type RNMT-RAM could rescue proliferation RNMT T77A-RAM did not. This 
suggests that RNMT T77 phosphorylation is required for normal cell proliferation and 
thus has a biological function in cells.  
 
4.2.4 Development of a phospho-specific antibody against 
RNMT Threonine-77 
To more efficiently and specifically investigate RNMT T77 phosphorylation a 
phospho-specific antibody against the T77 phosphorylation site was raised in sheep 
and affinity purified against phosphorylated peptides by the Division of Signal 
Transduction Therapy (DSTT) at the College of Life Sciences, Dundee. To characterise 
the antibody and test whether it was phospho-specific HA-RNMT WT or T77A was 
immunoprecipitated from HeLa cells and SDS-PAGE and western blots were 
performed (Figure 4.5a). The phospho-specific antibody only detected wild type protein 
but not the mutant. Furthermore, when RNMT was immunoprecipitated in the absence 
of phosphatase inhibitors no signal was detected for phosphorylated T77 (Figure 4.5b).  
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Figure 4.5 Characterisation of a phospho-specific antibody against RNMT 
Threonine-77. !
a) HA-RNMT was immunoprecipitated from 0.6 mg HeLa cells stably expressing 
HA-RNMT WT, T77A or an empty vector control (C) using 7 µg anti-HA antibody. 
Immunoprecipitates were resolved by SDS-PAGE and analysed by western blotting 
to detect T77-phosphorylated and total RNMT. !
b) As in a) but HA-RNMT WT was immunoprecipitated in the presence or absence 
of phosphatase inhibitors.!
c) Endogenous RNMT was immunoprecipitated from 0.6 mg HeLa cells using 1.5 
µg anti-RNMT antibody. Anti-HA antibody was used as a control. 
Immunoprecipitates were resolved by SDS-PAGE and analysed by western blotting 
to detect phosphorylated and total RNMT. !
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Finally, endogenous RNMT was immunoprecipitated using anti-RNMT antibodies 
and the phospho-specific antibody also recognised phosphorylation of the 
immunoprecipitated endogenous protein (Figure 4.5c). Therefore, the produced 
antibody specifically recognises T77 phosphorylated RNMT.  
 
4.2.5 Identification of a Cyclin-dependent kinase and cyclin 
consensus sequence 
Protein kinase substrate specificity is based not only on the phosphorylation site but 
also on a short consensus sequence flanking the phosphorylation site. The 
identification of a consensus sequence near a phosphorylated amino acid can indicate 
the kinase responsible for phosphorylation. The RNMT T77 phosphorylation site was 
analysed using the online motif search tools Scansite (http://scansite.mit.edu) and 
Eukaryotic Linear Motif (ELM) resource (http://elm.eu.org). Both resources compare 
user-submitted protein sequences with experimentally validated motifs and thus 
provide a tool to discover putative linear motifs in a target protein (Dinkel et al., 2012; 
Obenauer et al., 2003). Using these online resources the T77 site was recognised as a 
proline-directed Serine/Threonine kinase group and more specifically as a Cyclin-
dependent kinase motif (S/T-P-x-K/R). Furthermore, immediately adjacent to the T77 
phosphorylation site a cyclin recognition site (R-x-L) was predicted (Figure 4.6).  
It should be noted that further upstream of the T77 phosphorylation site, the RNMT 
sequence 62FEDDL resembles the mTOR signalling (TOS) motif (F-E/D/Q/S-M/I/L/V-
E/D-M/I/L/V) which is required for interacting with the mTORC1 subunit Raptor (Schalm 
and Blenis, 2002). However, the sequence does not match the TOS motif completely 
and incubation with the mTORC1 inhibitor Rapamycin did not affect RNMT T77 
phosphorylation (data not shown). 
 
Figure 4.6 RNMT Threonine-77 resides within a Cyclin-dependent kinase 
recognition site.!
Schematic diagram depicting the RNMT amino acid sequence around 
Threonine-77. Cyclin-dependent kinase and cyclin recognition sites are underlined 
and marked in bold and the consensus sequences are indicated below (Dinkel et 
al., 2012; Obenauer et al., 2003).!
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4.2.6 Cyclin-dependent kinases 
Cyclin-dependent kinases (CDKs) are a group of Serine-/Threonine-kinases that 
form complexes with cyclin proteins. Formation of the CDK-cyclin complex results in a 
conformational change that is required for the kinase activity. Substrate specificity of 
the complex is conferred by both the CDK and the cyclin; CDKs recognise a consensus 
sequence of S/T-P-x-K/R (x is any amino acid, phosphorylation site underlined) and 
cyclins bind a R-x-L motif in close proximity of the phosphorylation site providing further 
specificity (Adams et al., 1996; Chen et al., 1996; Songyang et al., 1994). 
CDKs in complex with cyclin are the main regulators of the eukaryotic cell cycle, 
which can be divided into four phases: G1, S, G2 and M-phase. During G1 or gap-
phase the cell prepares for DNA replication. S-phase is defined as the stage during 
which DNA synthesis occurs. After replication cells enter a second gap phase, G2, 
which is required to prepare for division. The last phase is called M-phase, which 
stands for mitosis. In M-phase the replicated chromosomes segregate into two new 
nuclei and finally the cell undergoes cytokinesis to form two daughter cells (Johnson 
and Walker, 1999). 
CDKs coordinate the events of the cell cycle and integrate extracellular and 
intracellular signals. They are activated during specific points during the cell cycle and 
when activated they phosphorylate selected proteins to induce downstream processes 
that control progression through the cell cycle. In humans nine CDKs have been 
identified of which four are active during the cell cycle (Figure 4.7a). CDK4/Cyclin D 
and CDK6/Cyclin D are active during G1 phase and are required for progression 
through G1 due to their ability to suppress the anti-proliferative effects of the 
retinoblastoma tumour suppressor protein (Rb). CDK2/Cyclin E controls the transition 
from G1 into S-phase and CDK2/Cyclin A is required for entry and completion of S-
phase. Cyclin A also associates with CDK1, which regulates the G2/M-phase transition. 
M-phase itself is mainly regulated by CDK1/Cyclin B, which phosphorylates targets  
CDK7/CyclinH!
  CDK8/CyclinC!
    CDK9/CyclinT!
      CDK12/Cyclin K!
        (CDK13/Cyclin K)!
P!P!P!
P!P!
RNA 
Pol II! DNA!
Transcription!
CDK4/!
Cyclin D!
!
CDK6/!
Cyclin D!
CDK2/Cyclin E!
CDK2/!
Cyclin A!
CDK1/!
Cyclin A!
CDK1/!
Cyclin B!
 M!
G1!
G0!
S!
G2!
Cell Cycle!
a)!
Figure 4.7 RNMT Cyclin-dependent kinases regulate the cell cycle and 
transcription.!
a) This schematic diagram illustrate the stages of the eukaryotic cell cycle 
(coloured arrows) and the CDK/Cyclin complexes (coloured lines) that are active 
during a specific phase of the cell cycle.!
b) This schematic diagram illustrate the major CDK/Cyclin complexes that regulate 
transcription by phosphorylating the C-terminal domain of RNA polymerase II.!
b)!
!
130!
	   	  131 
such as lamins, histones or components of the mitotic spindle. Finally, to exit mitosis 
cyclin A and B must be degraded leading to the inactivation of CDK1 (Johnson and 
Walker, 1999). 
As described in chapter 1, CDKs also play an important role in the regulation of 
transcription. RNA polymerase II function is highly dependent on sequential 
phosphorylation of several amino acids of its C-terminal domain (CTD) during 
transcription initiation, elongation and termination. Several CDKs have been implicated 
in CTD phosphorylation (Figure 4.7b): during transcription initiation the CTD is 
phosphorylated by CDK7/Cyclin H/MAT1, which is part of the general transcription 
factor TFIIH, and to some extent by CDK8/Cyclin C, which forms a subunit of the 
mediator complex. CTD phosphorylation by CDK9/Cyclin T, which is the catalytic 
subunit of the positive transcription elongation factor p-TEFb, is required for 
transcription elongation. Furthermore, there is initial evidence that CDK12 is also 
involved in CTD phosphorylation and CDK13 expressed CTD kinase activity in vitro. 
The phosphorylation pattern of the CTD mediates recruitment of many transcription 
and RNA processing factors and thus not only regulates transcription itself but also 
RNA maturation (Hsin and Manley, 2012). 
 
4.2.7 Regulation of the CDK/Cyclin complexes 
CDKs are regulated in many different ways including subunit binding and 
phosphorylation events. In an unmodified monomeric state CDKs are catalytically 
inactive. A flexible loop, called the T-loop or activation segment, blocks the substrate 
binding at the entrance of the active site cleft. Furthermore, several key residues in the 
ATP binding site are not correctly positioned. Thus, the primary mechanism of CDK 
activation is mediated by the binding of the cyclin subunit, which causes a major 
change in the conformation of the CDK active site (Jeffrey et al., 1995). The most 
obvious change is the orientation of the T-loop, which lies almost flat at the entrance of 
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the active site upon cyclin-binding. Furthermore, the residues of the active site are 
positioned in a way that allows interaction with ATP (Jeffrey et al., 1995). As mentioned 
above, CDK-cyclin binding is specific since CDKs do not bind all cyclins. The 
expression of most cyclins oscillates throughout the cell cycle. This is in part achieved 
by induction of transcription of many cyclins during G1/S transition and often involves 
positive feedback loops leading to a rapid rise in cyclin levels (Morgan, 1997). 
Furthermore, regulated ubiquitin-dependent proteolysis controls the levels of cyclins; 
mitotic cyclins are rapidly degraded towards the end of mitosis and this is necessary to 
prepare for the next cell cycle (King et al., 1996). Finally, cyclins can be regulated by 
subcellular localisation; the levels of mitotic cyclin B increase in S and G2 phase but 
remain in the cytoplasm and CDK1/Cyclin B is unable to phosphorylate its nuclear 
target proteins. Only during mitosis does cyclin B become phosphorylated which 
causes translocation of the complex into the nucleus (Li et al., 1997). 
In addition to cyclin binding, CDKs are activated by phosphorylation at a conserved 
site in the t-loop of the kinase domain. Phosphorylation of the t-loop does not 
substantially alter the conformation of the CDK/Cyclin complex but flattens the t-loop, 
which stabilises the interaction of the complex which may lead to improved protein-
substrate binding (Russo et al., 1996a). The t-loop phosphorylation is catalysed by the 
CDK-activating kinase (CAK), which is composed of CDK7/Cyclin H/MAT1. As 
mentioned above, in addition to its role as CAK, CDK7/Cyclin H/MAT1 also exists as a 
subunit in the TFIIH complex regulating transcription (Fisher, 2012). 
Phosphorylation of CDKs does not always lead to kinase activation. Phosphorylation 
of Tyrosine-15 or Threonine-14 inhibits CDK activation. The side chains of these amino 
acids form the roof of the ATP binding pocket and phosphorylation may alter their 
orientation (De Bondt et al., 1993; Jeffrey et al., 1995; Morgan, 1997). For example, 
CDK1 is kept inactive by Tyrosine-15 and Threonine-14 phosphorylation catalysed by 
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WEE1 and MYT1. During mitosis WEE1 and MYT1 activity drops and CDK1 inhibitory 
phosphorylation is removed by the phosphatase CDC25 (Boutros et al., 2006). 
Finally, the activity of many CDKs is inhibited by CDK-inhibitory subunits that 
interact with both cyclin and CDKs and occupy the ATP-binding site (Russo et al., 
1996b). These inhibitors, such as p21 or p27, control CDK activity in response to 
extracellular and intracellular signals. 
 
4.2.8 Identification of the signaling pathway regulating 
RNMT Threonine-77 phosphorylation 
As the RNMT T77 phosphorylation site resides within a CDK recognition site and 
next to a cyclin binding motif the possibility that CDK/Cyclin complexes regulate RNMT 
phosphorylation was explored using kinase inhibitors. The transcription-regulating 
subset of CDKs including CDK7, CDK8 and CDK9 can be inhibited by 5,6-dichloro-1-β-
D-ribofuranosylbenzimidazole (DRB) which leads to a reduction in RNA pol II CTD 
phosphorylation (Dubois et al., 1994; Yankulov et al., 1995). As RNMT is thought to 
function co-transcriptionally initial experiments were performed to investigate whether 
RNMT becomes phosphorylated by transcription-regulating CDKs by inhibiting CDK7, 
CDK8 and CDK9 activity with DRB. HeLa cells were stably transfected with HA-RNMT 
WT and T77A and incubated over a time course with 50 µM DRB at 37 °C. 
Immunoprecipitated HA-RNMT was resolved by SDS-PAGE and total and T77 
phosphorylated RNMT was analysed by western blot (Figure 4.8, upper panel). 
Unexpectedly, RNMT phosphorylation levels did not change upon DRB treatment. To 
confirm that CDK7, CDK8 and CDK9 were inhibited levels of RNA pol II CTD 
phosphorylation was detected by western blots (Figure 4.8, lower panel). While total 
RNA pol II levels did not change upon incubation with DRB, the phosphorylation pattern 
of Serine-2 and Serine-5 was altered which is indicative for inhibition of RNA pol II  
Figure 4.8 DRB does not inhibit RNMT Threonine-77 phosphorylation. !
HeLa cells stably expressing HA-RNMT WT or T77A were incubated with 50 μM 
5,6-Dichlorobenzimidazole-1-β-D-ribofuranoside (DRB) for the indicated time 
points. HA-RNMT was immunoprecipitated from 0.6 mg cell extracts using 7µg 
anti-HA antibody. Immunoprecipitates were resolved by SDS-PAGE and analysed 
by western blotting to detect Threonine-77 phosphorylated and total RNMT (upper 
panel). The same cell extracts were resolved by SDS-PAGE and western blots 
were performed to detect total (PAN), CTD Serine-2 phosphorylated (pS2) and 
Serine-5 phosphorylated (pS5) RNA polymerase II and Tubulin (lower panel). For 
total RNA polymerase II (PAN) short and long exposures are shown.!
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phosphorylation by DRB. RNA pol II was detected as a ladder with antibodies against 
both total (PAN) and CTD Serine-5/Serine-2 phosphorylated (pS5/pS2) RNA Pol II, 
which upon DRB treatment was shifted towards decreased molecular weight 
suggesting reduced phosphorylation levels of the CTD. Therefore, these experiments 
are indicating that transcription-regulating CDKs do not regulate RNMT T77 
phosphorylation. 
The remaining CDK/Cyclin complexes regulate the cell cycle. In order to investigate 
whether they phosphorylate RNMT T77 specific inhibitors were used. Roscovitine is an 
ATP-analogue that inhibits CDK1, CDK2, CDK5, CDK7, and CDK9 (Meijer and 
Raymond, 2003). Stably transfected HeLa cells were treated with a titration of 
Roscovitine for 20 minutes at 37°C. HA-RNMT was immunoprecipitated and western 
blots were performed (Figure 4.9a). Interestingly, a clear reduction in RNMT 
phosphorylation was observed upon incubation with Roscovitine. A time course over 60 
minutes with 50 µM Roscovitine also showed that T77 phosphorylation is impaired 
suggesting that cell cycle-regulating CDKs are responsible for RNMT phosphorylation 
(Figure 4.9b). 
One of few specific CDK inhibitors available is RO-3306 which shows very high 
specificity against CDK1 with an inhibitor constant (Ki) of 35 nM (Vassilev et al., 2006). 
Thus, RO-3306 was used to test whether specific inhibition of CDK1 would result in 
reduced RNMT T77 phosphorylation. Stably transfected HeLa cells were incubated 
with 9 µM RO-3306 over a time course of 120 minutes at 37°C. HA-RNMT was 
immunoprecipitated and western blots were performed (Figure 4.10). RO-3306 strongly 
impaired T77 phosphorylation within 5 minutes. Interestingly, when cells were treated 
with this compound for 30 minutes or longer, phosphorylation levels started to recover 
suggesting that other CDKs can partially compensate for CDK1 inhibition. Overall the 
kinase inhibitor experiments indicate that RNMT is phosphorylated by CDK1 and 
possibly additional cell cycle-regulating CDKs. 
Figure 4.9 Roscovitine inhibits RNMT Threonine-77 phosphorylation. !
a) HeLa cells stably expressing HA-RNMT WT or T77A were incubated for 20 min 
with the indicated concentration of Roscovitine. HA-RNMT was immunoprecipitated 
from 0.6 mg cell extracts using 7 µg anti-HA antibody, immunoprecipitates were 
resolved by SDS-PAGE and analysed by western blotting to detect Threonine-77 
phosphorylated and total RNMT.!
b) As above but cells were incubated with 50 μM Roscovitine for the indicated time 
points.!
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Figure 4.10 RO-3306 inhibits RNMT Threonine-77 phosphorylation. !
HeLa cells stably expressing HA-RNMT WT or T77A were incubated for the 
indicated time points with 9 µM RO-3306. HA-RNMT was immunoprecipitated from 
0.6 mg cell extracts using 7µg anti-HA antibody, immunoprecipitates were resolved 
by SDS-PAGE and analysed by western blotting to detect Threonine-77 
phosphorylated and total RNMT.!
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4.2.9 Analysis of RNMT Threonine-77 phosphorylation in 
synchronised cells 
In order to confirm that RNMT phosphorylation is cell cycle-regulated, experiments 
were performed with cells synchronised to the same point of the cell cycle. Initially, 
cells were synchronised at the entrance to S-phase using a double thymidine block. 
High concentrations of thymidine reversibly interrupt the deoxynucleotide metabolism 
pathway and hence inhibit DNA replication (Banfalvi, 2011). During the first treatment 
cells are arrested throughout S-phase. To get a synchronous population arrested at 
early S-phase cells are released from the block and treated with thymidine for a second 
time. 
HeLa cells stably expressing HA-RNMT were synchronised with a double thymidine 
block and released into the cell cycle for 0 to 12 hours. Cells were harvested every two 
hours and RNMT was immunoprecipitated and analysed by western blot (Figure 4.11a, 
upper panel). A clear cell cycle-dependent pattern in T77 phosphorylation could be 
observed. Very low levels of phosphorylation were detected in cells blocked in early S-
phase but the phospho-specific signal started to increase after 4 hours and peaked at 
around 8 hours after cells were released from the thymidine block. The signal was then 
rapidly lost after 12 hours. Cell synchronisation was monitored by western blot by 
observing levels of: Cyclin B1, which accumulates towards and is destroyed after 
G2/M-phase; Histone 3 Serine-10 phosphorylation, which is a marker of mitotic cells; 
Cyclin D1, which is synthesised during G1 (Figure 4.11a, lower panel) (Hendzel et al., 
1997; Johnson and Walker, 1999). A similar pattern of RNMT T77 phosphorylation was 
observed with endogenous protein confirming that this was not an artifact of ectopically 
expressed HA-RNMT (Figure 4.11b). Finally, cell cycle distribution of synchronised 
cells was analysed by flow cytometry (Figure 4.11c). In nonsynchronous cells (control) 
a typical cell cycle distribution was observed with a first peak of G1 cells containing one 
set of chromosomes followed by S-phase cells that gradually replicate their DNA and 
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Figure 4.11 RNMT is predominantly phosphorylated during G2/M phase of the 
cell cycle. !
a) HeLa cells stably expressing HA-RNMT WT were synchronised by a double 
thymidine block and released into normal growth medium for the indicated time 
points. Asynchronous HeLa cells expressing HA-RNMT WT or T77A were used as 
controls. HA-RNMT was immunoprecipitated from 0.6 mg cell extracts using 7µg 
anti-HA antibody. Immunoprecipitates were resolved by SDS-PAGE and analysed 
by western blotting to detect Threonine-77 phosphorylated and total RNMT (upper 
panel). The same cell extracts were analysed by western blotting to detect RNMT, 
Cyclin B1, phosphorylated Histone 3 Serine-10 (H3 pS10), Cyclin D1 and Tubulin 
(lower panel). !
b) Untransfected HeLa cells were synchronised as above and released into normal 
growth medium for the indicated time points. RNMT was immunoprecipitated from 
0.5 mg extracts using 1.5 µg anti-RNMT antibody. Immunoprecipitations with 
asynchronous HeLa cells using anti-HA and anti-RNMT antibodies were used as 
controls.!
c) HeLa cells were synchronised as above and released into normal growth 
medium for the indicated time points. Cells were stained with propidium iodide and  
cell synchrony was monitored by flow cytometry. DNA content and relative cell 
numbers are depicted in the diagram.!
!
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finally a second peak of cells in G2/M-phase that have two sets of chromosomes but 
have not yet undergone cytokinesis. The analysis of thymidine-treated cells (0 - 12 
hours) confirmed synchronous progression of the cell population from S into G2/M-
phase and finally into G1-phase. By comparing this analysis with the western blots it 
can be concluded that RNMT T77 phosphorylation is first detected when cells leave S-
phase and enter G2-phase. The peak of phosphorylation is reached when almost all 
cells are in G2/M phase and is abruptly lost after cells have completed mitosis and 
entered G1-phase. 
To independently confirm cell cycle-dependent phosphorylation of RNMT during 
G2/M-phase, cell synchronisation using a nocodazole block was performed. 
Nocodazole interferes with the polymerisation of microtubules and thus prevents 
formation of the mitotic spindle (Banfalvi, 2011). The absence of microtubule 
attachment to kinetochores results in activation of the spindle assembly checkpoint and 
thus arrest in prometaphase. Initially, cells were treated with thymidine to arrest cells 
throughout S-phase. After release from the thymidine block cells were allowed to 
initiate mitosis before the addition of nocodazole arrested the cells in mitosis.  
Stably transfected HeLa cells were synchronised with nocodazole and HA-RNMT 
was immunoprecipitated and analysed by western blot (Figure 4.12a, upper panel). A 
strong phosphorylation signal was observed in cells arrested in mitosis. When cells 
were released from the nocodazole block the phosphorylation levels decreased at first 
but started to accumulate after 10 - 12 hours. Western blot analysis of cell extracts of 
the corresponding samples confirmed mitotic arrest and subsequent progression into 
G1 of the synchronised cells (Figure 4.12a, lower panel). Analysis of endogenous 
RNMT showed the same pattern as exogenous HA-RNMT (Figure 4.12b) confirming 
high levels of T77 phosphorylation during mitosis and loss of the signal in G1. Lastly, 
flow cytometry analysis was performed which confirmed synchronous progression of 
the cell population from mitosis into G1, S and G2/M-phase. At the time points when no  
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Figure 4.12 Nocodazole block confirms G2/M-phase specific phosphorylation 
of RNMT Threonine 77. !
a) HeLa cells stably expressing HA-RNMT WT were synchronised by a thymidine 
block followed by a nocodazole block and released into normal growth medium for 
the indicated time points. Asynchronous HeLa cells expressing HA-RNMT WT or 
T77A were used as controls. HA-RNMT was immunoprecipitated from 0.6 mg cell 
extracts using 7µg anti-HA antibody. Immunoprecipitates were resolved by SDS-
PAGE and analysed by western blotting to detect Threonine-77 phosphorylated 
and total RNMT (upper panel). The same cell extracts were analysed by western 
blotting to detect RNMT, Cyclin B1, phosphorylated Histone 3 Serine-10 (H3 pS10), 
Cyclin D1 and Tubulin (lower panel). !
b) Untransfected HeLa cells were synchronised as above and released into normal 
growth medium for the indicated time points. RNMT was immunoprecipitated from 
0.5 mg extracts using 1.5 µg anti-RNMT antibody. Immunoprecipitations with 
asynchronous HeLa cells using anti-HA and anti-RNMT antibodies were used as 
controls.!
c) HeLa cells were synchronised as above and released into normal growth 
medium for the indicated time points. Cells were stained with propidium iodide and  
cell synchrony was monitored by flow cytometry. DNA content and relative cell 
numbers are depicted in the diagram.!
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phospho-signal was detected by western blots most cells were in G1-phase. The 
phosphorylation levels started to increase when cells progressed through S-phase and 
entered G2/M phase. 
Overall, the two independent cell synchronisation methods performed demonstrated 
that RNMT is phosphorylated at T77 in a cell cycle-dependent manner and peaks 
during G2/M-phase. 
 
4.2.10 In vitro phosphorylation of RNMT by CDK1/Cyclin B 
CDK1/Cyclin B is the most active CDK in G2/M-phase and is efficiently inhibited by 
RO-3306 and Roscovitine. Thus, the cell synchronisation experiments showing high 
RNMT phosphorylation during G2/M-phase, together with the results obtained with 
kinase inhibitors suggest that RNMT T77 is a substrate of CDK1/Cyclin B. To test 
whether CDK1/Cyclin can phosphorylate RNMT, in vitro phosphorylation experiments 
were performed. Recombinant RNMT/RAM was incubated with CDK1/Cyclin B and 
[32P]-ATP, resolved by SDS-PAGE and subjected to autoradiography (Figure 4.13a). 
As expected, RNMT WT was radioactively labeled whereas RNMT T77A was not. 
Furthermore, no radioactive signal was detected for RAM (data not shown). This 
confirms that the RNMT T77 site can be specifically phosphorylated by CDK1/Cyclin B 
in vitro. The same result was obtained when the assays were performed with cold ATP 
and the phosphorylation status was detected by western blot instead (Figure 4.13b).  
Finally, in order to determine the stoichiometry of RNMT phosphorylation by 
CDK1/Cyclin B, in vitro phosphorylation was performed with [32P]-ATP over a time 
course experiment of 2 hours. RNMT phosphorylation reached saturation of [32P] 
incorporation after 80 minutes and, considering the specific activity of [32P]-ATP and 
the radioactive label of RNMT, a maximum stoichiometry of 65% was calculated 
(Figure 4.13c).  
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Figure 4.13 RNMT Threonine-77 is phosphorylated by CDK1/Cyclin B in vitro.!
In vitro  phosphorylation of recombinant HIS-RNMT WT or T77A in complex with 
GST-RAM 1-90 was performed with the kinase complex CDK1/Cyclin B. !
a) RNMT/RAM and CDK1/Cyclin B were incubated with [γ-32P]-ATP for 30 min, 
separated by SDS-PAGE and detected by autoradiography (upper panel) or 
stained with Coomassie blue (lower panel).!
b) RNMT/RAM and CDK1/Cyclin B were incubated with cold ATP for 30 min, 
separated by SDS-PAGE and western blots were performed to detect Threonine-77 
phosphorylated or total RNMT.!
c) RNMT/RAM and CDK1/Cyclin B were incubated with radioactive [γ-32P]-ATP for 
indicated time points, separated by SDS-PAGE and detected by autoradiography 
(upper panel) or stained with Coomassie blue (lower panel). The stoichiometry of 
the reaction is indicated on the top.!
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4.2.11 In vitro phosphorylation of RNMT by CDK2/Cyclin A 
The peak of RNMT T77 phosphorylation was observed in G2/M phase but lower 
levels of RNMT phosphorylation were also detected during S-phase. CDK2/Cyclin A is 
the major kinase controlling progression through S-phase and therefore it was tested 
whether CDK2/Cyclin A can phosphorylate RNMT in vitro. In vitro phosphorylation 
assays were performed with CDK2/Cyclin A as described before for CDK1/Cyclin B. 
Recombinant RNMT/RAM was incubated with CDK2/Cyclin A and [32P]-ATP, resolved 
by SDS-PAGE and subjected to autoradiography (Figure 4.14a). RNMT WT exhibited a 
radioactive signal whereas RNMT T77A did not. Furthermore, incubation of 
RNMT/RAM with CDK2/Cyclin A in the presence or absence of cold ATP followed by 
SDS-PAGE and analysis by western blot confirmed the specificity of CDK2/Cyclin A in 
vitro (Figure 4.14b). A phospho-specific signal was only detected when CDK2/Cyclin A 
was incubated in the presence of ATP with RNMT WT but not with RNMT T77A. 
Finally, the stoichiometry of RNMT phosphorylation by CDK2/Cyclin A was estimated 
over a time course of 2 hours and a maximum stoichiometry of 59% was observed after 
120 minutes (Figure 4.14c).  
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Figure 4.14 RNMT Threonine-77 is phosphorylated by CDK2/Cyclin A in vitro.!
In vitro  phosphorylation of recombinant HIS-RNMT WT or T77A in complex with 
GST-RAM 1-90 was performed with the kinase complex CDK2/Cyclin A. !
a) RNMT/RAM and CDK2/Cyclin A were incubated with [γ-32P]-ATP for 30 min, 
separated by SDS-PAGE and detected by autoradiography (upper panel) or 
stained with Coomassie blue (lower panel).!
b) RNMT/RAM and CDK2/Cyclin A were incubated with or without cold ATP for 30 
min, separated by SDS-PAGE and western blots were performed to detect 
Threonine-77 phosphorylated or total RNMT.!
c) RNMT/RAM and CDK2/Cyclin A were incubated with radioactive [γ-32P]-ATP for 
indicated time points, separated by SDS-PAGE and detected by autoradiography 
(upper panel) or stained with Coomassie blue (lower panel). The stoichiometry of 
the reaction is indicated on the top.!
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4.3 Discussion 
In order to elucidate how the cap methyltransferase is regulated we investigated 
whether RNMT is post-translationally modified. Initial analysis by 2D gel 
electrophoresis suggested that RNMT carries several post-translational modifications. 
Orthophosphate labelling demonstrated that RNMT is phosphorylated and we identified 
two phosphorylation sites by mass spectrometry. To date no validated RNMT 
phosphorylation sites have been reported but studies exploiting high-throughput 
phosphoproteomic analysis have detected several phosphorylation sites in mouse 
(Hornbeck et al., 2012). Furthermore, high-throughput data from Cell Signalling 
Technology available on the PhosphoSitePlus resource lists a number of 
phosphorylation sites identified in human Jurkat cells (Hornbeck et al., 2012). The two 
phospho-peptides identified in our study have been detected both in mouse and human 
high-throughput analyses.  
Our mass spectrometry analysis suggested that only a small portion of exogenous 
HA-RNMT is phosphorylated as the phospho-peptides were only detected with highly 
sensitive mass spectrometers and the overall Mascot scores were not very high. The 
exact phosphorylation sites could not be determined by mass spectrometry analysis as 
the phospho-peptide contained several candidate amino acids that could potentially be 
phosphorylated. 
Mutation of candidate phosphorylated amino acids combined with orthophosphate 
labelling was performed to identify and validate the exact phosphorylation sites. This 
analysis revealed Threonine-77 as the predominant RNMT phosphorylation site in our 
experimental system. Mutation of Threonine-77 abolished orthophosphate 
incorporation whereas mutation of Serine-79 and candidates of the first 
phosphorylation sites only modestly reduced or did not alter the [32P] signal 
respectively. Though the RNMT S79A mutation resulted in a reduction of 
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orthophosphate labelling it is likely that T77 is the major phosphorylation site due to the 
much higher Mascot score in the mass spectrometry analysis and additional reports of 
this site by other studies (Hornbeck et al., 2012). Furthermore, T77 resides within a 
CDK recognition site and T77 but not S79 is predicted to be targeted for Proline-
directed phosphorylation by CDKs. Finally, S79 is located immediately next to the T77 
phosphorylation site and thus the reduced orthophosphate signal in S79A could have 
been caused by reduced kinase recruitment to T77. 
Due to the location of the RNMT T77 within a CDK consensus motif and next to a 
cyclin binding site the possibility that this site was recognised by a CDK/Cyclin complex 
was explored. RNMT T77 phosphorylation was strongly reduced after incubation with 
compounds inhibiting cell cycle-regulating CDKs and more specifically CDK1/Cyclin B. 
In addition, cell synchronisation experiments revealed that RNMT phosphorylation is 
cell cycle-dependent and peaks in G2/M-phase. This data together demonstrates that, 
in the experimental system used, RNMT T77 is phosphorylated in a cell-cycle 
dependent manner by CDK1/Cyclin B. In vitro kinase experiments demonstrated that 
CDK1/Cyclin B specifically phosphorylates RNMT at T77. However, the possibility that 
other CDK/Cyclin complexes active during late S-phase or early G2-phase may also 
contribute to RNMT phosphorylation cannot be excluded. For example, CDK2/Cyclin 
A2, which is expressed during S-phase was also able to specifically phosphorylate 
RNMT T77 in vitro and the stoichiometry of RNMT phosphorylation reached similar 
values as observed with CDK1/Cyclin B. 
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Chapter 5:                                                         
RNMT Threonine-77 phosphorylation activates 
cap methyltransferase activity and negatively 
regulates the interaction of RNMT with KPNA2 
 
 
5.1 Introduction 
In mammalian cells RNMT exists in a complex with a 14 kDa protein termed RNMT 
activating miniprotein (RAM) (Gonatopoulos-Pournatzis et al., 2011). In addition to 
RAM, a second RNMT-binding protein has been identified; Wen and Shatkin (2000) 
demonstrated that KPNA2 directly binds to RNMT both in vitro and in vivo. KPNA2 is a 
member of the Importin-α family that together with Importin-β mediates nuclear import 
of protein cargos carrying a classical nuclear localisation signal (NLS). KPNA2 was 
described to bind to the N-terminal region of RNMT, which contains three NLSs. 
KPNA2 was also demonstrated to bind to RNA and to activate cap methyltransferase 
activity in vitro by increasing RNMT-binding to capped RNA. The interaction partner of 
KPNA2, Importin-β, did not inhibit KPNA2-RNMT complex formation but it disrupted 
KPNA2-RNMT-RNA complexes and blocked the stimulatory effect of KPNA2 on RNMT 
(Wen and Shatkin, 2000). 
As discussed above, RNMT activity can be regulated by an interaction with RAM 
and KPNA2. Furthermore, it is possible that cap methyltransferase activity is regulated 
by RNMT phosphorylation. The addition of a negatively charged phosphate group often 
causes conformational changes in the protein, which can be caused by electrostatic 
attraction or repulsion between the phospho group and charged amino acids. This in 
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turn can alter the catalytic properties of the enzyme or affect the interaction with other 
proteins. Hence, this chapter aims to elucidate whether RNMT phosphorylation 
regulates cap methyltransferase activity or protein-protein interactions. 
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5.2 Results 
5.2.1 Investigation of the effect of RNMT Threonine-77 
phosphorylation on cellular RNMT activity 
To address whether RNMT T77 phosphorylation could regulate cellular RNMT 
activity, cap methyltransferase activity assays were performed with HA-RNMT 
constructs immunoprecipitated from stably expressed HeLa cells (Figure 5.1a). RNMT 
T77A exhibited reduced activity suggesting that loss of phosphorylation reduces 
cellular RNMT activity. The drop in activity was only about 25 % but these experiments 
were performed with non-synchronised cells and thus, only a minor portion of wild type 
RNMT was expected to be in G2/M-phase and hence to be phosphorylated. To mimic 
constitutive phosphorylation Threonine-77 was replaced with Aspartate (D). Unlike the 
loss of phosphorylation mutant RNMT T77A, the phosphorylation-mimicking mutant 
RNMT T77D did not show any change in activity compared to RNMT WT. 
To increase the phosphorylated portion of RNMT, cap methyltransferase assays were 
performed with synchronised cell extracts. Cells were arrested in S-phase using a 
double thymidine block and subsequently released into the cell cycle for 8 hours. 
According to previous results, cells are in G2/M-phase at this time point and show 
maximal phosphorylation levels. Cell extracts in G2/M-phase (T8) exhibited increased 
cap methyltransferase activity compared to cells arrested in S-phase (T0) (Figure 
5.1b). This increase was prevented by incubation with the CDK-inhibitors Roscovitine 
and RO-3306. Together, these experiments suggest that phosphorylation of RNMT T77 
increases cellular RNMT activity. However, whether the activation is directly caused by 
the phosphorylation itself, for example via a conformational change, or whether it is 
mediated via interaction with other proteins is not known. Furthermore, the exact 
stoichiometry of RNMT T77 phosphorylation during G2/M-phase is unknown and thus it 
is not clear to what extent RNMT is activated by phosphorylation.  
Figure 5.1: Loss of Threonine-77 phosphorylation reduces cellular RNMT 
activity.!
a) Cellular HA-RNMT was immunoprecipitated from 100 μg cell extracts HeLa cells 
stably expressing HA-RNMT WT, T77A or T77D using 1 μg anti-HA antibody and 
cap methyltransferase assays were performed for 5 min with the 
immunoprecipitates. Charts depict the average and standard deviation of three 
independent experiments. Samples were normalised to RNMT WT. T-test p-value 
<0.05 is indicated by an asterisk."
b) HeLa cells were synchronised by a double thymidine block and released into 
normal growth medium for 0 hour (S) or 8 hours (G2/M). Cells released for 8 hours 
were treated with 50 μM Roscovitine or 9 μM RO-3306 for 15 minutes prior to 
lysing. Cap methyltransferase assays were performed with 2 μg of cell extracts for 
10 minutes. The activity normalised to T0 control is depicted for the average and 
standard deviation of four independent experiments. T-test p-value <0.05 is 
indicated by asterisk."
0"
0.25"
0.5"
0.75"
1"
1.25"
W
T"
T7
7A
"
T7
7D
"
Re
lat
ive
 C
ap
 M
et
hy
lat
ion
"
a)"
0"
0.25"
0.5"
0.75"
1"
1.25"
1.5"
b)"
Co
n"
Co
n"
Ro
sc
ov
itin
e"
RO
-3
30
6"
Re
lat
ive
 C
ap
 M
et
hy
lat
ion
"
S" G2/M"
*"*"
"
153"
	   	  154 
5.2.2 Analysis of RNMT activity after in vitro 
phosphorylation 
In order to elucidate and quantify whether T77 phosphorylation directly activates 
RNMT activity, methyltransferase activity assays were performed with recombinant 
RNMT/RAM after in vitro phosphorylation. RNMT/RAM was incubated in the presence 
or absence of CDK1/Cyclin B and ATP, affinity purified and washed before activity 
assays were performed (Figure 5.2a). Incubation of RNMT with CDK1/Cyclin B or ATP 
alone did not alter basal cap methyltransferase activity of unphosphorylated RNMT. 
However, when RNMT was incubated with both CDK1/Cyclin B and ATP, a 35 - 45 % 
increase in activity was observed. The stoichiometry of RNMT T77 phosphorylation 
after 30 minutes under the conditions used in this experiment was determined as 40 % 
(Figure 5.2b). Therefore, these experiments suggest that RNMT T77 phosphorylation 
increases the cap methyltransferase activity of RNMT/RAM by two-fold in the in vitro 
assay. 
 
5.2.3 Investigation of phosphorylation-dependent protein 
interactions 
Next, the possibility that RNMT T77 phosphorylation may influence RNMT protein 
interactions was explored. To test this hypothesis peptide affinity purification with 
unphosphorylated and phosphorylated RNMT peptides containing the T77 site were 
performed. Biotinylated peptides of 35 amino acids in length were incubated with HeLa 
cell extracts and affinity purified. Precipitated protein was resolved by SDS-PAGE and 
stained with Coomassie blue (Figure 5.3a, left panel). Two bands of around 130 and 80 
kDa in size were enriched in pull-downs with unphosphorylated peptides and were 
further investigated as proteins that interact with RNMT in a phosphorylation-
dependent manner. The candidate gel bands from the unphosphorylated T77 peptide 
pull-down and the corresponding bands form the phosphorylated T77 peptide pull- 
Figure 5.2: Phosphorylation of RNMT Threonine-77 increases RNMT activity. 
a) 900 ng recombinant purified His-RNMT/GST-RAM 1-90 was incubated in the 
presence or absence of 10 ng CDK1/Cyclin B and 100 μM ATP. After in vitro 
phosphorylation, His-RNMT/GST-RAM 1-90 was affinity purified using glutathione 
sepharose and 3.33 % of purified RNMT was assessed in a cap methyltransferase 
assay for the time points indicated. Charts depict the average and standard 
deviation of three independent experiments performed in triplicate. T-test p-value 
<0.05 is indicated with an asterisk."
b) RNMT/RAM and CDK1/Cyclin B were incubated with radioactive [32P]-ATP for 
the indicated time points, separated by SDS-PAGE and detected to 
autoradiography (upper panel) or stained with Coomassie blue (lower panel). The 
stoichiometry of the reaction is indicated above."
[min] Time"
RNMT WT/RAM"
RNMT T77A/RAM"
CDK1/Cyclin B"
+"
-"
-"
120"
+"
-"
+"
2"
+"
-"
+"
5"
+"
-"
+"
10"
+"
-"
+"
20"
+"
-"
+"
40"
+"
-"
+"
80"
-"
-"
+"
120"
RNMT"
(Coomassie)"
-"
+"
-"
120"
-"
+"
+"
120"
+"
-"
+"
120"kDa"
0.
48
"
0.
5"
0.
5"
0.
3"
0.
18
"
0.
12
"
0.
1"
0"0" 0" 0"
Stoichiometry"
(RNMT)"
RNMT"
(Autorad.)"
b)!
82"
64"
82 "
64"
0"
0.5"
1"
1.5"
2"
2.5"
3"
5" 10" 15" 5" 10"15" 5" 10"15"
CDK1/CyclinB"
ATP"
+"
+"
+"
-"
-"
+"
Re
lat
ive
 C
ap
 M
et
hy
lat
ion
"
[min] time"
a)!
*" *"
"
155"
T7
7"
T7
7"
pT
77
"
pT
77
"
be
ad
s"
ce
ll l
ys
at
e"
Streptavidin"
affinity"
kDa"
116"
182"
82 "
64"
49"
37"
19"
15"
26"
6"
1
*
*
2
Input"
a)"
Proteins enriched 
with T77 peptide!
Score!
T77!
Score!
pT77!
Importin Subunit Beta-1 
(KPNB1)" 6623" 2999"
Nuclear pore complex 
protein 153 (NUP153)" 726" 34"
Importin Subunit Alpha-2 
(KPNA2)" 4414" 2732"
Importin Subunit Alpha-3 
(KPNA3)" 667" 105"
Importin Subunit Alpha-4 
(KPNA4)" 959" 144"
1
*
*
2
Figure 5.3: KPNA2 preferentially binds to unphosphorylated RNMT 
Threonine-77 peptide.!
a) 10 mg of HeLa cell extracts were incubated with 3 μg of biotinylated RNMT 
peptides containing either unphosphorylated (T77) or phosphorylated (pT77) 
Threonine-77. The peptides were affinity purified using streptavidin beads and the 
bound proteins were separated by SDS-PAGE and stained with Coomassie blue 
(left panel). The gel bands marked with an asterisk were excised and proteins 
identified by mass spectrometry analysis. The most abundant proteins enriched in 
the T77 peptide pull-down are listed with their Mascot score (right panel)."
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Figure 5.3: KPNA2 preferentially binds unphosphorylated RNMT 
Threonine-77 peptide.!
b) HeLa cells were transiently transfected with pcDNA5 Myc-KPNA2 or vector 
control. 2.2 mg of cell extracts were incubated with 1 μg of biotinylated RNMT T77 
or pT77 peptides and affinity purified using streptavidin beads. Bound proteins 
were separated by SDS-PAGE and western blot was performed to detect 
exogenous Myc-KPNA2 using anti-9E10 antibodies."
c) 3 mg of HeLa cell extracts were incubated with 1.5 μg of biotinylated RNMT T77 
or pT77 peptides and affinity purified using streptavidin beads. Bound proteins 
were separated by SDS-PAGE and western blot was performed to detect 
endogenous KPNA2 using KPNA2-antibodies."
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down were extracted and proteins identified by mass spectrometry. In the upper gel 
band two proteins were detected to be enriched with the unphosphorylated T77 
peptide: Importin-β (Importin Subunit Beta-1, KPNB1) and the nuclear pore complex 
protein 153 (NUP153) (Figure 5.3a, right panel). The Mascot score of NUP153 was 
much lower than that of Importin-β. In the lower gel band three proteins were identified 
to be enriched with the unphosphorylated T77 peptide: Importin Subunit Alpha-2 
(KPNA2), Importin Subunit Alpha-3 (KPNA3) and Importin Subunit Alpha-4 (KPNA4). 
The protein with the highest Mascot score was KPNA2. All identified proteins are part 
of the classical nuclear protein import machinery, which recognizes nuclear localisation 
signals (NLS). There is a NLS immediately adjacent to the RNMT T77 and hence it was 
not completely surprising that parts of the nuclear import machinery were purified with 
the peptides. However, the fact that these proteins expressed differential affinity to 
unphosphorylated and phosphorylated RNMT peptides raises the possibility that RNMT 
T77 phosphorylation regulates the interaction with the nuclear import machinery. 
It is well established that the KPNA protein family interacts with KPNB1 and binding of 
both KPNA2 and KPNB1 to NUP153 was reported (Moroianu et al., 1997; Shah et al., 
1998). Of the proteins identified in the peptide pull-downs only KPNA2 was previously 
described to directly interact with RNMT (Wen and Shatkin, 2000). Due to these 
previous reports further investigation focused on KPNA2. Peptide affinity purification 
was repeated with HeLa cells transfected with Myc-tagged KPNA2. Precipitates were 
analysed by western blot to detect exogenous Myc-KPNA2 using anti-9E10 antibody, 
which recognises the Myc-tag (Figure 5.3b). Myc-KPNA2 was strongly enriched in the 
unphosphorylated T77 peptide pull-down and only a very weak signal was detected 
with phosphorylated T77 peptide. The experiment was repeated with untransfected 
cells and endogenous KPNA2 was strongly enriched in the unphosphorylated peptide 
pull-down compared to the phosphorylated peptide pull-down confirming the mass 
spectrometry result (Figure 5.3c).   
	   	  159 
5.2.4 Characterisation of RNMT interaction with KPNA2 
To confirm that the KPNA2-interaction occurs with full-length RNMT, HeLa cells 
were transfected with pcDNA5 Myc-KPNA2 and immunoprecipitations were performed 
with anti-RNMT, anti-9E10 and control antibodies (Figure 5.4a, for untransfected 
control 9E10-IP see 5.4c). Immunoprecipitation of Myc-tagged KPNA2 resulted in the 
co-purification of RNMT. However, Myc-KPNA2 was not detected when RNMT was 
immunoprecipitated. The co-immunoprecipitation experiments were repeated with 
untransfected HeLa cells and endogenous protein was detected by western blot (Figure 
5.4b). Endogenous KPNA2 immunoprecipitation resulted in co-purification of RNMT but 
KPNA2 was not detected in RNMT immunoprecipitates. 
In order to test whether the interaction observed between RNMT and KPNA2 is 
dependent on the phosphorylation status of RNMT, HeLa cells stably expressing HA-
RNMT WT, HA-RNMT T77A, HA-RNMT T77D or vector control were transfected with 
Myc-KPNA2. Exogenous KPNA2 was immunoprecipitated and the interaction with the 
RNMT constructs detected by western blot (Figure 5.4c). As observed with 
endogenous RNMT, HA-RNMT co-immunoprecipitated with Myc-KPNA2. A much 
stronger interaction was detected with the unphosphorylated HA-RNMT T77A. In 
contrast, the signal for the phospho-mimicking mutant HA-RNMT T77D was very weak 
in the Myc-KPNA2 immunoprecipitates. This suggests that the interaction with KPNA2 
is reduced when RNMT T77 is phosphorylated. 
The experiments were repeated using anti-KPNA2 antibodies to immunoprecipitate 
endogenous KPNA2 (Figure 5.4d). As with exogenous KPNA2 immunoprecipitation of 
endogenous KPNA2 resulted in the co-immunoprecipitation of RNMT WT and T77A but 
a much lower signal of RNMT T77D was observed (see top band of RNMT western 
blots in Figure 5.4d). Together, co-immunoprecipitation of KPNA2 confirmed the 
interaction with RNMT and furthermore, demonstrated a strong preference of KPNA2 
binding to unphosphorylated RNMT T77. 
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Figure 5.4: KPNA2 preferentially interacts with RNMT T77A.!
a) HeLa cells were transiently transfected with pcDNA5 Myc-KPNA2. RNMT and 
Myc-KPNA2 were immunoprecipitated from 1.5 mg of cell extract using 1.5 μg anti-
RNMT and anti-9E10 antibodies respectively. Immunoprecipitation with anti-HA 
antibody was used as a control. Immunoprecipitates were separated by SDS-
PAGE and western blots were performed to detect Myc-KPNA2 and RNMT."
b) KPNA2 and RNMT was immunoprecipitated from 1.5 mg of untransfected HeLa 
cell extracts with 1.5 μg anti-KPNA2 or anti-RNMT antibodies respectively. 
Immunoprecipitations with anti-Tubulin or anti-HA antibodies were used as a 
control. Immunoprecipitates were separated by SDS-PAGE and western blots were 
performed to detect KPNA2, RNMT and RAM. Nonspecific bands are indicated 
with an asterisk."
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Figure 5.4: KPNA2 preferentially interacts with RNMT T77A.!
c) HeLa cells stably expressing HA-RNMT WT, T77A, T77D or a vector control (C) 
were transiently transfected with pcDNA5 Myc-KPNA2 or vector control (Con). 
Myc-KPNA2 was immunoprecipitated from 1.5 mg of cell extract using 1.5 μg 
anti-9E10 antibodies. Immunoprecipitates were separated by SDS-PAGE and 
western blots were performed to detect Myc-KPNA2, HA-RNMT, RNMT and RAM 
(left panel). The same extracts were analysed by western blotting to detect Myc-
KPNA2, RNMT and Tubulin (right panel). Nonspecific bands are indicated with an 
asterisk."
d) KPNA2 was immunoprecipitated from 1.5 mg of extracts from HeLa cells stably 
expressing HA-RNMT WT, T77A, T77D or a vector control (C) using 1.5 μg anti-
KPNA2 antibodies. Immunoprecipitates were separated by SDS-PAGE and 
western blots were performed to detect KPNA2 and RNMT. The same extracts 
were analysed by western blotting to detect KPNA2, RNMT and Tubulin (right 
panel)."
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5.2.5 Analysis of RNMT-KPNA2 interaction during the cell 
cycle 
As KPNA2 was demonstrated to preferentially interact with unphosphorylated 
RNMT, this association was monitored throughout the phases of the cell cycle when 
RNMT phosphorylation changes. HeLa cells were transfected with Myc-KPNA2 and 
synchronised using a double thymidine block. Cells were released into the cell cycle 
and harvested after 2 hours when cells were in S-phase and RNMT T77 exhibited low 
phosphorylation or released for 8 hours when cells were in G2/M-phase and RNMT 
T77 exhibited high phosphorylation. Myc-KPNA2 was immunoprecipitated from extracts 
at different stages of the cell cycle and binding to endogenous RNMT was detected by 
western blot (Figure 5.5a). As expected, a weaker interaction between KPNA2 and 
RNMT was observed during G2/M-phase compared to S-phase. Interestingly, inhibiting 
CDK1/Cyclin B by treatment with RO-3306 increased the binding of RNMT to KPNA2 
during G2/M-phase. This suggests that the interaction during G2/M-phase is 
interrupted by RNMT T77 phosphorylation. 
A similar experiment was repeated with untransfected cells (Figure 5.5b). Again, 
reduced association of RNMT with KPNA2 during G2/M-phase was observed, which 
could be increased by treatment with the compounds RO-3306 or Roscovitine. 
 
5.2.6 Affinity purification of recombinant RNMT and KPNA2 
In order to test whether the interaction between RNMT and KPNA2 is direct, affinity 
purifications with recombinant proteins were performed. Untagged RNMT was 
specifically co-purified with GST-KPNA2 but not with GST (Figure 5.6a). A specific 
interaction was also observed when KPNA2 was co-purified with GST-RNMT (Figure 
5.6b). This result confirms the previous report of a direct association between RNMT 
and KPNA2 performed with in vitro translated protein (Wen and Shatkin, 2000).  
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Figure 5.5: KPNA2-RNMT interaction is reduced in G2/M phase but can be 
rescued using CDK1 inhibitors. !
a) HeLa cells were transiently transfected with pcDNA5 Myc-KPNA2. Cells were 
synchronised using a double-thymidine block and released into normal growth 
media for 2 (S) or 8 hours (G2/M) and incubated with 9 μM RO-3306 for 15 
minutes (G2/M + RO-3306). Nonsynchronous (NS) vector control (Con) transfected 
cells were used as a control. Myc-KPNA2 was immunoprecipitated from 1.5 mg of 
cell extract using 1.5 μg anti-9E10 antibodies. Immunoprecipitates were separated 
by SDS-PAGE and western blots were performed to detect KPNA2 and RNMT (left 
panel). The same extracts were analysed by western blotting to detect KPNA2, 
RNMT, Cyclin B1 and Tubulin (right panel)."
b) Untransfected HeLa cells were synchronised using a double-thymidine block 
and released into normal growth media for 2 (S) or 8 hours (G2/M) and incubated 
with 9 μM RO-3306 (G2/M + RO-3306) or 50 μM Roscovitine (G2/M + Roscov.) for 
15 minutes. KPNA2 was immunoprecipitated from 1.5 mg of cell extracts from 
untransfected HeLa cells using 1.5 μg anti-KPNA2 antibodies. Immuno-
precipitations with nonsynchronous cells (NS) using anti-Tubulin (Tub) and anti-
KPNA2 antibodies were used as a control. Immunoprecipitates were separated by 
SDS-PAGE and western blots were performed to detect KPNA2 and RNMT (left 
panel). The same extracts were analysed by western blotting to detect KPNA2, 
RNMT, Cyclin B1 and Tubulin (right panel). Nonspecific bands are indicated with an 
asterisk."
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Figure 5.6: KPNA2 and RNMT interact directly.!
a) 2 μg of purified recombinant GST-KPNA2 was incubated with purified 
recombinant RNMT and affinity purified with glutathione-sepharose. Proteins eluted 
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purified recombinant KPNA2 and affinity purified with glutathione-sepharose. "
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5.2.7 In vitro cap methyltransferase assays with RNMT and 
KPNA2 
In addition to the direct interaction between RNMT and KPNA2, Wen and Shatkin 
(2000) also reported that KPNA2 enhanced RNMT binding to capped RNA and 
stimulated cap methyltransferase activity. Therefore, activity assays were performed to 
confirm this result and to investigate how KPNA2 might modify the activity of 
phosphorylated RNMT. 
In vitro cap methyltransferase assays were performed with recombinant RNMT and 
a titration of recombinant KPNA2 or BSA (Figure 5.7). Addition of BSA only had a 
subtle effect and increasing the molar ratio did not alter RNMT activity. However, 
increasing the molar ratio of KPNA2:RNMT strongly inhibited RNMT activity. Whereas 
an equal amount of RNMT and KPNA2 did not affect RNMT activity, a five-fold excess 
of KPNA2 decreased the activity by over 50 % and a ten-fold excess of KPNA2 led to a 
reduction of RNMT activity by 90 %. This result was unexpected and contradicts the 
previous study reporting that KPNA2 activates RNMT with an increasing molar ratio 
(Wen and Shatkin, 2000). 
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Figure 5.7: KPNA2 inhibits RNMT activity.!
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5.3 Discussion 
In order to elucidate the function of RNMT T77 phosphorylation initial experiments 
were performed to determine whether it regulates cap methyltransferase activity. 
Immunoprecipitation of cellular HA-RNMT demonstrated that loss of phosphorylation 
reduces RNMT activity. The reduction in RNMT T77A is relatively small but it should be 
considered that this experiment was performed with nonsynchronous cells and thus 
only a small portion of RNMT WT was actually phosphorylated. Interestingly, the T77D 
phospho-mimicking mutant was more active than the T77A mutant but did not show an 
increase in activity compared to wild type protein. Thus, T77D mutation might not fully 
represent the properties of phosphorylated T77.  
Performing activity assays with synchronised cell extracts also suggested that 
phosphorylation of RNMT increases cap methyltransferase activity. G2/M-phase 
extracts showed increased activity compared to S-phase extracts and this increase 
could be blocked with CDK inhibitors. The activation in G2/M-phase was minor but 
despite observing maximal phosphorylation levels in G2/M-phase it is unknown what 
proportion of total RNMT is phosphorylated during that stage of the cell cycle. 
To test whether phosphorylation of T77 activates RNMT directly and to quantify a 
change in activity we performed in vitro phosphorylation assays before assessing 
RNMT activity. These experiments demonstrated that T77 phosphorylation activates 
RNMT directly by two-fold. It should be mentioned that this analysis was performed 
with RNMT/RAM complexes and RAM itself activates RNMT five-fold (Gonatopoulos-
Pournatzis et al., 2011). Thus, the phosphorylation-mediated increase in activity 
represents a further increase by two-fold. Further investigation is required to determine 
the mechanism of this activation. The RNMT-RAM interaction does not seem to be 
affected by T77 phosphorylation (data not shown) but it is possible that the 
phosphorylation causes a conformational change of the N-terminus. Crystal structures 
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from human and fungal RNMT are only available for the catalytic domain (Fabrega et 
al., 2003; Wu et al., 2007; Zeng et al., 2008) and thus there is no information about the 
orientation of the N-terminal domain. 
In addition to assessing the influence of T77 phosphorylation on RNMT activity the 
ability of RNMT phosphorylation to regulate interactions with other proteins was 
investigated. As expected, the interaction of RNMT with RAM was not affected by 
RNMT T77 phosphorylation (data not shown) since RAM directly binds to the catalytic 
domain of RNMT (Gonatopoulos-Pournatzis et al., 2011). However, affinity purification 
with phosphorylated or unphosphorylated RNMT T77 peptides revealed that 
phosphorylation reduces an interaction with the nuclear import machinery. Mass 
spectrometry analysis identified Importin-β (Importin Subunit Beta-1, KPNB1) and 
KPNA2 (Importin Subunit Alpha-2) as the most abundant proteins enriched with 
unphosphorylated T77 peptides. Both proteins are part of the classical nuclear protein 
import pathway in which cargos carrying classical NLSs are bound by Importin-α that 
serves as an adaptor between the cargo and Importin-β. Importin-β then mediates 
translocation through the nuclear pore complex. In the nucleus Importin-β dissociates 
from Importin-α and the cargo is then released from Importin-α. Since Importin-α is the 
component that directly binds the cargo and an interaction between KPNA2 and RNMT 
has been previously reported (Wen and Shatkin, 2000) we aimed to further 
characterise this interaction. Co-immunoprecipitation experiments confirmed a specific 
interaction with RNMT. However, the interaction between RNMT and KPNA2 could only 
be detected after immunoprecipitation of KPNA2 but not vice versa. Since it is possible 
that the antibody used for immunoprecipitation of RNMT could interrupt the association 
with KPNA2 we used both antibodies against the HA-tag or against RNMT itself but no 
KPNA2 was detected after RNMT immunoprecipitation with either antibody. However, a 
direct interaction was confirmed with both KPNA2 and RNMT affinity purifications using 
recombinant RNMT and KPNA2. Furthermore, the interaction of cellular KPNA2 with 
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RNMT was found to be negatively regulated by T77 phosphorylation. This result was 
observed with both endogenous and exogenous protein. 
Wen and Shatkin (2000) mapped the RNMT and KPNA2 interaction domains using 
truncation mutants and reported that KPNA2 binds to RNMT between amino acid 96-
144. In contrast, our analysis suggests that the major KPNA2-binding site is located 
further towards the N-terminus. However, since RNMT contains three NLS it is likely 
that KPNA2 can bind RNMT at more than one site. However, although the data is not 
shown, Wen and Shatkin (2000) reported that KPNA2 interacts with RNMT via its C-
terminal domain and not via its NLS-binding domain. To the contrary, our data shows 
that phosphorylation of RNMT T77 located next to a NLS disrupts the interaction with 
KPNA2 and thus indicates an NLS-directed interaction.  
Furthermore, KPNA2 was reported to increase RNMT-binding to GpppG-RNA and to 
increase cap methyltransferase activity (Wen and Shatkin, 2000). Thus, we tested 
whether activation of RNMT by KPNA2 can be confirmed and whether phosphorylation 
would abolish this effect. Unexpectedly, it was found that KPNA2 reduces RNMT 
activity, which contradicts the data shown by Wen and Shatkin. The exact mechanism 
of RNMT inhibition by KPNA2 is unclear. KPNA2 was demonstrated to bind to RNA 
(Wen and Shatkin, 2000) and thus KPNA2 could titrate RNA away from RNMT. 
Alternatively, binding of KPNA2 to RNMT could inhibit RNMT catalytic activity by 
blocking the active site or causing a conformational change. Theoretically, this could be 
addressed by repeating the activity assay with the phospho-mimicking RNMT T77D 
mutant that doesnʼt bind to KPNA2. Thus, recombinant RNMT WT, T77A and T77D 
were purified and in vitro affinity purifications were performed. However, unlike cellular 
RNMT, all recombinant RNMT constructs interacted with KPNA2 (data not shown). 
Hence, further work is required to elucidate the molecular mechanism of negative 
regulation of RNMT by KPNA2. Cap methyltransferase assays could be performed with 
KPNA2 mutants deficient in RNA-binding (KPNA2 72-529) or RNMT-binding (KPNA2 
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1-455) (Wen and Shatkin, 2000). Furthermore, in vitro phosphorylated RNMT could be 
assessed for its interaction with KPNA2 instead and subsequently be used in RNMT 
activity assays. 
Experiments performed with cell extracts demonstrated that KPNA2 and RNMT 
interact with each other and further in vitro data showed that this leads to the inhibition 
of RNMT catalytic activity. However, it remains unclear whether this interaction occurs 
at the site where RNA guanosine caps are methylated in vivo and thus KPNA2 directly 
regulates RNMT activity in vivo. KPNA2 is expected to dissociate from its cargo after 
nuclear translocation due to the high Ran-GTP content in the nucleus. However, it is 
possible that a pool of KPNA2 may exhibit additional functions in the nucleus. 
Finally, at an equimolar ratio of RNMT and KPNA2 no effect was observed on 
RNMT catalytic activity. Only with increasing amounts of KPNA2 cap methyltransferase 
activity was inhibited in vitro. Therefore, in order to exhibit an effect on RNMT activity in 
vivo, KPNA2 would need to accumulate at high stoichiometry around RNMT. Further 
experiments are required to investigate the biological relevance of the inhibition of 
RNMT by KPNA2. For example, gel filtration experiments may reveal information about 
the molar ratio of the RNMT-KPNA2 interaction. 
 
Together, this work has identified cell cycle-dependent phosphorylation of RNMT 
T77 and shown that this phosphorylation activates RNMT activity in vitro. Furthermore, 
a phosphorylation-dependent interaction with KPNA2 was identified and it was 
demonstrated that at high stoichiometry KPNA2 can act as an inhibitor of RNMT 
activity in vitro. Thus, experiments performed in cells and in vitro suggest that RNMT 
phosphorylation can act as a direct activator of RNMT but also indirectly via decreasing 
RNMT interaction with the negative regulator KPNA2.   
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Chapter 6:                                                 
Investigation of the biological function of RNMT 
Threonine-77 phosphorylation 
 
 
6.1 Introduction 
The previous chapters described cell-cycle dependent phosphorylation of the human 
cap methyltransferase RNMT and how the effect of this post-transcriptional 
modification was investigated in vitro. This final chapter aims to elucidate the biological 
function of the T77 phosphorylation site in cells.  
The RNMT phosphorylation site identified in chapter 4 resides next to a nuclear 
localisation signal (NLS). Furthermore, experiments described in chapter 5 
demonstrated that T77 phosphorylation negatively regulates the interaction of RNMT 
with the nuclear import machinery. Thus, RNMT T77 phosphorylation may regulate 
subcellular localisation during the cell cycle. It has been demonstrated that 
phosphorylation can regulate nuclear protein import in many different ways (Nardozzi 
et al., 2010); directly by increasing the affinity of a protein with importins or by causing 
a conformational change, which exposes a previously inaccessible NLS. Examples for 
enhanced nuclear import after phosphorylation have been described for the Epstein-
Barr virus nuclear antigen 1 (EBNA-1) or for the capsid surface protein PKC of the 
human hepatitis virus (Kann et al., 1999; Kitamura et al., 2006). Phosphorylation in the 
proximity of a NLS may also disrupt the interaction with importins, as is the case for the 
nuclear factor of activated T-cells (NFAT) or the yeast Swi6p transcription factor that is 
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phosphorylated in a cell cycle specific manner (Belfield et al., 2006; Sidorova et al., 
1995). 
Maximum RNMT T77 phosphorylation levels were observed in G2/M-phase and the 
localisation of several factors functioning at chromatin is regulated during this stage of 
the cell cycle. The majority of the gene expression machinery is displaced from mitotic 
chromatin but some gene promoters remain associated with transcription factors. The 
retention of specific transcriptional regulatory factors at target gene promoters on 
mitotic chromatin is a form of gene bookmarking (Zaidi et al., 2011). It is thought that 
mitotic retention of nuclear factors enables rapid transcriptional reactivation during 
M/G1-transition or early G1-phase and it could also serve to maintain lineage and 
differentiation-specific gene expression patterns (Kadauke and Blobel, 2013). For 
example, during mitosis the lineage-specific transcription factor Runx2 binds to 
particular genes to ensure the expression of lineage specific genes in daughter cells 
(Young et al., 2007a, 2007b). Moreover, Brd4 binds acetylated histones and marks 
specific genes for post-mitotic transcription (Dey et al., 2009). Phosphorylation plays a 
critical role in the functional regulation of some transcription factors during mitosis. For 
instance, phosphorylation of the transcription factor Oct1 displaces it from mitotic 
chromosomes while TFIID remains associated with mitotic chromosomes but its activity 
is inhibited by phosphorylation (Roberts et al., 1991; Segil et al., 1991, 1996). Thus, 
this represents another example of how cell cycle-dependent phosphorylation can 
affect the subcellular localisation or function of target proteins. 
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6.2 Results 
6.2.1 Experimental system employing siRNA-resistant HA-
RNMT 
The aim of this chapter is to further investigate the biological function of RNMT T77 
phosphorylation in cells. To study the effect of exogenously expressed RNMT 
phosphorylation mutants in the absence of endogenous RNMT expression, siRNA-
resistant HA-RNMT constructs were designed and stably expressed in IMEC or HeLa 
cells. Upon treatment with siRNAs targeting RNMT, endogenous RNMT was depleted 
while exogenous HA-RNMT expression remained unaltered (Figure 6.1). Thus, this 
experimental system allowed partial replacement of endogenous RNMT with HA-RNMT 
mutants expressed at endogenous levels. 
 
6.2.2 Study of RNMT localisation during mitosis 
RNMT was previously described as a nuclear protein with three nuclear localisation 
signals (NLS) in its N-terminal region (Shafer et al., 2005). The RNMT T77 
phosphorylation site resides immediately next to one of the three NLSs and results 
described in chapter 5 revealed that RNMT T77 phosphorylation negatively regulates 
an interaction with KPNA2, which is part of the nuclear import machinery. Moreover, 
RNMT phosphorylation peaks during G2/M-phase and, as described above, the 
localisation of several proteins is regulated by mitotic phosphorylation. To determine 
whether RNMT T77 phosphorylation affects RNMT localisation immunofluorescence 
experiments were performed to monitor subcellular localisation of RNMT during 
interphase and different stages of mitosis. 
Mitosis can be divided into five different stages: at prophase the replicated 
chromosomes condense and the mitotic spindle starts to assemble; at prometaphase 
the nuclear envelope breaks down and the chromosomes attach to the mitotic spindle;   
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Figure 6.1: Experimental system to study the biological function of RNMT 
Threonine-77 phosphorylation.!
HeLa cells (upper panel) or IMEC cells (lower panel) stably expressing siRNA-
resistant HA-RNMT WT, T77A and T77D constructs or vector control (C) were 
transfected with siRNAs against RNMT or control-treated with transfection reagent. 
48 hours post-transfection western blots were performed to detect RNMT and 
Tubulin.!
64!
64!
RNMT!
Tubulin!
C!T7
7A
!
W
T!
Control!
T7
7A
!
W
T!
siRNMT!
C!kDa! T
77
D!
T7
7D
!
!
175!
	   	  176 
at metaphase the chromosomes align in the middle of the cells; at anaphase the 
daughter chromosomes are separated and moved towards the spindle pole and at 
telophase the chromosomes arrive at the spindle poles and the nuclear envelope 
reassembles forming two nuclei to complete mitosis. Finally, after mitosis the cell 
undergoes cytokinesis in which the cytoplasm is divided and two daughter cells are 
formed.  
Initially, localisation of endogenous RNMT during mitosis was characterized by 
immunofluorescence in IMEC cells using an anti-RNMT antibody (Figure 6.2). DAPI-
stained chromosomes and the mitotic spindle, detected with an anti-Tubulin antibody, 
served to determine mitotic stages in the nonsynchronous cell pool. As expected, non-
mitotic cells exhibited nuclear localisation of RNMT and the same was observed at 
entrance of mitosis (prophase). When the mitotic spindle started to form in 
prometaphase RNMT did not perfectly colocalise with DAPI staining but started to 
show a cytoplasmic signal. At metaphase RNMT was completely delocalised from 
mitotic chromosomes and this remained unaltered during anaphase. In telophase 
RNMT and DAPI staining started to colocalise and the nuclear RNMT signal was 
perfectly restored at the end of telophase. Thus, the immunofluorescence analysis 
suggests that RNMT disperses into the cytoplasm when the nuclear envelope breaks 
down after prophase. Furthermore, RNMT remains delocalized from condensed mitotic 
chromosomes and moves back into the nucleus once it is reformed in telophase. 
To investigate whether loss or gain of RNMT T77 phosphorylation would alter RNMT 
localisation IMEC cells stably expressing siRNA-resistant HA-RNMT constructs were 
transfected with siRNMT or control-treated with transfection reagent for 72 hours. 
Immunofluorescence analysis was performed to detect RNMT and Tubulin as well as 
nuclear envelope component Lamin B1 which was used to monitor the status of the 
nuclear envelope throughout mitosis. Compared to control-treated cells the RNMT 
signal detected in siRNMT-treated vector control cells was strongly depleted confirming 
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Figure 6.2: RNMT is delocalised from chromatin during mitosis.!
Immunofluorescence analysis was performed to detect the subcellular localisation 
of RNMT and Tubulin during mitosis in IMECs. DNA staining by DAPI was used to 
detect nuclei and a bright field view to detect the cell membrane. Arrows mark cells 
in the mitotic stage indicated on the top of the diagram. Representative pictures of 
three independent experiments are shown!
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efficient knockdown of endogenous RNMT (Figure 6.3a). Immunofluorescence analysis 
of siRNMT-transfected cells stably expressing siRNA-resistant HA-RNMT WT showed 
a similar pattern as observed for endogenous RNMT (Figure 6.3b): in non-mitotic cells 
HA-RNMT is a nuclear protein. When the nuclear envelope starts to break down HA-
RNMT is dispersed into the cytoplasm and stays delocalised from mitotic 
chromosomes. In telophase when the nuclear envelope is reformed HA-RNMT re-
establishes nuclear localisation. Immunofluorescence analysis was also performed on 
cells stably expressing RNMT with the loss of phosphorylation mutation T77A or the 
gain of phosphorylation mutation T77D and no difference was observed with either 
mutant compared to HA-RNMT WT (Figure 6.3c and d). Hence, RNMT T77 
phosphorylation during G2/M-phase does not seem to regulate RNMT subcellular 
localisation or bookmark the protein to mitotic chromosomes. 
 
6.2.3 Cell cycle progression of HA-RNMT WT and T77A 
expressing cells 
Replacement of endogenous RNMT with RNMT T77A resulted in reduced cell 
proliferation compared to cells expressing wild type RNMT (proliferation experiments 
performed by Victoria Cowling, data not shown). Since T77 phosphorylation is 
regulated during the cell cycle and loss of phosphorylation reduced cell proliferation it 
was tested whether cells expressing the phosphorylation mutant T77A show a defect in 
cell cycle progression. HeLa cells stably expressing siRNA-resistant HA-RNMT 
constructs were transfected with siRNAs against RNMT for 48 hours. Cells were 
stained with propidium iodide and were analysed by flow cytometry to quantify the cell 
cycle distribution (Figure 6.4a and b). Depletion of RNMT with siRNA did not alter the 
normal cell cycle distribution and no change was observed in cells expressing RNMT 
T77A compared to RNMT WT. 
 
Figure 6.3: Mutation of RNMT Threonine-77 did not influence RNMT 
localisation during mitosis.!
Immunofluorescence analysis was performed to detect the subcellular localisation 
of RNMT, Tubulin and Lamin B1 during mitosis in IMEC cells. DNA staining by 
DAPI was used to detect nuclei and a bright field view to detect the cell membrane. 
Arrows mark cells in the mitotic stage indicated on the top of the diagram. 
Representative pictures of three independent experiments are shown.!
a) IMEC cells expressing vector control (C) were transfected with siRNAs against 
RNMT or control-treated with transfection reagent for 72 hours and 
immunofluorescence analysis was performed.!
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Figure 6.3: Mutation of RNMT Threonine-77 did not influence RNMT 
localisation during mitosis.!
b) IMEC cells expressing siRNA-resistant HA-RNMT WT were transfected with 
siRNAs against RNMT for 72 hours and immunofluorescence analysis was 
performed.!
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Figure 6.3: Mutation of RNMT Threonine-77 did not influence RNMT 
localisation during mitosis.!
c) IMEC cells expressing siRNA-resistant HA-RNMT T77A were transfected with 
siRNAs against RNMT for 72 hours and immunofluorescence analysis was 
performed.!
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Figure 6.3: Mutation of RNMT Threonine-77 did not influence RNMT 
localisation during mitosis.!
d) IMEC cells expressing siRNA-resistant HA-RNMT T77D were transfected with 
siRNAs against RNMT for 72 hours and immunofluorescence analysis was 
performed.!
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Figure 6.4: Loss of RNMT Threonine-77 phosphorylation does not affect cell 
cycle progression.!
HeLa cells stably expressing siRNA-resistant HA-RNMT WT, T77A or vector control 
(C) were transfected with siRNAs against RNMT or control-treated with transfection 
reagent. 48 hours post-transfection cells were stained with propidium iodide and 
cell cycle distribution was monitored by flow cytometry. !
a) DNA content and cell numbers of a representative experiment are depicted.!
b) Cell cycle distribution was estimated using the Watson model. The chart depicts  
average and standard deviation of three independent experiments.!
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6.2.4 Measurement of chromatin recruitment of RNMT T77A 
Work presented in chapter 3 demonstrated that the N-terminal 120 amino acids of 
RNMT are essential for its recruitment to chromatin. To test whether RNMT T77 
phosphorylation regulates recruitment to transcription start sites (TSS), chromatin 
immunoprecipitation (ChIP) experiments were performed as described in chapter 3: 
HeLa cells were transiently transfected with HA-RNMT WT or T77A and FLAG-RAM or 
vector control and, after crosslinking nucleic acid-protein complexes with formaldehyde, 
RNMT-RAM complexes were purified with anti-HA and anti-FLAG antibodies. ChIP 
analysis with anti-HA antibody showed that RNMT T77A is recruited to similar or 
slightly higher levels compared to WT protein (Figure 6.5a). A similar result was 
obtained after performing FLAG-RAM ChIP with FLAG-antibodies (Figure 6.5b). Thus, 
these experiments suggest that RNMT T77 phosphorylation is not required for 
recruitment of RNMT to TSS. 
 
6.2.5 Introduction to the regulation of gene expression 
during the cell cycle 
Several in vitro experiments described in chapters 4 and 5 demonstrated that RNMT 
phosphorylation on T77 increased cap methyltransferase activity in a direct manner 
and indirectly by interrupting the inhibitory interaction of RNMT with KPNA2. As 
described in detail in chapter 1, the N7-methylguanosine cap is essential for eukaryotic 
gene expression and cell proliferation. It stabilises RNA pol II transcripts by protecting 
them from 5ʼ to 3ʼ exoribonucleolytic degradation, and interacts with the cap-binding 
complex (CBC) and the eukaryotic translation initiation factor 4E (eIF4E), thus 
promoting transcription, splicing, polyadenylation, nuclear export and translation 
initiation (Cowling, 2009; Topisirovic et al., 2011). However, cell cycle-regulated 
formation or functions of the N7-methylguanosine cap have not been reported to date. 
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Figure 6.5: Loss of RNMT Threonine-77 phosphorylation did not alter 
chromatin recruitment of RNMT.!
a) Chromatin immunoprecipitation was performed on HeLa cells transiently 
transfected with pcDNA4 HA-RNMT WT or T77A plus pcDNA4 FLAG-RAM or with 
pcDNA4 (C). An anti-HA antibody was used to immunoprecipitate RNMT. PCR 
analysis was performed against promoter proximal regions of the genes indicated 
or 2000 bases upstream of the transcription start site of c-Myc (-2000). The charts 
depict the average mean signal relative to input and normalised to control for five 
independent experiments and the error bars represent the standard deviation.!
b) As in a) but immunoprecipitations were performed with anti-FLAG antibodies to 
detect RAM. !
!
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A study of the transcriptional profile of human fibroblasts progressing through the 
cell cycle identified approximately 700 genes that displayed expressional periodicity 
(Cho et al., 2001). Furthermore, the expression of over 800 transcripts in HeLa cells 
has been shown to exhibit periodic variation throughout the cell cycle, of which 24 % 
peaked during G2/M-phase and 17 % at M/G1-phase (Whitfield et al., 2002). Cyclic 
transcription ensures that proteins required for different cell cycle phases are produced 
at the appropriate time. Not surprisingly, many of the periodically expressed genes 
encode proteins that are directly involved in various aspects of the cell cycle such as 
DNA replication or cell division.  
With the exception of specific genes required during M-phase, basal gene 
expression is strongly impaired during mitosis through the inhibition of both RNA and 
protein synthesis. The reduction in transcription during mitosis was shown by the 
reduced incorporation of radioactive RNA precursors into nascent transcripts from the 
end of prophase to telophase (Prescott and Bender, 1962; Taylor, 1960). 
Transcriptional inhibition may be caused by the condensation of mitotic chromatin, 
physically blocking the association of the transcription machinery with DNA, or by the 
inactivation of transcription initiation factors. Immunofluorescence and ChIP 
experiments revealed that the majority of RNA pol II is displaced from mitotic chromatin 
(Blobel et al., 2009; Christova and Oelgeschläger, 2002; Parsons and Spencer, 1997; 
Spencer et al., 2000). However, loss of mitotic transcription can occur independently of 
chromatin condensation as shown by the inhibition of transcription of non-condensed 
viral DNA (Spencer et al., 2000). This suggests that inactivation of certain transcription 
factors may be sufficient to block transcription.  
Several factors involved in transcription initiation are targeted for phosphorylation 
during mitosis. The RNA pol II CTD kinase TFIIH is repressed during mitosis, which is 
mediated through phosphorylation of the CDK7 subunit at the T-loop by CDK1/Cyclin B 
(Akoulitchev and Reinberg, 1998; Long et al., 1998). Furthermore, TFIID, which 
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contains the TATA box-binding protein, is phosphorylated during mitosis abolishing its 
function in transcription activation (Segil et al., 1996). In addition to RNA pol II, 
transcription mediated by RNA pol I and RNA pol III is also inhibited by mitotic 
phosphorylation events (Hartl et al., 1993; Heix et al., 1998; Klein and Grummt, 1999; 
White et al., 1995). 
The rate of protein synthesis varies throughout the cell cycle; translation in mitotic 
cells is reduced by 60 - 80 % (Bonneau and Sonenberg, 1987; Fan and Penman, 
1970). Reduction of protein synthesis during mitosis is predominantly achieved through 
reduced translation initiation. During mitosis eIF4E phosphorylation is impaired 
reducing its affinity for the N7-methylguanosine cap and the translation initiation 
complex, eiF4F, is disrupted through the sequestering of eIF4E by the 4E-BPs as a 
result of hypophosphorylation of 4E-BPs. These events lead to a rapid reduction of 
cap-dependent translation (Pyronnet et al., 2001). Furthermore, several other 
translation initiation factors, polyadenylation proteins and RNA binding factors have 
been found to be regulated by mitotic phosphorylation, which may also contribute to 
reduced translation rates during mitosis (Le Breton et al., 2005). Moreover, the tumour 
suppressor 14-3-3σ inhibits cap-dependent translation during mitosis through binding 
to several translation initiation factors (Wilker et al., 2007). Several studies suggest that 
IRES-mediated translation could be utilised by the cell to bypass the suppression of 
cap-dependent translation during mitosis. A growing list of mRNAs, such as p58PITSLRE 
(CDK11B) or c-Myc, have been demonstrated to be translated via cap-independent 
IRES-mediated translation during M-phase (Cornelis et al., 2000; Kim et al., 2003; 
Pyronnet et al., 2000). After the completion of mitosis, total protein synthesis rate 
rapidly increases. Interestingly, 4E-BP1 phosphorylation has been observed to 
increase towards the end of mitosis which may act to restimulate cap-dependent 
translation as cells enter G1 (Heesom et al., 2001). 
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6.2.6 Analysis of gene expression in cells expressing HA-
RNMT WT or T77A 
To investigate whether cell cycle-dependent RNMT phosphorylation regulates gene 
expression, transcript and protein levels were studied in HeLa cells stably expressing 
siRNA-resistant HA-RNMT WT or T77A. Initially, 35S-labelling experiments were 
performed to estimate global protein synthesis (Figure 6.6). Knockdown of endogenous 
RNMT decreased 35S-incorporation however this effect could not be rescued by the 
stable expression of RNMT WT. Unexpectedly, a lower 35S-signal was detected in 
control-treated cells expressing both endogenous and exogenous RNMT. Although 
RNMT T77A expressing cells showed reduced 35S-incorporation compared to RNMT 
WT expressing cells this difference was not significant. 
As the experiment measuring global protein synthesis was not successful the 
possibility that RNMT T77 phosphorylation regulates gene expression in a gene- or cell 
cycle-specific manner was investigated. This hypothesis was tested by measuring 
transcript levels of genes that are periodically expressed during the cell cycle or that 
are cell cycle independent (Whitfield et al., 2002). HeLa cells stably expressing siRNA-
resistant HA-RNMT were transfected with siRNMT or control-treated with transfection 
reagent for 48 hours and RNA was extracted and analysed by RT-PCR (Figure 6.7). 
The depletion of RNMT was monitored by using primers recognising endogenous 
RNMT (5ʼ UTR) or total RNMT (RNMT). As expected, RNMT mRNA was significantly 
reduced in siRNMT-treated vector control cells. However, the other investigated 
transcripts were largely unaffected by the knockdown of RNMT, though CCDN1 
showed a significant increase in siRNMT-treated control cells. No significant changes 
in periodically expressed genes were observed between cells expressing HA-RNMT 
WT and T77A. Interestingly, the transcript levels of two non-periodically expressed 
genes were found to be significantly reduced in T77A cells: NME1 and c-Myc. 
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Figure 6.6: Loss of RNMT Threonine-77 phosphorylation modestly reduces 
total protein synthesis.!
HeLa cells stably expressing siRNA-resistant HA-RNMT WT or T77A were 
transfected with siRNAs against siRNMT or control-treated with transfection 
reagent. 48 hours post-transfection cells were labelled with 35S Methionine and 
Cysteine for 15 minutes and total cell extracts were separated by SDS-PAGE and 
subjected to autoradiography. Charts depict the average mean and standard 
deviation of four independent experiments.!
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Figure 6.7: Loss of RNMT Threonine-77 phosphorylation reduces specific 
transcript levels.!
HeLa cells stably expressing vector control (1,4) or siRNA-resistant HA-RNMT WT 
(2,5) or T77A (3,6) were transfected with siRNAs against RNMT (4-6) or  control-
treated with transfection reagent (1-3). 48 hours post-transfection RNA was 
extracted and reverse transcribed into cDNA. RT-PCR analysis was performed to 
detect periodically (G1/S, G2, G2/M, M/G1) and non-periodically expressed 
transcripts as indicated on top of each chart. Charts depict the average mean and 
standard deviation of three independent experiments. T-Test p-value < 0.05 are 
indicated with an asterisk.!
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6.3 Discussion 
To investigate the biological function of RNMT T77 phosphorylation cell lines stably 
expressing siRNA-resistant RNMT WT or T77A phosphorylation mutant at levels 
similar to endogenous protein were used. Upon treatment with siRNMT endogenous 
RNMT levels were depleted whereas the expression of exogenous was not affected. 
This system enabled the effect of exogenous RNMT T77A phosphorylation mutant to 
be studied whilst RNMT levels were strongly reduced. Although siRNMT treatment 
resulted in depletion of the majority of endogenous RNMT it must be noted that low 
levels of endogenous RNMT remained. 
Subcellular localisation of RNMT was analysed throughout mitosis. In contrast to the 
other stages of the cell cycle, mitotic cells can be relatively easily identified by 
immunofluorescence microscopy due to their characteristic architecture including 
condensed chromatin, formation of the mitotic spindle and rounded cells underging 
cytokinesis towards the end of mitosis. Immunofluorescence analysis of endogenous 
RNMT confirmed nuclear localisation throughout interphase but revealed displacement 
from chromatin and cytoplasmic localisation during mitosis. At prometaphase, probably 
when the nuclear envelope breaks down, RNMT starts to disperse into the cytoplasm 
and is completely displaced from chromatin in meta- and anaphase. Towards the end 
of telophase RNMT is localised to the reformed nucleus and colocalises with 
chromatin.  
Phosphorylation of certain proteins has been described to ʻbookmarkʼ proteins to 
chromatin throughout mitosis and it was investigated whether RNMT phosphorylation 
during G2/M-phase has a ʻbookmarkingʼ effect. The localisation of RNMT during the 
cell cycle may also be affected by T77 phosphorylation negatively regulating the 
interaction of RNMT with the protein import machinery, which possibly is due to the T77 
phosphorylation site interfering with an adjacent NLS. To address these two 
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possibilities subcellular localisation of the phosphorylation mutants T77A and T77D 
were compared with RNMT WT, however, no change in the localisation pattern 
throughout mitosis was detected. This indicates that T77 phosphorylation does not 
ʻbookmarkʼ RNMT to chromatin in this experimental system, however it should be noted 
that the phospho-mimetic aspartic acid does not fully represent the characteristics of 
phosphorylation. Since RNMT T77D, which does not efficiently interact with KPNA2, 
translocates to the nucleus at the end of M-phase it is likely that the NLS starting at 
K81 does not play an essential role for nuclear import in telophase but may be 
redundant with the other two NLS present in RNMT. 
Although reduced cell proliferation was observed in RNMT T77A expressing cells 
when endogenous RNMT was depleted, no effect was detected on cell cycle 
distribution of HeLa cells upon treatment with siRNMT or when comparing cells stably 
expressing RNMT WT to T77A. This suggests that RNMT depleted cells or cells 
lacking RNMT T77 phosphorylation either display a slower proliferation rate or 
increased apoptosis. Indeed, knockdown of RNMT in HeLa cells was previously 
reported to induce apoptosis (Chu and Shatkin, 2008). 
The identified T77 phosphorylation site resides on the RNMT N-terminus and 
experiments described in chapter 3 demonstrated that this domain is essential for 
recruitment of RNMT to chromatin. Thus, ChIP experiments were performed with HA-
RNMT WT and T77A in order to test whether RNMT phosphorylation is important for 
recruitment of RNMT to TSS. No significant difference was observed between wild type 
RNMT and the phosphorylation mutant T77A detected at a number of gene 
transcription start sites indicating that RNMT phosphorylation does not seem to be 
required for chromatin recruitment. This was expected since N7-methylguanosine cap 
formation occurs co-transcriptionally and RNMT exists in an unphosphorylated state 
throughout most of the cell cycle. Immunofluorescence analysis performed with RNMT 
T77A and T77D showed that the phosphorylation mutants are displaced from mitotic 
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chromatin in a similar manner to wild type RNMT. However, it is possible that RNMT 
T77 phosphorylation may regulate RNMT recruitment to specific genes that remain 
associated with RNA pol II during mitosis. 
Since the N7-methylguanosine cap is essential for eukaryotic gene expression it 
was investigated whether RNMT T77 phosphorylation affects transcript or protein 
levels. 35S-labelling experiments showed no significant changes in global protein 
synthesis rates between cells expressing RNMT WT or T77A. However, a trend in 
reduced translation detected upon depletion of RNMT in vector control cells was not 
rescued by the expression of wild type HA-RNMT. This was unexpected and suggests 
that the experimental system used was not ideal for this assay. The stress caused by 
RNMT depletion together with amino acid starvation may have impacted protein 
synthesis in an unpredicted way.  
Finally, whether RNMT T77 phosphorylation affects gene expression in a gene-
specific way was investigated by measuring the transcript levels of various genes. The 
N7-methylguanosine cap structure is thought to stabilize transcripts and also promote 
various RNA processing events, which is mediated mainly by the cap-binding complex 
(Topisirovic et al., 2011). Thus, depletion of RNMT was expected to reduce transcript 
levels. However, the levels of most transcripts investigated were not reduced upon 
treatment with siRNAs against RNMT for 48 hours. Although RNMT transcript levels 
dropped by over 60 % the remaining RNMT pool may have been sufficient to keep 
normal gene expression intact. Furthermore, previous work in the Cowling laboratory 
demonstrated that the effect of RNMT depletion on transcript levels is not uniform but 
certain transcripts are more sensitive than others.  
Since RNMT T77 is phosphorylated in a cell cycle dependent manner it was tested 
whether mRNA levels of periodically expressed genes were affected by the loss of 
RNMT phosphorylation. No change was observed in any cell cycle-regulated transcript 
investigated. RNMT T77 phosphorylation may have no effect on cell cycle-specific 
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transcripts or remaining endogenous RNMT may have rescued any phenotype. 
Interestingly, a significant reduction in NME1 and c-Myc mRNAs in cells expressing 
RNMT T77A was observed. These genes were not identified as periodically expressed 
but are involved in cell proliferation, which may partially explain the reduction in cell 
proliferation observed in cells stably expressing RNMT T77A. Overall, the transcript 
analysis suggests that RNMT T77 phosphorylation may regulate gene expression in a 
gene-specific manner but a genome-wide study is required to identify target genes 
regulated by RNMT T77 phosphorylation. Furthermore, an improved experimental 
system allowing more efficient depletion or complete replacement of endogenous 
RNMT is required to study the effects of RNMT phosphorylation mutants on gene 
expression. 
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Chapter 7:                                                            
Final discussion and future work 
 
 
7.1 Summary 
The N7-methylguanosine (m7G) cap structure is essential for cell viability from yeast 
to man as it influences several steps of eukaryotic gene expression such as mRNA 
processing, RNA export and mRNA translation. The m7G cap is added co-
transcriptionally to the 5ʼ end of nascent RNA transcribed by RNA pol II. In mammalian 
cells two enzymes catalyse its synthesis: RNGTT adds the guanosine cap to the 5ʼ end 
of the transcript and RNMT methylates the cap structure at the N7-position, which is 
required for the recognition of the cap by the cap-binding proteins CBC and eIF4E. 
RNMT consists of two domains: a C-terminal catalytic domain (amino acids 121-
476) in which the active site essential for cap methyltransferase activity resides and an 
N-terminal domain (amino acids 1-120) that contains two nuclear localisation 
sequences (NLS) towards the C-terminal end but remains functionally uncharacterised. 
Thus, an aim of this thesis was to investigate whether the RNMT N-terminal domain 
has a biological function in mammalian cells. 
In vitro cap methyltransferase activity assays performed with cellular RNMT and an 
N-terminal deletion mutant (RNMTcat, amino acids 121-476) demonstrated that the N-
terminus is not required for catalytic activity. However, cell proliferation was reduced in 
mammalian cells expressing RNMTcat compared to RNMT WT indicating that the N-
terminus has a biological function in cells (Aregger and Cowling, 2013). To investigate 
whether the N-terminal domain is involved in RNMT recruitment to transcription start 
sites (TSS), chromatin immunoprecipitation (ChIP) was performed with cells expressing 
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RNMT WT, RNMTcat or RNMT-N (amino acids 1-120). These experiments revealed 
that the N-terminal domain is required and is sufficient for RNMT recruitment to TSS. 
Further ChIP experiments suggested that RNMT recruitment is dependent on 
phosphorylated RNA pol II CTD as DRB-treatment abolished RNMT recruitment to TSS 
(Aregger and Cowling, 2013). However, no direct interaction of RNMT with RNA pol II 
could be detected and thus, the exact molecular mechanism of RNMT recruitment to 
chromatin remains unclear. 
There is accumulated evidence that m7G cap synthesis is not a constitutive but a 
regulated process (Cowling, 2009). Therefore, another aim of this thesis was to 
elucidate whether RNMT is regulated by signalling pathways. Two-dimensional gel 
electrophoresis, orthophosphate labelling and mass spectrometry analysis revealed 
that RNMT carries post-translational modifications including phosphorylation. Site-
specific mutations in combination with orthophosphate labelling revealed that in the 
human cell lines utilised in this study RNMT is predominantly phosphorylated at 
Threonine-77 (T77). A phospho-specific antibody was raised against this 
phosphorylation site, which was subsequently used to detect RNMT T77 
phosphorylation levels in cells. 
The RNMT T77 phosphorylation site resides within a Cyclin-dependent kinase 
(CDK) recognition site and next to a Cyclin-binding motif. Incubation of cells with 
specific inhibitors against cell cycle-regulating kinases, including the CDK1-targeting 
compound RO-3306, reduced RNMT T77 phosphorylation. The analysis of RNMT T77 
phosphorylation levels throughout several stages of the cell cycle confirmed that RNMT 
T77 is phosphorylated in a cell cycle-dependent manner and maximal phosphorylation 
levels were detected during G2/M-phase. Furthermore, CDK1/Cyclin B specifically 
phosphorylated RNMT T77 in vitro. 
In vitro phosphorylation followed by cap methyltransferase activity assays 
demonstrated that T77 phosphorylation stimulates RNMT activity in vitro by two-fold. 
	   	  198 
Furthermore, peptide pull-downs and immunoprecipitation experiments revealed that 
T77 phosphorylation negatively regulates the interaction between RNMT and KPNA2 
(Importin-α). In vitro cap methyltransferase activity assays with recombinant RNMT and 
KPNA2 revealed that KPNA2 inhibits RNMT activity. 
To investigate the biological function of RNMT T77 phosphorylation in vivo, siRNA-
resistant exogenous wild type RNMT or phosphorylation mutants were stably 
expressed while endogenous RNMT was depleted with siRNAs against RNMT. 
Immunofluorescence analysis confirmed the nuclear localisation of RNMT throughout 
interphase and revealed that RNMT is dispersed into the cytoplasm once the nuclear 
envelope breaks down at the beginning of mitosis. It was found that RNMT stays 
delocalised from mitotic chromatin throughout M-phase and only translocates back to 
the nucleus at the end of M-phase when the nuclear envelope reforms. RNMT loss 
(T77A) or gain (T77D) of phosphorylation mutants did not express an altered 
localisation pattern indicating that T77 phosphorylation does not regulate subcellular 
RNMT localisation throughout G2/M-phase or interphase. 
Cells transiently expressing RNMT T77A displayed reduced cell proliferation 
compared to RNMT WT expressing cells. However, analysis of the cell cycle 
distribution of cells stably expressing exogenous RNMT constructs while endogenous 
RNMT was depleted did not reveal any evidence that RNMT T77 phosphorylation is 
required for progression through the cell cycle. Furthermore, no changes in RNMT 
recruitment to TSS were observed in ChIP experiments when the T77 phosphorylation 
site was mutated. Since the m7G cap is essential for eukaryotic gene expression the 
impact of RNMT T77 phosphorylation on transcript levels or translation was 
investigated. However, the experimental system described above proved not to be 
suitable for these analysis. Exogenous RNMT could not rescue the drop in translation 
observed upon depletion of endogenous RNMT. Furthermore, depletion of endogenous 
RNMT did not result in reduced transcript levels indicating that remaining RNMT levels 
	   	  199 
were sufficient to maintain normal transcript levels. Nonetheless, a significant reduction 
in c-Myc and NME1 transcript levels was observed in RNMT T77A expressing cells 
indicating that RNMT T77 phosphorylation may specifically regulate certain transcripts 
rather than acting globally. 
In summary, the previously uncharacterised N-terminal domain of RNMT was found 
to mediate RNMT recruitment to TSS and to be targeted at T77 for cell cycle-
dependent phosphorylation (Figure 7). RNMT T77 phosphorylation activates RNMT in 
vitro and negatively regulates the interaction of RNMT with KPNA2. The biological role 
of RNMT T77 phosphorylation during G2/M-phase remains unclear and further 
experiments are required to investigate its function in vivo. 
 
 
7.2 Regulation of N7-methylguanosine cap formation 
Several recent studies suggested that the synthesis of the m7G cap is not a 
constitutive but a regulated process. A pool of incompletely capped mRNA, lacking the 
methyl moiety on the cap or lacking the entire cap structure, was detected both in yeast 
and mammalian cells (Chang et al., 2012; Cole and Cowling, 2009; Cowling and Cole, 
2007b; Fernandez-Sanchez et al., 2009; Jiao et al., 2010, 2013). In addition, the finding 
that eukaryotic cells possess a 5ʼ quality control mechanism that selectively degrades 
aberrantly capped transcripts suggests that m7G cap formation does not always occur 
to completion (Chang et al., 2012; Jiao et al., 2010, 2013). Furthermore, it was found 
that growth factors stimulate m7G cap levels in yeast (Jiao et al., 2010). Finally, the 
Myc and E2F1 transcription factors can promote the formation of the m7G cap on 
specific transcripts in mammalian cells (Aregger and Cowling, 2012; Cole and Cowling, 
2009; Cowling and Cole, 2007b; Fernandez-Sanchez et al., 2009).  
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Figure 7: The N-terminal domain of RNMT is required for RNMT recruitment 
to chromatin and is targeted for cell cycle-dependent phosphorylation.!
a) The RNMT N-terminal domain mediates RNMT recruitment to chromatin and is 
phosphorylated at Threonine-77. Nuclear localisation signals are indicated with an 
asterisk and the Threonine-77 phosphorylation site is indicated with a red P.!
b) RNMT T77 phosphorylation negatively regulates the interaction of RNMT with 
KPNA2 (Importin-α).!
c) RNMT T77 is phosphorylated in a cell cycle-dependent manner during G2/M-
phase by CDK1/Cyclin B.!
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The identification of cell cycle-dependent phosphorylation of RNMT further supports 
the notion that m7G cap synthesis is regulated in cells. Whereas previous studies 
described the regulation of proteins influencing cap methylation, this thesis presents 
the first evidence that the capping machinery itself can be regulated. In vitro data 
suggests that phosphorylation of RNMT T77 activates cap methyltransferase activity. It 
can be speculated that this increased activity may be required to methylate a dormant 
pool of incompletely capped RNA during G2/M-phase in order to efficiently translate 
these transcripts upon exit of mitosis or during entrance of G1-phase. When the 
nuclear envelope breaks down during mitosis RNMT is dispersed into the cytoplasm. It 
is possible that increased RNMT catalytic activity and delocalisation of RNMT from 
KPNA2 may be required for RNMT to function in the absence of a nucleus and 
dissociated from chromatin. 
Interestingly, the disassembly of the nucleus during mitosis is not a conserved 
eukaryotic feature. Many lower eukaryotes such as fungi or protists undergo a ʻclosed 
mitosisʼ in which the daughter chromosomes migrate to opposite poles of the intact 
nucleus, which subsequently divides into two (De Souza and Osmani, 2007). The cap 
methyltransferase of these organisms does not encounter a cytoplasmic environment 
during mitosis, which correlates with the absence of a cap methyltransferase N-
terminal domain in lower eukaryotes. However, it is unlikely the RNMT N-terminus has 
solely evolved for a possible mitotic function since open mitosis occurs in most 
metazoans (Güttinger et al., 2009) but the RNMT T77 phosphorylation site is only 
conserved in mammals. Furthermore, the N-terminal domain was shown to not only 
regulate RNMT activity but also mediate recruitment to TSS in mammalian cells. 
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7.3 The N7-methylguanosine cap and cancer 
mRNA translation is a highly regulated process with the initiation phase as the rate-
limiting step. Translation initiation is regulated by the PI3K and MAPK signalling 
pathways (Blagden and Willis, 2011). PI3K is activated by nutrient and energy signals 
and via Akt activates mTORC1. mTORC1 phosphorylates 4E-BPs and S6K, which 
promotes the formation of the eIF4F complex and increases translation initiation. The 
MAPK pathway is activated by stress, growth factors, hormones and other factors and 
via p38 and ERK activates Mnk1. Activated Mnk1 phosphorylates eIF4E which 
increases eIF4E cap-binding activity and thus promotes translation initiation (Blagden 
and Willis, 2011).  
Deregulation of the components of the PI3K and MAPK pathway are often 
associated with cancer. In addition, aberrant expression of several translation initiation 
factors has been demonstrated to cause tumour growth. Overexpression of eIF4E was 
found to promote tumorigenic transformation of fibroblasts and to cause tumour 
formation in mice, which was further promoted by Mnk1-mediated phosphorylation of 
eIF4E (Lazaris-Karatzas et al., 1990; Ruggero et al., 2004; Wendel et al., 2007). 
Increased eIF4E expression was detected in several cancers such as breast, head and 
neck, bladder, colon, cervix, lung and prostate cancers when compared with normal 
tissues (Blagden and Willis, 2011). Furthermore, increased phosphorylation of 4E-BPs 
correlates with poor clinical outcome (Petricoin et al., 2007; Rojo et al., 2007). Since 
increased translation rates play a critical role in tumourigenesis, eIF4E and other 
translation initiation factors have been targeted for drug screening and several new 
drugs inhibiting cap-dependent translation are currently in clinical trial (Blagden and 
Willis, 2011). 
Recently, the formation the m7G cap has also been associated with oncogenic cell 
transformation. Overexpression of RNMT in fibroblasts increases Cyclin D1 expression 
	   	  203 
and promotes cell transformation (Cowling, 2010). Furthermore, the proto-oncogenes 
c-Myc and E2F1 were found to upregulate m7G cap levels of specific transcripts (Cole 
and Cowling, 2009; Cowling and Cole, 2007b; Fernandez-Sanchez et al., 2009). Upon 
elevated c-Myc expression transcript levels were typically increased by 2-fold whereas 
m7G cap levels of specific transcripts were found to be upregulated by up to 8-fold. 
Furthermore, increased cap methylation was required for c-Myc to promote protein 
synthesis, cell proliferation and cell transformation, and inhibition of cap methylation is 
synthetically lethal with elevated c-Myc expression (Fernandez-Sanchez et al., 2009). 
Therefore, formation of the m7G cap is rate limiting for Myc-induced cell transformation 
and thus the capping machinery potentially provides a novel therapeutic target in Myc-
overexpressing tumours.  
Several different approaches to target cap methylation are currently being 
investigated in the Cowling laboratory. RAM was found to activate RNMT and to be 
essential for cap methylation in cells (Gonatopoulos-Pournatzis et al., 2011). Therefore, 
targeting the interface between RAM and RNMT to disrupt the RNMT-RAM interaction 
may be a promising approach to inhibit m7G cap formation in cells. Furthermore, the 
Cowling laboratory is currently screening compounds that would inhibit cap 
methyltransferase activity of RNMT. The findings that RNMT is phosphorylated during 
the cell cycle and that mutation of the T77 phosphorylation site reduces cell 
proliferation indicate that RNMT phosphorylation contributes to driving cell proliferation. 
This novel information may potentially be exploited to develop drugs directed against 
cap methyltransferase function in the future. 
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7.4 Future work 
To investigate the biological function of RNMT T77 phosphorylation an experimental 
system is required that allows efficient replacement of wild type proteins with 
phosphorylation mutant constructs (RNMT T77A or RNMT T77D). Several novel 
techniques allowing sequence-specific ʻgenome editingʼ such as zinc finger nucleases 
(ZFNs), transcription activator like effector nucleases (TALENs) and the clustered 
regularly interspaced short palindromic repeats (CRISPRs)/Cas-system (Gaj et al., 
2013), could be exploited to completely replace wild type RNMT with phosphorylation 
mutants. 
To investigate the biological role of RNMT T77 phosphorylation in mammalian cells 
one of the experimental systems described above could be exploited to compare gene 
expression patterns between cells expressing RNMT WT, T77A or T77D. The 
combination of the following genome-wide experiments would identify direct gene-
specific effects of RNMT T77 phosphorylation: 
1. ChIP-sequencing 
RNMT T77 is phosphorylated during the cell cycle, which activates RNMT in vitro. 
As discussed above it is possible that RNMT functions in the cytoplasm during 
mitosis, however, it is thought that RNMT functions predominantly near 
chromatin. Thus, it would be interesting to investigate the chromatin distribution 
of wild type RNMT during the cell cycle to reveal any direct targets of capping 
during G2/M-phase when RNMT maximal T77 phosphorylation levels are 
observed. To address this, ChIP experiments can be performed in combination 
with DNA sequencing.  
2. CLIP-sequencing 
RNMT crosslinking-immunoprecipitation (CLIP) during G2/M-phase combined 
with RNA sequencing could provide a genome-wide overview of nascent or 
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incompletely capped transcripts that are bound by RNMT. This analysis could 
reveal specific transcripts that are targeted for cap methylation during G2/M-
phase and thus may be regulated by RNMT T77 phosphorylation. 
3. m7G-IP combined with RNA sequencing 
If phosphorylation of RNMT T77 affects cap methyltransferase activity in vivo this 
would ultimately result in changes of m7G cap levels. This hypothesis can be 
investigated with an anti-N7-methylguanosine antibody (Cowling and Cole, 
2007b), which specifically binds to the methylated cap structure but not the 
unmethylated cap. Thus, m7G-capped transcripts can be immunoprecipitated 
using this antibody and subsequently be identified by RNA sequencing. By 
comparing the sequencing profile between cells expressing wild type RNMT or 
T77 mutant RNMT, specific transcripts could be identified that are targeted for 
regulation by RNMT T77 phosphorylation.  
4. RNA sequencing of total mRNA 
Since the m7G cap is essential for RNA stability and influences transcription, 
detection of total mRNA levels can be used as a means to identify transcripts that 
are regulated by RNMT T77 phosphorylation. Total mRNA levels can be selected 
by poly(A) purification and can subsequently be analysed by RNA sequencing. 
As above, the sequencing profile can be compared between RNMT wild type or 
phosphorylation mutant expressing cells to identify transcripts regulated by T77 
phosphorylation.  
 
The combination of the above proposed genome-wide experiments would allow to 
discriminate between direct and indirect effects such as increased m7G cap formation 
and increased transcription, respectively. 
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If the above experiments reveal gene expression patterns that are regulated by 
RNMT T77 phosphorylation, an RNMT T77A or T77D knock-in mouse would provide 
an excellent model to investigate the biological relevance of RNMT T77 
phosphorylation. The experiments performed in this thesis and discussed above were 
performed in human cell lines, however, it would be interesting to test the effects of 
RNMT T77 phosphorylation in an animal model. This would reveal possible effects 
during development or allow to assess the oncogenic potential of this phosphorylation 
site. 
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